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1. Introduction 
The field of immunology deals with the study of the host organisms defence against 
invading pathogens or pathologic processes. There are various pathogens, like 
bacteria, viruses, fungi and small eukaryotic organisms, which can cause disease in 
all kinds of life. In contrast to these external infections, disease can also be caused 
by internal mechanisms (cancer and autoimmunity). The immune system seeks to 
provide protection against all kinds of disease development. Whereas invertebrates 
only possess an innate immune system, vertebrates have developed an additional 
system, the adaptive immune system, which can confer specific immunity against a 
pathogen and immunological memory for any subsequent encounters. (93, 211, 218) 
1.1 The innate immune system 
The innate immune system is the less specific component of the immune system and 
becomes immediately activated after invasion of an organism with a pathogen. The 
mechanisms of innate immune system action are not specific to a certain pathogen 
but recognise distinct molecular structures, called pathogen associated molecular 
patterns (PAMPs), and can therefore provide the first line of defence during formation 
of the adaptive immune response. The parts of the innate immune system are of 
varying natures including: molecular (antimicrobial compounds), cellular 
(macrophages and neutrophils) and more complex (skin). The innate immune system 
can be further subdivided into four types of defence: anatomical barriers, 
physiological barriers, phagocytosis and inflammation. (112)  
 
PAMPs are recognised by pattern recognition receptors (PRRs) and these molecules 
can either be soluble or cell-associated. Examples of PRRs are the macrophage 
mannose receptor, complement, toll-like-receptors (TLRs) nucleotide-binding 
oligomerisation domain receptors, cytoplasmatic RNA sensors like RIG-I and MDA-5 
(recognises dsRNA) and cytosolic DNA sensors like cGAS (recognises dsDNA) 
(288). These receptors trigger various responses, like phagocytosis, chemotaxis, up-
regulation of co-stimulatory molecules or secretion of cytokines (112, 211). 
 
One such group of cytokines are interferons (IFN), which can be induced as a result 
of PRR stimulation by its ligand resulting from different infections. Type I interferons 
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(IFNα and IFNβ) are important players in the immediate anti-viral response. Almost 
all cells express the interferon receptor. Upon binding of its ligand an anti-viral state 
is induced, which is characterised by the expression of hundreds of interferon-
stimulated genes that are able to reduce viral replication and modulate immune cell 
responses. (211, 217) 
 
Natural killer (NK) cells belong to the innate immune system, as they are able to 
respond to pathogens immediately in a non-specific manner. Once activated, they kill 
virus-infected or tumour cells by the release of cytotoxic granules, containing 
granzymes (Gzm) and perforin. This leads to the induction of apoptosis in the target 
cells. NK cells also express ligands for death receptors like TRAIL (tumour-necrosis-
factor-related-apoptosis-inducing ligand) or FasL, which kill cells through binding their 
receptors on the target cells. (211, 217) 
 
A further feature of the innate immune response is the mechanism of phagocytosis. 
This is carried out by specialised immune cells; macrophages/monocytes, dendritic 
cells (DCs) and granulocytes (especially neutrophils); which can engulf and destroy 
pathogens in phagosomes. Monocytes (in the blood) or macrophages (in tissues) are 
long-lived phagocytic cells which help to induce immune responses by secreting 
signalling proteins like cytokines and chemokines to attract other immune cells. In 
this capacity, activated macrophages initiate the process of inflammation. 
Additionally, DCs can take up large amounts of extracellular fluid and its content 
(macropinocytosis). Their main function is the recognition and degradation of 
invading pathogens. Resulting from this, DCs present antigens within the major 
histocompatibility complex (MHC) molecules on their surface to naïve T lymphocytes. 
The first encounter happens in peripheral lymphoid organs to initiate the adaptive 
immune response. DCs are also able to produce cytokines that influence the innate 
and adaptive immunity. The mechanism of antigen presentation provides the crucial 
connection between innate and adaptive immunity and is essential to initiate an 
effective immune response against a pathogen. (112, 211) 
1.2 The adaptive immune system 
While the innate immune response is activated within hours, it takes days to weeks 
for the adaptive immune system to develop its protective effects. Adaptive immunity 
is different to innate immunity in the way that it is pathogen specific, it takes time to 
  Introduction 
3 
develop and a memory response can be launched at second encounter with an 
antigen. The adaptive immune system can be divided into the cellular (T and B cells) 
and humoral (antibodies) components.  
 
Recognition of invading pathogens by DCs leads to their activation, causing the up-
regulation of MHC class I and class II, as well as co-stimulatory molecules to initiate 
an effective T cell response. After migration to lymphoid organs, DCs present non-
self-peptides bound to MHC molecules on their surface to naïve CD4+ and CD8+ T 
cells. CD4+ T cells only interact with peptide bound to MHC class II and CD8+ T cell 
only recognise peptides bound to MHC class I. Whereas almost all nucleated body 
cells express MHC class I, MHC class II is only present on professional antigen 
presenting cells (APCs), like DCs. There are two different pathways that lead to the 
presentation of a peptide on an MHC molecule. Peptides presented on MHC class I 
molecules are of cytosolic or endoplasmatic reticulum (ER) origin, whereas peptides 
presented on MHC class II molecules are derived from endosomes. All peptides are 
usually of pathogenic origin and the result from different routes of infection or 
pathogen encounter. (211) 
 
For MHC class I loading endogenous antigens are generated. These are derived 
from misfolded proteins of cellular or pathogenic origin, or proteins produced within 
an infected cell. These proteins are cleaved into smaller peptides by the proteasome. 
The unloaded MHC class I molecule is initially located in the luminal side of the ER 
membrane. Therefore, peptides must be transported into the ER lumen via the 
transporter associated with antigen processing (TAP). TAP has the highest affinity for 
peptides with a length of 8 to 10 amino acids and with hydrophobic and basic 
carboxy-terminal amino acids, which present the optimal size and anchor charge for 
MHC class I binding. The process of MHC class I:peptide-complex assembly is highly 
chaperone guided. The fully assembled complex is then transported to the surface of 
the cell via the Golgi apparatus, where it can be recognised by specific CD8+ T cells. 
(79, 112) 
MHC class II loading occurs in a different process with peptides derived from 
exogenous antigens captured through phagocytosis or endocytosis. The internalised 
antigens become degraded in increasingly acidified compartments (early endosome 
– endolysosome – lysosome) containing hydrolytic enzymes. In this process 
oligopeptides with a length of 13 to 18 amino acids are produced, which are able to 
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bind to the peptide binding groove of the MHC class II complex. The assembly of the 
two chains of the MHC class II complex takes place in the ER, where an invariant 
chain blocks the peptide binding groove from binding endogenous peptides and 
stabilises the complex. After passing through the Golgi apparatus, the MHC class 
II:invariant chain-complex is included in the endosomal-lysomsomal pathway. The 
invariant chain is degraded, leaving only a small fragment blocking the peptide 
binding groove (CLIP, class II-associated invariant chain peptide). In a chaperon-
mediated pathway, the CLIP is released and replaced by a peptide produced from 
the endosomal-lysosomal pathway. The MHC class II:peptide-complex is then 
presented on the surface of APCs, where it can be recognised by specific CD4+ T 
cells. (79, 112) 
 
B cells are APCs and thereby able to activate naive CD4+ T cells. Their principle role 
is in the production of antibodies, as part of the humoral immune response to 
pathogens. B cells mature into antibody-producing plasma cells and memory B cells 
in an antigen-driven way. B cells can be activated in two different ways: by thymus-
independent antigens and thymus-dependent antigens, which is mediated with the 
help of CD4+ T cells. In response to stimulation, B cells produce antibodies and this 
process can be divided into primary and secondary responses. In the primary 
response, naïve B cells become activated to produce antibodies, whereas in the 
secondary response, plasma cells are activated to produce more specific antibodies 
of different classes. These antibodies from the secondary response are more specific 
because the B cells have undergone clonal selection, expansion and differentiation in 
germinal centres. Antibody production is important for specific pathogen recognition 
and elimination (complement activation, opsonisation and neutralisation of pathogens 
and phagocytosis of pathogens). (112) 
1.2.1 Effector T cells  
T cells are generated in the bone marrow. They mature in the thymus, where they 
are subject to positive and negative selection. The process of positive selection sorts 
for T cells that are able to recognise self-MHC molecules (self-restriction), whereas 
negative selection only protects T cells not recognising self-MHC:self-peptide-
complexes (self-tolerance). These two processes provide a T cell repertoire capable 
of binding to self-MHC in combination with foreign antigens to mount a strong and 
  Introduction 
5 
specific immune response upon encountering a pathogen. After thymic maturation, T 
cells leave the thymus as naïve CD4+ or CD8+ T cells. (112) 
1.2.1.1 The activation of T cells 
T cells become stimulated via the interaction of their T cell receptor (TCR)/CD3-
complex binding to their specific antigen presented in the context of a self-MHC 
molecule, either MHC class I or MHC class II, which are also bound by the co-
receptor CD8 or CD4, respectively, presented on the T cell (signal 1). This results in 
multiple intracellular signalling events leading to T cell activation, proliferation and 
differentiation into effector or memory cells. Moreover, the expression of various co-
stimulatory molecules is also required (signal 2). This second signal is primarily 
provided by CD28 on T cells and molecules of the B7 family (B7-1 (CD80) and B7-2 
(CD86)) on APCs. There are also inhibitory molecules, which can inhibit T cell 
activation. If the second signal does not follow the initial activation, anergy occurs, 
leading to unresponsive T cells. In addition to these signals, the T cell response is 
also shaped by various cytokines secreted by APCs, T cells and other activated cells 
(signal 3).  
 
Activated T cells carry out different effector functions. Naïve CD8+ T cells develop 
into cytotoxic CD8+ T cells (CTLs) and naïve CD4+ T cells differentiate into different 
helper T cell populations (Th), dependent on the cytokine milieu provided. Whereas 
CTLs primarily kill infected cells, Th cell populations are important for the recruitment 
and activation of other cells mediated through cytokine release, and providing 
assistance to B cells and CD8+ T cells. However, under special conditions, Th cells 
are also able to kill infected or pathogenic (tumour) cells. The effector phase is 
followed by a down-phase in which most antigen-specific T cells are eliminated in a 
process called activation-induced cell death (AICD), leaving a smaller pool of 
memory T cells. (112, 211) 
1.2.1.2 Common markers used for CD4+ and CD8+ T cell characterisation 
Activation and homing markers 
A whole host of molecules have been described as markers for T cell activation and 
homing. The markers mentioned in this section have been highlighted due to their 
widespread use and the fact that they have been utilised in this thesis. CD69, or very 
early activation antigen, is expressed on various leukocytes. Due to the activation of 
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T, B and NK cells, CD69 is up-regulated on the surface, which suggests a role in 
lymphocyte activation (335). CD43 (leukosialin or sialophorin) is expressed on 
peripheral T cells, thymocytes and early hematopoietic precursors in the bone 
marrow. It exists as different isoforms due to O-linked glycosylation and this is an 
effect of T cell activation. CD43 is involved in T cell mediated responses, co-
stimulation, enhanced cytotoxicity of CD8+ T cells and leukocyte adhesion (16, 276). 
CD11a, or integrin alpha L, is expressed on leukocytes and is an important adhesion 
molecule involved in T cell function and co-stimulation, which becomes up-regulated 
upon T cell stimulation (258). CD44 functions as an adhesion molecule and is 
involved in T cell activation. It is expressed on various hematopoietic and non-
hematopoietic cells and peripheral B and T cells can up-regulate CD44 upon antigen 
encounter (191, 306).  
 
CD62L is a member of the selectin family and is expressed on many different 
leukocytes. Its function is important for the rolling of lymphocytes on activated 
endothelium at the site of inflammation and homing to high endothelial venules of 
peripheral lymphoid tissues. Naïve and central memory T cells express CD62L, 
whereas its down-regulation indicates T cell activation (104). CD103 is the integrin 
alpha E and expressed on some DCs and a small subset of peripheral lymphocytes. 
CD103 is important for homing of T cells to the intestinal epithelium (176).  
 
Co-stimulatory markers and inhibitory receptors 
Co-stimulatory and inhibitory molecules are important for the activation of T cells 
through DCs. Many of these molecules have been identified and this section focuses 
on the ones that have been well characterised. The TCR-inducible co-stimulatory 
receptor (ICOS), homologous to CD28 and cytotoxic T lymphocyte antigen-4 (CTLA-
4), interacts with its ligand on APCs thereby enhancing effector T cell responses 
(275). ICOS becomes up-regulated within 6 to 48 hours after stimulation on T cells 
and delivers a co-stimulatory signal to T cells. This enhances T cell dependent 
antibody production and cytokine secretion by CD4+ T cells (49). The glucocorticoid-
induced tumour necrosis factor receptor (TNFR) family related gene (GITR) is a co-
stimulatory molecule expressed on T cells (250). 
 
T cell immunoglobulin mucin 3 (TIM3) is usually expressed on Th1 and some CD8+ T 
cells and acts as a negative regulator on these cells, inducing apoptosis. TIM3 is up-
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regulated during a late stage of T cell differentiation and is expressed on 
dysfunctional or exhausted CD8+ T cells (98, 220). Programmed cell death-1 (PD-1) 
is described to be a co-inhibitory receptor expressed on T cells and signalling 
through it attenuates TCR signalling and inhibits cytotoxic functions. Following TCR 
stimulation, PD-1 is expressed on T cells and binds members of the B7 family (PD-L1 
(B7-H1) and PD-L2 (B7-DC)). Its ligand PD-L1 is up-regulated on hematopoietic and 
non-hematopoietic cells and its signalling down-regulates TCR signalling, inhibiting 
proliferation and cytokine secretion which promotes anergy and apoptosis, leading to 
immune suppression (99, 220). CTLA-4 is an inhibitory molecule and a homolog of 
the co-stimulatory molecule CD28. It has higher affinity than CD28 to the B7 family 
ligands CD80 and CD86. CTLA-4 becomes transiently up-regulated on T cells shortly 
after activation and interaction with its ligands prevents continuous T cell co-
stimulation and activation (220). The lymphocyte-activation gene 3 (Lag3) is a CD4 
homolog which binds MHC class II molecules with a higher affinity than CD4 (124). It 
is up-regulated on T cells after activation and negatively regulates T cell expansion 
and activation (127, 329). 
 
Differentiation and proliferation markers 
Different markers are described to indicate differentiation and proliferation of T cells 
and the most commonly used are described here. CD127 is the IL7 receptor α chain 
and is expressed at low levels on T cells in circulation. The down-regulation of 
CD127 indicates activation and differentiation of T cells, but also the transition to a 
memory T cell phenotype (284). The killer cell lectin-like receptor G1 (KLRG1) is 
expressed on some NK and T cells. KLRG1 has been described as a marker for 
terminally differentiated antigen-experienced T cells that lack proliferative capacity 
(311, 312).  
Ki67 is a nuclear protein absent in resting cells (G0 phase) and present in the active 
stages of the cell cycle (G1, S, G2 and M phase) (109, 278). It can therefore be used 
to determine the proliferative potential of cell populations, although another technique 
to determine cell proliferation is to measure the incorporation of BrdU, a thymidine 
analogue, into the chromosomal DNA. 
1.2.1.3 Mechanisms of CD8+ T cell mediated killing 
CD8+ T cells are the main effector cells during the adaptive immune response to viral 
infections. CD8+ T cells recognise virus-infected MHC class I presenting cells and 
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can kill them directly via a multitude of mechanisms involving Gzms, perforin and 
Fas-FasL interactions (Figure 1. 1). These cells are also able to secrete various 
cytokines, like IFNγ and tumour necrosis factor α (TNFα), and chemokines, like MIP-
1α, MIP-1β (macrophage inflammatory protein) and RANTES (regulation on 
activation, normal T expressed and secreted). (211) 
 
 
 
Figure 1. 1 Pathways of CTL mediated killing of target cells. The different mechanisms of 
CLTs – TNFα, IFNγ, granzyme/perforin and Fas-FasL – killing are displayed in this simplified 
schematic. (299) 
 
 
Gzms are serine proteases that are stored in specialised lytic granules of CTLs and 
NK cells along with perforin. In mice, ten Gzms (A-G, M and gene duplications) and 
in humans five Gzms (A, B, H, K and M) have been described. When CD8+ T cells 
become activated and recognise their antigen in an MHC class I context, these 
granules can be released and the Gzms can kill the target cell (Figure 1. 1). For the 
Gzms to enter the target cell, perforin pores are formed in the target cell membrane 
in a calcium dependent manner. It should be noted, however, that other attack 
mechanisms have been described (38, 209, 234). Upon entry into the target cell, 
Gzms induce proteolytic cleavage of caspases eventually leading to DNA 
fragmentation and cell apoptosis (232). In addition to activating caspases, Gzms can 
also activate caspase-independent mitochondrial collapse, resulting in the release of 
cytochrome c, a pro-apoptotic protein (21).  
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The Fas (CD95) – FasL (CD95L) pathway is another pathway through which CTLs 
can induce apoptosis in target cells (Figure 1. 1). Fas is a member of the TNFR 
family and contains an intracellular death domain to deliver an apoptotic signal upon 
FasL binding. Fas expression is induced by TNFα and IFNγ or the activation of 
lymphocytes and FasL is expressed after TCR engagement on CD8+ T cells. The 
activation of the Fas – FasL pathway results in the activation of caspases causing 
apoptosis (168). The Fas – FasL pathway plays an important role in AICD to limit 
clonal T cell expansion after elimination of the antigen and to restrict auto-reactive T 
cells (318). 
 
In addition to the above mechanisms, cytokines like IFNγ and TNFα are secreted by 
activated CD8+ T cells. It should, however, be noted that these cytokines can be 
secreted by a variety of other immune cells as well (T cells, NK cells, APCs). IFNγ is 
the only member of the type II interferons and its functions have a wide range, 
including: leukocyte attraction, maturation and differentiation of many cell types, NK 
cell activity enhancing action and regulation of B cell functions and altering 
macrophage function during infections. IFNγ is also involved in the up-regulation of 
MHC class I and the immunoproteasome, therefore providing efficient recognition of 
virus-infected cells by CTLs. Furthermore, IFNγ also up-regulates factors involved in 
CD4+ T cell recognition and induces further MHC class II expression on APCs and 
other cells. It also elicits direct antiviral effects by regulating antiviral proteins 
(induces an antiviral state) and has anti-proliferative and pro-apoptotic effects (free 
radical production and ER stress) (Figure 1. 1) (263, 299).  
 
TNFα is a pleiotropic pro-inflammatory cytokine that exists as both a soluble 
(solTNFα) and a membrane-bound (mbTNFα) form, both of which are trimers. There 
are two receptors that bind TNFα: TNFRI and TNFRII. TNFRI is ubiquitously 
expressed at a low level on most cells and is associated with most TNFα-induced 
effects (37, 298). TNFRII is more restricted in its expression, and can mainly be 
found on cells of hematopoietic origin and endothelial cells (164, 187). TNFRI binds 
to both solTNFα and mbTNFα, whereas TNFRII only has high affinity for mbTNFα, 
which resulted from the observation that TNFRII can only be fully activated by 
mbTNFα (Figure 1. 2) (120, 121).  
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In contrast to TNFRI, which can mediate pro-apoptotic pathways (Figure 1. 1 and 
Figure 1. 2), TNFRII does not possess a death domain and mainly mediates anti-
apoptotic pathways (313). mbTNFα is cleaved and released from the cell surface by 
the action of the metalloprotease TACE (TNFα convertase). The expression of TACE 
on hematopoietic cells is dependent on iRhom2, a rhomboid family member (5, 198, 
273). TNFα was first described to exhibit anti-tumour activities and conferred 
resistance to certain infections, however TNFα has multiple functions (cell activation, 
proliferation, NK stimulation and cytokine production) and a variety of different 
signalling pathways are activated by its presence (211). The best described effect of 
TNFα is the induction of apoptosis upon binding to its receptor TNFRI (Figure 1. 1 
and Figure 1. 2). TNFα induces a variety of responses like transcriptional activation, 
reactive oxygen or nitrogen radical production and activation of caspases via the 
intracellular death domain of TNFRI (142).  
 
 
 
Figure 1. 2 Interactions of TNFα with its receptors. SolTNFα preferentially binds to TNFRI 
and TNFRII has the highest affinity for mbTNFα. Binding to the different receptors induces 
different pathways. NF- κB – nuclear factor κB. Adapted from (46). 
 
 
A way to determine if cells recently de-granulated, is to analyse the surface 
expression of CD107a (lysosomal-associated membrane protein-1). CD107a is 
located on the surface of intracellular granules designated for exocytosis. Upon de-
granulation of these intracellular bodies CD107a becomes exposed on the cell 
surface until it is recycled (26). 
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1.2.1.4 The different CD4+ T cell subsets and their functions 
Naïve CD4+ T cells differentiate into various CD4+ T helper subsets after activation 
and several rounds of division. The nature of the CD4+ T cell response is dependent 
on the cytokine milieu, and differentiated CD4+ T cell subsets have different functions 
and effector or helper mechanisms. The best described subsets are Th1 and Th2 
cells, which are characterised by strong IFNγ or IL4 production, respectively. 
Whereas Th1 cells activate macrophages and drive inflammation, Th2 cells induce 
an effective humoral antibody-mediated immune response. In a viral infection, the Th 
cell response consists mainly of Th1 cells, where they are important for enhancing 
the CD8+ T cell responses and memory cell development. Throughout the years 
different other Th subsets have been described, like T follicular helper cells (Tfh) 
(specialised B helper cells), Th17 (pro-inflammatory), Th9 (possibly involved in 
defence against parasitic helminth infections), Th22 (potentially involved in skin 
homeostasis and pathology), cytotoxic CD4+ T cells (mediating direct killing) and 
induced regulatory T cells (iTreg) (immunosuppressive). Th cell subsets have a 
certain level of plasticity and can convert under special circumstances (change of 
cytokine milieu) into other Th subsets (150, 293). The different Th types are depicted 
in Figure 1. 3.  
 
 
Figure 1. 3 CD4+ T cell subsets differentiating from naïve CD4+ T cells. Due to a different 
cytokine milieu (polarising milieu) in the periphery, naïve CD4+ T cells differentiate into 
different T helper cell populations after activation. These Th cell populations secrete various 
molecules (effector mediators, mostly interleukins) thereby mediating specific effector 
functions dependent on infection or inflammation. The different transcription factors involved 
in Th cell differentiation are shown inside the cells. Adapted from (293). 
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1.2.2 Regulatory T cells 
The concept of T cell-induced suppression of immune responses was first postulated 
in the early 1970s (110, 111, 196), but due to a lack of markers to identify a specific 
cell subset, the concept of suppressor T cells was dismissed in the 70’s and 80’s 
(134, 170, 279). However, in 1995 suppresser T cells were rediscovered and given a 
new name: regulatory T cells (Tregs). Sakaguchi et al. found that CD4+ T cells, from 
which the CD4+CD25+ subset were removed, induced organ-specific autoimmunity 
after transfer into nude mice lacking endogenous T cells. These mice could be 
rescued by the transfer of additional CD4+CD25+ T cells in a dose-dependent 
manner. Furthermore, they could show that nude mice developed an immune 
response to allogenic skin transplants after the transfer of CD4+CD25- T cells, 
whereas the reaction was quashed when additional CD4+CD25+ T cells were 
transferred (254).  
 
Since then, the existence of Tregs has been widely accepted and studied in a variety 
of different models or disease. It is now established that Tregs constitute a major 
subset of immune suppressive T cells that mediate a balance between pro- and anti-
inflammatory reactions (202). The function of Tregs is essential in the prevention of 
autoimmune diseases, maintaining peripheral tolerance and protection from immune 
response-mediated tissue damage during a variety of pathological situations (163, 
202). In contrast to their beneficial role, Tregs can limit the immune responses during 
cancer or viral infections, preventing sterile immunity (202, 310, 317, 319).  
 
CD25 expression has been found to be a hallmark of Tregs (254). CD25 represents 
the IL2 receptor α (IL2Rα) chain of the high affinity IL2-receptor. It is an important 
survival factor for Tregs and other T cells, but is not actually produced by Tregs (20, 
96, 192, 261). The field of Treg biology made a great leap when the transcription 
factor forkhead box P3 (Foxp3) was discovered and determined to be the 
transcription factor regulating the development and the suppressive function of Tregs 
(95, 97, 136). For example, Foxp3 represses the expression of IL2 in Tregs and 
therefore renders them dependent on paracrine IL2 (108). Foxp3 was discovered by 
analysing the genetic defect of patients suffering from the X-linked diseases IPEX 
(immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome) or 
XLAAD (X-linked autoimmunity-allergic dysregulation syndrome) or in scurfy mice, 
  Introduction 
13 
displaying a similar phenotype of multiorgan autoimmune diseases (40, 52, 322). In 
mice, all T cells expressing Foxp3 are Tregs, whereas Foxp3 can also be a marker of 
activation in human T cells and is therefore not unique to Tregs (208, 249, 315). The 
use of CD25 and CD127 has been shown to be useful for the characterisation of 
human Tregs, as it was shown that there is a 90% correlation of Foxp3+ expression 
with CD4+CD25+CD127low T cells (185, 264). 
1.2.2.1 Treg subsets and their developmental origin 
In the following section, the different Treg subsets will be described with a focus on 
CD4+ Tregs. However, it should be noted that other regulatory cell populations do 
exist (CD8+ Tregs, γδ CD8+ T cells, NK and NKT cells, Bregs) (202). In general two 
subsets of CD4+ Tregs exist, differing in their developmental origin, specificity, 
mechanisms and dependence on TCR and co-stimulatory signalling. These are 
classified as: natural Tregs (nTreg) or induced Tregs (iTreg) (Figure 1. 4). 
 
 
 
Figure 1. 4 Developmental origin of the different Treg subsets. CD4+ T cells develop in 
the thymus and are present in the periphery as naïve CD4+ T cells. With the appropriate 
cytokine and co-stimulatory milieu provided, these naïve CD4+ T cells can then differentiate 
into various subsets of the T helper effector lineage (Th1, Th2, Th17, Tfh), into Foxp3- iTregs 
(Tr1 and Th3) and Foxp3+ iTregs. nTregs develop in the thymus and leave into the periphery 
as pre-formed Foxp3+ nTregs (76). 
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Natural Tregs 
Natural Tregs are generated in the first few days of life in the thymus as CD4+ T cells 
(254, 255) and undergo normal positive and negative selection before they are 
released into the periphery (Figure 1. 4). In the thymus, intermediate antigenic 
signals are required to generate nTregs (24, 332). In addition, co-stimulatory signals 
through CD28 might also be required for thymic selection of Tregs and peripheral 
maintenance (257). The absence of CD28 or CD80/CD86 has been shown to result 
in a substantial reduction of Tregs in lymphoid tissue or in the development of 
autoimmunity (178, 257). The antigen-specificity of these nTregs in not completely 
known, but it is presumed that they are a polyclonal population specific for multiple 
self-antigens of unknown nature (269). Furthermore, it has been shown that the TCR 
repertoire of Tregs has little overlap with the TCR repertoire of Tcon (92, 138, 229). 
nTregs survive in the periphery as a long-lived population and are important to 
maintain peripheral self-tolerance (30). Once exported into the periphery nTregs 
express high levels of CD25, CTLA-4, GITR and Foxp3 (257, 271). nTregs appear to 
conduct their suppressive mechanisms in a contact-dependent, cytokine-independent 
manner (30). 
 
Since the discovery of nTregs, there has been a great search for nTreg specific 
markers. Two markers have gained importance in recent years for the 
characterisation of mouse nTregs, Helios and Neuropilin 1 (Nrp1). Helios belongs to 
the family of Ikaros transcription factors and is expressed during thymic development 
of T cells. It is up-regulated in Tregs but not in other T cell populations outside the 
thymus (17, 126). It has also been described as a marker able to distinguish nTregs 
from iTregs (286, 301). Recently it was shown that Helios can be induced in iTregs 
and has therefore been re-classed as an activation marker rather than a marker for 
nTregs (7, 117, 309). Nrp1, which was already described as a marker for Tregs (39), 
was shown to be able to distinguish between nTregs (Nrp1+) and iTregs (Nrp1-) (320, 
331). However, the function of Nrp1 is not well understood, but it is thought to be 
involved in T cell activation and strengthens contacts between Tregs and APCs (39, 
259).  
 
Induced Tregs 
Induced Tregs are generated from naïve CD4+ T helper cells in the periphery. Both, 
effector and regulatory T cells can be generated from the same mature precursor, 
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leading to specificity for the same antigen (18, 149). It is thought that the 
development of iTregs depends on qualitative and/or quantitative differences in their 
antigen exposure (30). It was shown that some APCs are more efficient in inducing 
iTregs than others, for example skin langerin+ DCs or pDCs at mucosal sites (141, 
186). By ex vivo induction it was demonstrated that iTregs could be generated using 
antigen or polyclonal activators and immunosuppressive cytokines, like IL10 (18, 
179). It has also been shown that the frequency of Foxp3+ Tregs is higher at mucosal 
sites compared to other tissues (210, 287), which is probably due to peripheral 
induction of Tregs caused by the microbial environment (228, 281). For example 
bacteria of the genus of Clostridium or Bacillus fragilis were able to cause Foxp3 
expression in Tcon (14). 
  
Interestingly, iTregs can be induced by different routes of antigen administration, like 
intra-nasal or oral (59). Chen et al. showed that that oral tolerance was associated 
with the generation of transforming growth factor β (TGFβ) producing T cells in the 
gut. These were different from Th2 cells and were named Th3 cells (Figure 1. 4) (59). 
Groux et al. were able to show that repeated stimulation of T cells with their cognate 
antigen in vitro with high concentrations of IL10 present in the culture lead to the 
expansion of an iTreg population producing IL10. These Tr1 termed iTregs were able 
to suppress Th1 responses in vitro and in vivo (Figure 1. 4) (125, 197).  
 
The induction of virus-specific iTregs has been observed in multiple viral infections of 
humans, with many of these being chronic infections. In hepatitis C virus (HCV) 
infection Tr1 cells and Th1 cells were induced against the same core protein epitope 
(189). Additionally, virus-specific Foxp3+ Tregs were found in hepatitis C virus (HCV) 
infection (86) and similar findings were made for human immunodeficiency virus-1 
(HIV-1) infection where Foxp3-IL10+ suppressive virus-specific Tregs were found 
(304). However, virus-specific iTregs can also be induced in acute viral infections that 
are cleared. An example for this is the induction of IL10 producing Tregs (Foxp3+ and 
Foxp3-) specific for matrix-1 of influenza A virus in individuals displaying influenza-
specific immunity (233). 
 
In general, iTregs vary in their expression of CD25 and Foxp3 (Figure 1. 4) (114, 
332). Interestingly, unlike nTregs, iTregs seem to mainly use immunosuppressive 
cytokines, such as IL10 and TGFβ, for their suppressive mechanisms (15, 158, 216). 
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1.2.2.2 Mechanisms of Treg mediated suppression 
Many different mechanisms of Treg mediated suppression have been observed in 
various in vivo and in vitro models, showing overlapping mechanisms for nTregs and 
iTregs (310). Many different targets of Treg mediated suppression, including T cells, 
B cells, NK cells, DC, macrophages and osteoclasts have been described. The 
suppression can result in loss of proliferation, diminished cytotoxic potential, 
decreased cytokine production or even cell death (270). In general, the suppressive 
mechanisms of Tregs can be classed into four different categories: action via 
inhibitory cytokines, cytolysis of adjacent cells, suppression via metabolic disruption 
and inhibition of DCs, which ultimately results in the suppression of T cells. These 
mechanisms can be either contact-dependent or -independent and directly or 
indirectly suppress the effector cells (Figure 1. 5). 
 
 
Figure 1. 5 Supression mechanisms utilised by Tregs. (A) With the secretion of inhibitory 
cytokines (TGFβ, IL35 or IL10) Tregs can inhibit effector T cell function. (B) The secretion of 
cytotoxic molecules (GzmA, GzmB and perforin) by Tregs can mediate the apoptosis of 
surrounding effector T cells. (C) Metabolic disruption of effector T cells resulting in inhibition 
or cell death can be achieved by multiple mechanisms carried out by Tregs, like IL2 
consumption, production of adenosine with the help of CD39 and CD73 and cAMP transfer 
through gap junctions. (D) Tregs can also directly target DCs via different molecules (CTLA-4 
or Lag3), which results in impaired DC maturation and function and therefore in suppression 
of effector T cell functions, for example via indolamine 2,3-dioxygenase (IDO). (310) 
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The search for Treg mechanisms has shown that Tregs are able to suppress via 
different immunosuppressive molecules (Figure 1. 5 A). In allergy and asthma 
models it was demonstrated that Tregs can mediate suppression, at least in part, via 
IL10 and TGFβ (11, 133). The role of soluble TGFβ is still critically discussed, 
however there have been reports showing that membrane-tethered TGFβ plays a 
crucial role and is important for cell contact dependent mechanisms of Treg mediated 
suppression (216, 310). Another inhibitory cytokine produced by Tregs is IL35, which 
has been described to be required for their suppressive activity (71). So far it remains 
to be determined in what way IL35 acts and which cells are generally affected. 
 
It was long thought that cytolysis is only mediated by CD8+ effector T cells and NK 
cells, but recently it has been shown that CD4+ effector T cells and Tregs can also 
express Gzms (123, 182). A reduced suppressive activity was described for mouse 
Tregs in GzmB-deficient mice. This GzmB-mediated suppression appeared to be 
perforin-independent and resulted in the apoptosis of effector T cells (Figure 1. 5 B) 
(113). Strong evidence exists in tumour models for GzmB-mediated killing as an 
effector mechanism of Tregs towards NK and CD8+ T cells (6, 47). Additional 
mechanisms of cell cytolysis by Tregs have been investigated and it has been 
suggested that Tregs can induce apoptosis in a TRAIL-DR5 (TRAIL – death receptor 
5) dependent manner (242) or via galectin-1 (106).  
 
The next mechanism by which Tregs are able to suppress effector cell responses is 
by metabolic disruption (Figure 1. 5 C). It has always been a matter of debate if the 
consumption of IL2 by Tregs, through high expression of CD25 on Tregs, and 
therefore deprivation of effector T cells of this important cytokine is a mechanism of 
Treg mediated suppression (310).  
 
An interesting and newly described mechanism involving the two ecto-enzymes 
CD39 (ecto-nucleoside triphosphate diphosphohydrolase 1 or ATPase/ADPase) and 
CD73 (ecto-5’-nucleotidase) has been discovered for Tregs, which removes the pro-
inflammatory signal ATP from extracellular spaces and generates anti-inflammatory 
adenosine (Figure 1. 5 C and Figure 1. 6) (241). Mouse Tregs show co-expression of 
both enzymes and CD39 is the rate-limiting enzyme in the cascade. It converts 
immune activating extracellular ATP or ADP into AMP, which can then be used by 
CD73 to generate adenosine. Adenosine is an immune suppressive molecule and 
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binds to the A2A receptor on effector T cells, which then become suppressed 
because of elevated intracellular production of cyclic AMP (cAMP) (34, 78, 162). 
Adenosine has also been shown to modulate DC maturation and thereby favour a 
tolerogenic phenotype (243). Adenosine has a very short half-life, which makes close 
proximity necessary for effective suppression through this pathway. Interestingly, it 
has also been shown that the transfer of cAMP from Tregs through gap junctions into 
effector cells or DCs can directly inhibit these cells (Figure 1. 5 C) (33).  
 
 
Figure 1. 6 The CD39-CD73 cascade of adenosine generation and subsequent Tcon 
suppression. Tregs are able to express both ectoenzymes, CD39 and CD73. CD39 first 
metabolises ATP or ADP to AMP and in a second process CD73 generates adenosine from 
AMP. This adenosine is then able to bind to the A2A receptor (A2AR) on effector cells, which 
leads to increased intracellular cAMP levels. This activates ICER (Inducible cAMP early 
repressor) and NFAT (nuclear factor of activated T cells) driven IL2-transcription is 
abolished, thereby suppressing T cells (31). 
 
The last mechanism of Treg mediated suppression concerns the suppression by 
targeting DCs (Figure 1. 5 D). There have been reports showing that the expression 
of CTLA-4 on Tregs is important to inhibit DCs by interaction with CD80/CD86 on the 
DCs (226, 267). Tregs were also shown to induce the production of IDO by DCs 
resulting in suppression of effector T cells (91). Other studies have also shown that 
Tregs down-regulate the expression of co-stimulatory molecules on DCs rendering 
them less potent for the induction of effector T cell responses (51, 267). The CD4 
homolog Lag3, expressed on Tregs, strongly binds to MHC class II molecules and 
has also been shown to block DC maturation (139).  
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In summary, there are many possible mechanisms of Treg mediated suppression, 
which have been observed in different settings for nTregs and iTregs. It appears that 
Treg-mediated suppression depends on the disease (autoimmunity, cancer, 
pathogen encounter) and the organ affected (or experimental system). The cytokine 
milieu and other environmental factors might play a role in shaping the suppressive 
repertoire of Tregs. It is possible that Tregs act via multiple mechanisms (153). 
1.2.2.3 Regulatory T cells in viral infections 
Tregs have two potential roles during infections. Beneficially, they can limit immune 
mediated tissue damage during infection, or detrimentally, they can lead to the 
suppression of beneficial immune responses and impair pathogen clearance, aiding 
in the establishment of a chronic infection. These effects critically depend on the ratio 
of effector to regulatory T cells and pathogen abundance (Figure 1. 7) (202). In the 
following section a few examples of how Tregs influence the immune response 
during infection will be given. 
 
 
 
Figure 1. 7 Positive and negative effects of Treg-mediated suppression during 
infection. (23) 
 
 
In HCV infection virus-specific Tr1 cells were induced (189) and also nTregs were 
expanded during chronic HCV-infection (45, 285). CD4+CD25+ Tregs isolated from 
HCV-infected patients showed suppression of HCV-specific CD4+ and CD8+ T cell 
responses in vitro (32, 45, 285). The induction of iTregs and activation of nTregs 
during HCV-infection is associated with viral persistence and chronic HCV infection 
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(285). However, it has been shown that HCV-infected patients with low amounts of 
CD4+CD25+ Tregs develop an autoimmune syndrome characterised by B cell 
proliferation and autoantibody production with higher incidence (35). 
Decreased immunopathology due to Treg action could have important implications 
for protecting immune-privileged environments like the liver or the eyes. It has been 
shown that Tregs can suppress the CD8+ T cell response directed against herpes 
simplex virus-1 (HSV-1) and the removal of CD4+CD25+ Tregs improves viral 
clearance after footpad infection of mice (291). If mice were depleted for Tregs 
before infection, the subsequent infection resulted in a strong Th1 response and 
severe eye lesions (290). For this reason Tregs are likely beneficial in limiting the 
migration of pathogenic CD4+ T cells to sites of inflammation. 
Lund et al. showed that Tregs increased in vaginally HSV-2-infected mice. However, 
when the Tregs were depleted, increased viral replication was observed at epithelial 
sites and the infection was able to rapidly spread to the central nervous system 
causing paralysis and death. This was contradictious at first, but they could show that 
Treg depletion resulted in increased effector T cells, cytokines and chemokines in the 
lymph nodes of these mice. However, because of the lack of Tregs, there was a 
reduction of DC, NK and T cell recruitment to the site of infection in the mucosa, and 
the virus could replicate more efficiently, causing the fatal disease (188). In 
conclusion, by suppressing the immune response in the initial infection, Tregs 
redirect immune cells to the site of infection and help promote an antiviral immune 
response where needed.  
Similar results were obtained for the infection with respiratory syncytial virus (RSV). 
Fulton et al. demonstrated that CD4+Foxp3+ accumulate in the lung-draining 
mediastinal lymph nodes and the lung during acute RSV-infection. These Tregs 
showed an activated phenotype and Treg depletion resulted in delayed viral 
clearance, exacerbated disease severity and an early lack of CD8+ T cell recruitment 
to the lung. However, an increase in virus-specific IFNγ and TNFα producing CD8+ T 
cells was detected. This shows that Tregs play a critical role during acute pulmonary 
infections in limiting immunopathology (101).  
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1.3 Retroviruses 
Members of the retrovirus family (REverse TRanscripase Oncovirus) can be found in 
all vertebrates and are a large and diverse group of viruses. Retroviruses have a 
unique life cycle which accounts for their diverse biological activities. The discovery, 
structure and life cycle of retroviruses will be described here. 
1.3.1 Discovery of Retroviruses 
The first isolates of retroviruses, now collectively known as avian leucosis virus, were 
discovered by two investigators in 1909. Ellermann and Bang showed that chicken 
leucosis could be transmitted by a cell-free filterable agent. In 1911, Rous also 
discovered a filterable agent which was able to induce sarcoma in chickens (Rous 
sarcoma virus). Over the following decades, when cell culture techniques improved, 
further tumour-inducing viruses were discovered in mammalian species. In 1936, 
Bittner discovered the transmission of mammary carcinoma in mice through a 
filterable agent detected in milk (mouse mammary tumour virus (MMTV)). 1957. 
Gross found a leukaemia virus transmitted vertically in mice (murine leukaemia virus 
(MLV)). In the following years, more and more such tumour inducing agents were 
discovered and became important model systems for studying retroviruses. The 
hallmark of retroviruses, the reverse transcriptase (RT), an RNA-dependent DNA 
polymerase, was discovered by Baltimore in 1970.  
 
The first human retrovirus to be discovered was human T-cell leukaemia virus in 
1981. At the same time a mysterious epidemic disease of immunodeficiency 
(acquired immunodeficiency syndrome (AIDS)) arose in developed countries and 
soon after the discovery of HIV-1 was made. HIV-1 was later shown to be the 
causative agent of AIDS. (70) 
1.3.2 Taxonomy of retroviruses 
Viruses of the Retroviridae family can be subdivided into several genera. Alpha-, 
beta- and gamma- retroviruses are considered simple retroviruses, because they 
only encode the three core genes: gag (group-specific antigen), pol (polymerase) and 
env (envelope) (Figure 1. 8 A). In contrast to this delta- and epsilon-retroviruses as 
well as lenti- and spuma-viruses are considered complex retroviruses (Figure 1. 8 A). 
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Complex retroviruses encode additional gene products over the top of gag, pol and 
env. (161) 
1.3.3 Genomic organisation and virion structure of retroviruses 
The genome of retroviruses is a homodimer of linear, positive sense single-stranded 
RNA sequences (+ssRNA) with a size of 7 to 13 kilobases per molecule. The 
genome exhibits many features in common with mRNAs, like a 5’ cap and a 3’ polyA 
tail. All replication competent retroviruses contain three core genes which are 
arranged in the genome from 5’ to 3’: gag, pol and env. Gag encodes for the 
structural proteins: matrix (MA), capsid (CA) and nucleocapsid (NC). Pol encodes for 
the enzymes: protease (PR), reverse transcriptase (RT) and integrase (IN). The env 
gene encodes for the components of the envelope glycoprotein complex: surface 
glycoprotein (SU) and transmembrane (TM).  
 
In addition to the coding sequences, the retroviral genome contains a number of 
sequence blocks with different functions clustered at the terminal ends of the RNA. At 
the 5’ end these sequences are R (repeated region), U5 (unique 5’) and pbs (primer 
binding site). The U5 contains an att site required for proviral integration. The pbs is 
important for hybridisation of the tRNA for initiation of minus-strand DNA synthesis. 
This is followed by the Psi (Ψ) element, containing signals for encapsidation. Closer 
to the 5’ end of the genome, the ppt (polypurine tract, initiation of plus-strand DNA 
synthesis), U3 (unique 3’, containing cis-acting elements for viral gene expression 
and an att site) and R sequences are located.  
 
When the retroviral RNA genome is reverse transcribed the U3 and U5 regions are 
duplicated, resulting in a longer pre-integrative dsDNA compared to the RNA 
template. These extended sequence blocks consist of U3, R and U5 are called long 
terminal repeats (LTRs). The sequences for accessory and regulatory proteins, 
encoded by complex retroviruses, are situated in the pol-env-U3 region (Figure 1. 8 
A). 
 
Mature virions (Figure 1. 8 B) are spherical with a rough diameter of 100-120 nm. All 
retroviruses are enveloped and contain a lipid bilayer membrane derived from the 
membrane of the producer cell, which contains the Env glycoprotein complex. The 
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MA protein is thought to be associated with the two envelope proteins. The viral 
capsid core is formed by CA and NC coating the viral RNA (Figure 1. 8 B). (50, 161) 
 
 
 
Figure 1. 8 Genome organisation and structure of the retroviral particle. (A) The proviral 
genome of a simple (MLV) and a complex (HIV-1) retrovirus is shown. Vif, vpr, vpu, ref, tat 
and nef indicate the regulatory and accessory proteins of HIV-1. Adapted from (36). (B) This 
schematic shows the principle organisation of a retroviral particle. A lipid bilayer in which the 
env products SU and TM are anchored surrounds the capsid core. The core is formed by CA 
and encloses the viral RNA dimer to which NC is bound (70).  
 
1.3.4 The retroviral life cycle 
The retroviral life cycle (Figure 1. 9) begins with the attachment of the mature virion 
to the target cell. Interaction between the Env glycoprotein complex and its specific 
receptor on the cell surface causes conformational changes in the TM protein, 
resulting in fusion of the viral membrane with the cellular membrane, releasing the 
viral capsid core into the cytoplasm. After its entry into the cytoplasm, the viral RNA 
is reversed transcribed within the reverse transcription complex (RTC). In the RTC, 
the viral enzyme RT converts the viral RNA into the dsDNA viral genome, flanked by 
the LTRs. After synthesis of the viral DNA the complex is often referred to as a pre-
integration complex (PIC). Once the PIC has reached the nuclear periphery it must 
gain access to the host chromatin for integration to occur. Simple retroviruses require 
breakdown of the nuclear membranes to access the chromosomes, whereas 
complex retroviruses, like the lentiviruses, are able to access the nuclear 
compartment through an active mechanism. Once in the nucleus the viral dsDNA can 
be integrated into the host DNA with the help of the virally encoded IN enzyme. 
Integration into the genome is a significant feature of retrovirus biology as it leads to 
persistent viral infection despite host immune responses. 
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Once integrated, the viral genome is transcribed by the RNA polymerase II, where 
the LTRs serve as transcription initiation and termination sites. The full length 
transcribed viral RNA is exported into the cytoplasm using different transport 
mechanisms depending on the retrovirus in question. The viral RNA either serves as 
a template for translation of the Gag or Gag-Pol poly-proteins or as the genome for 
progeny virions. The Env proteins TM and SU are generated from a spliced mRNA 
by translation into the rER, glycosylation and transport through the Golgi where host 
proteases cleave Env into TM and SU, which remain in close proximity. They are 
then transported to the cell membrane. 
  
After synthesis of the viral genome and proteins the viral particles assemble at the 
plasma membrane. It should be noted that not all retroviruses assemble at the 
plasma membrane and some assemble at cytoplasmic membranes. Gag and Gag-
Pol proteins become anchored to the plasma membrane, which is stabilised by the 
interaction of the MA domain in Gag with the plasma membrane. The viral RNA is 
bound by the NC domain and becomes coated with many copies of Gag and a few 
Gag-Pol copies. The immature virion then buds from the cell membrane acquiring its 
virion membrane. The final stage of retrovirus generation is maturation. Maturation 
occurs when PR cleaves the Gag and Gag-Pol poly-proteins, resulting in a mass 
rearrangement within the core, which produces the infectious mature virus. (50) 
 
 
Figure 1. 9 Retroviral life cycle. Schematic showing the main steps in retroviral replication. 
The early stages of the retroviral life cycle are depicted in orange and the later stages in 
black. Picture kindly provided by D. J. Wight. 
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1.3.5 Endogenous Retroviruses 
Endogenous retroviruses (ERV) are derived from retroviral infections of germ line 
cells. Typically, retroviral infection is not cytolytic and therefore a daughter cell can 
inherit the integrated provirus. ERVs are usually transmitted in a stabile Mendelian 
fashion and are replicated and transcribed as cellular genes. It is estimated that up to 
30% of the sequence in mammalian genomes is of retroviral or transposable element 
origin (25). Endogenous retroviruses have colonised vertebrates at different times 
throughout history. The discovery that MLVs and endogenous MMTVs (mtv) are only 
present in some subspecies of mice indicates their origin from a recent integration 
event (167). In contrast, human endogenous retroviruses (HERVs) can be found at 
the same chromosomal location in baboons and humans, dating the origin at least 30 
million years ago, when the divergence of these species occurred (115). 
 
Even though ERVs have the same general structure as exogenous retroviruses they 
are often transcriptionally silenced, caused by heavy methylation and many 
alterations in their sequence, making them replication incompetent (25). Regardless 
of these silencing mechanisms, viral RNAs are often produced from the ERVs which 
can be packed efficiently by exogenous retroviruses. These ERV sequences can 
then alter the genome of exogenous viruses by the virtue of homologous 
recombination (161).  
 
Interestingly, some ERVs may actually provide a selective advantage to the host, for 
example by inhibiting infection with pathogenic exogenous retroviruses (25). 
Examples for this are the mouse genes Fv1 (derived from the Gag region of an 
ancient retrovirus) and Fv4 (a gp70 molecule related to SU of ecotropic viruses), 
which protect the host from infection by exogenous Friend virus (FV). Another 
example is the superantigen (Sag) gene of mtv, which results in thymic deletion of T 
cells when present in the genome, and thereby protects from MMTV-induced disease 
(25, 161). 
1.3.5.1 Endogenous retroviral superantigens 
Sags are viral or bacterial proteins that can activate T cells by crosslinking a specific 
Vβ chain of the TCR with an MHC class II molecule. This causes “clonal” stimulation 
of T cells and thus T cell activation and proliferation. Sags of bacteria are secreted 
  Introduction 
26 
upon infection as soluble proteins like the staphylococcal enterotoxins or toxic-shock-
syndrome toxins (327). Some viruses also encode Sags in their genome and the 
most prominent example is the retrovirus MMTV. MMTV initially infects B and T cells 
and uses the Sag to stimulate proliferation, which increases the pool of cellular 
targets for MMTV. However, due to its nature as a retrovirus, MMTVs have become 
incorporated into the mouse genome as defective ERVs. The Sag is encoded in the 
3’ LTR region of the virus and is still present in the integrated endogenous virus. If 
expressed in the thymus, the Sag functions as a self-antigen and causes deletion of 
reactive T cells, resulting in the depletion of certain Vβ-bearing T cells dependent on 
the mtv incorporated into the mouse genome. Different mouse strains usually contain 
a limited number of mtv Sags, which possess different specificities for Vβ chains (2, 
302, 325). 
1.4 Human Immunodeficiency Virus-1 
HIV-1 the causative agent of AIDS (acquired immunodeficiency syndrome) was 
discovered in 1983 (19, 105). It is a complex retrovirus (lentivirus) and possesses all 
components of a simple retrovirus with the addition of regulatory (Tat and Rev) and 
accessory (Nef, Vif, Vpr and Vpu) proteins. HIV-1 infects cells by binding of gp120 to 
CD4, present on CD4+ T cells, macrophages and DCs as well as by interaction with a 
co-receptor. There are two co-receptors which can potentiate infection, CXCR4 and 
CCR5. Different strains of HIV-1 can utilise these two co-receptors to varying 
degrees which is a major determinant of viral tropism. HIV-1 infection causes a long 
lasting disease characterised by a long incubation period, which is usually 
asymptomatic, and eventual progression to AIDS, if untreated (69). The routes of 
transmission are either horizontally; by sexual contacts or contact to contaminated 
blood (blood transfusion, intravenous drug use); or vertically (mother to child) (146). 
(199). 
 
The first antiretroviral drugs were developed in the nineties and given in single or 
dual combination. However, this could only control viral loads temporarily due to drug 
resistance by viral escape mutants. In the following years, the highly active 
antiretroviral therapy (HAART) a combination of three different antiretroviral drugs 
was developed. There are different antiretroviral drugs available targeting different 
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stages of the retroviral life cycle: reverse transcriptase inhibitors (nucleoside or non-
nucleoside), protease inhibitors, entry blockers and integrase inhibitors. This 
combination therapy has been shown to be more efficient in suppressing viral loads 
and reducing the levels of drug resistant HIV-1 strains in infected individuals. Some 
retroviral drugs have severe side effects, but due to the development of new drugs 
and better treatment regimes, these side effects have been greatly reduced. This 
makes HIV-1 infection a chronic but treatable disease in the western world where the 
access to HAART is available. However, due to the high costs of HAART and 
insufficient education about HIV-1 infection routes, there is still a high incidence of 
HIV-1 infection and AIDS-induced death in developing countries, with millions of new 
infections every year. (70, 199) 
1.4.1 Pathogenesis and role of the immune system 
The HIV-1 infection can be classed into three phases: the acute infection 
(asymptomatic or flu-like symptoms), the chronic stage (first asymptomatic, then non-
AIDS defining symptoms) and AIDS. The acute phase is characterised by the spread 
of the virus from the site of infection throughout the whole body, especially into the 
lymph nodes and other lymphoid organs. Massive virus production by gastro-
intestinal associated lymphoid tissue (GALT) is often observed. In the first few weeks 
a rapid decline of CD4+ T cells is observed, most pronounced in the GALT. When the 
adaptive cellular and antibody immune response starts the viral load drops 
immediately and reaches an equilibrium between viral replication and the 
suppressive immune response. However, due to limited capacity of CD4+ T cell 
renewal, the CD4+ T cell count declines gradually. This phase can last up to ten 
years, with no obvious symptoms. Eventually, the immune system becomes 
exhausted due to chronic immune activation, T cell depletion and degeneration of 
lymphoid organs. This results in opportunistic infections which cannot be controlled 
as they would in an immune-competent patient, resulting in severe diseases. Typical 
AIDS-related diseases are also various neoplasms (like Kaposi’s sarcoma). (70, 199) 
1.4.2 Regulatory T cells in HIV-1 infection  
It has been described that Tregs expand during chronic HIV-1 infection in the lymph 
nodes, GALT and the blood (206). Two hypothesises have been postulated based on 
several findings: (i) Tregs have a detrimental role in HIV-1 infection by suppressing 
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anti-viral immune responses (1, 87, 222, 321) or (ii) Tregs have a beneficial role 
during infection by limiting the generalised immune activation thereby controlling the 
repertoire of HIV-1 target cells and limiting immunopathological effects (48, 177, 184, 
207). 
 
HIV-1 can infect DCs at low levels and alter their function and maturation, which 
could lead to the induction of Tregs by immature HIV-1-infected DCs (181). It has 
been shown that iTregs from HIV-1 infected patients were able to suppress CD4+ and 
CD8+ T cell responses. Additionally, nTregs have also been shown to be involved in 
HIV-1 infection, where it has been postulated that they have a beneficial role for the 
host, as infection-induced depletion of nTregs contributed to immune activation and 
higher viral loads resulting in disease progression (251). Despite some evidence for 
Treg involvement in HIV-1 infection, the actual role of Tregs in this infection remains 
controversial. 
1.4.3 Approaches to study HIV-1 
Humans and chimpanzees are hosts for HIV-1, and for this reason either in vitro 
studies with human blood or in vivo studies with chimpanzees can be done. Although 
chimpanzees are susceptible to HIV-1 infection, the replication is greatly inhibited 
and usually there is no progression to AIDS (223, 225). Simian immunodeficiency 
virus (SIV) is very similar to HIV-1 and has been used in its natural host (sooty 
mangabeys), although the infection does not induce immune activation and 
progression to an AIDS-like syndrome is rare. However, the infection of rhesus 
macaques with SIV results in a decline of CD4+ T cells and the progression to AIDS 
(274). The downside of these in vivo models for HIV-1 infection is that they are very 
expensive with very low numbers of animals available due to ethical issues. 
Furthermore these animals are not inbred and thus there is a great level of genetic 
heterogeneity often making the results of such studies difficult to interpret. 
1.4.3.1 In vitro mucosal infection with HIV-1 
Certain steps of HIV-1 infection can be investigated in vitro. In vivo DCs can be 
infected with HIV-1 or unspecifically take up virus at the mucosal sites after initial 
encounter with the virus. The infected DCs are able to transmit HIV-1 to CD4+ T cells 
via the immunological synapse formed between DCs and CD4+ T cells. This 
mechanism is thought to have important implications for HIV pathogenesis (330). 
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With the help of in vitro co-culture between infected DCs and CD4+ T cells, these 
mechanisms can be investigated. 
1.4.3.2 Small animal models for retroviral infections 
Studies in mice are easier to realise as large numbers of these animals with a highly 
controlled and homogenous genomic background are available. Additionally, the 
immune system of mice is very well known and different congenic, transgenic and 
knockout strains are breed. Compared to bigger animal models, mice are also 
cheaper. However, mice are not susceptible to HIV-1 infection but can be infected 
with mouse retroviruses such as the Friend retrovirus (FV). 
  
An interesting prospect is the study of humanised mice that can be infected with HIV-
1 due to their humanised immune system. The most successful approach in this 
regard is the BLT (bone marrow-liver-thymus) model. Immunodeficient mice receive a 
transplant of foetal human liver and thymus under the kidney capsule. This transplant 
forms an organoid, able to mature human T cells, provided by the additional transfer 
of human hematopoietic stem cells from the same donor. In these mice, a normal 
human T and B cell system develops, which can be used to study HIV-1 infections 
(80). Unfortunately the immune system of these mice does not function normally and 
is constitutively activated. In the worst form, these mice suffer from graft-versus-host 
disease (GVHD) which eventually leads to the rejection of the transplant. Recently, 
an interesting approach was carried out where an additional knockout of CD47 was 
included for the generation of BLT humanised mice. These C57BL/6 Rag2-/- γc-/- 
CD47-/- mice do not show any signs of GVHD and were shown to be efficiently 
infected with HIV-1 with the development of virus-specific T and B cell responses 
(174). The down-side of this model, however, is that it is relatively expensive and 
time consuming to generate and care for these mice. 
 
FV induces an acute infection followed by a chronic phase in resistant C57BL/6 (B6) 
mice. This mouse system is not applicable to pathological studies of HIV-1 infection, 
although there is a high level of similarity in the T and B cell responses during HIV-1 
and FV infection. This makes it possible to use FV as a tool to study the 
immunological effects of retroviral infections. 
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1.5 The Friend Virus model for retroviral infections 
FV was originally discovered by Charlotte Friend in 1957 (100) and is an ecotropic 
gammaretrovirus complex composed of the pathogenic spleen focus forming virus 
(SFFU) and the apathogenic helper virus, the Friend murine leukaemia virus (F-
MuLV). Both retroviruses have high sequence homology. Due to major deletions in 
the env gene of SFFV it is not able to produce its own particles, therefore F-MuLV is 
necessary for the replication and packaging of the SFFV genome into viral particles 
(67). FV infects cells presenting the cationic amino acid transporter mCAT-1 
(ecotropic receptor), which is expressed on all mouse cells but hepatocytes (8, 190, 
333). During the acute infection predominantly erythroid precursors are infected, 
however other dividing cells, including lymphocytes, can also be infected (85). 
1.5.1 Pathogenesis of FV infection in mice 
F-MuLV is apathogenic in adult mice but can cause splenomegaly, anaemia and 
erythroleukaemia in new born mice that have not yet developed an effective adaptive 
immune system (100). The FV complex is able to induce a severe splenomegaly and 
lethal erythroleukaemia associated with generalised immunosuppression in 
immunocompetent susceptible adult mice (67). The initial step of FV-induced disease 
is caused by a false proliferation signal transmitted to erythroid precursors by binding 
between the SFFV gp55 envelope glycoprotein and the erythropoietin receptor. This 
causes uncontrolled expansion of erythroid precursors leading to grossly enlarged 
spleens and provides a perfect target population for further infection.  
 
The second step is the transformation phase where SFFV integrates eventually into 
specific target sites, usually the spi-1 locus (SFFV proviral integration site-1; 95% of 
FV tumour cells), which is transformation-associated. This results in enhanced 
transcription factor PU.1 levels in erythroid cells and inhibits their commitment to 
differentiation (205). At a later time point, loss of p53 (tumour suppressor gene) 
function often occurs resulting in full cell transformation (67). The disease severity in 
resistant mice is minimal, as these mice are able to mount efficient immune 
responses and eliminate transformed cells. However, they are unable to completely 
clear the infection and remain chronically infected for life (205). 
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1.5.2 Immunity to FV infection 
The development of the FV-induced disease is dependent on the initial dose of virus 
and the mouse strains’ genetic background. Mice contain several host genes that are 
responsible for susceptibility to FV infection. These host genes comprise the Friend 
virus susceptibility factors Fv (1-6) (non-immunological) and at least four genes in the 
MHC (immunological), which influence cellular and antibody mediated immune 
responses to FV infection (62). There are several genes that interfere with the 
infection (Fv1 and Fv4) and others that interfere with the immune response (Rfv1-3) 
or regulate erythroid cell proliferation and differentiation (Fv2, Fv5) (219). Fv2r 
prevents the polyclonal cell activation of erythroid progenitor cells thereby limiting 
splenomegaly, whereas Fv2s makes mice susceptible to FV-induced splenomegaly. 
The Fv2 gene encodes for the tyrosine kinase Stk/RON, which in its short form (sf-
Stk) accounts for the susceptible phenotype, whereas in resistant mice a longer form 
of Stk is present that cannot mediate the signalling from gp55 (205). The H-2D genes 
are important for effective presentation of viral T cell epitopes. For example mice 
bearing H-2Db/b have a high incidence of recovery from FV leukaemia due to efficient 
presentation of FV-epitopes. (62, 132). 
1.5.3 Immune responses during FV infection 
B6 mice (H-2Db/b, Fv-1b/b, Fv-2r/r, Rfv3r/r) are resistant to FV induced 
erythroleukaemia but develop a chronic infection, like other resistant mouse strains 
(61). All these mice carry different resistance genes which enable them to mount an 
efficient B and T cell response against the pathogen. However, when either CD4+ or 
CD8+ T cell populations are deleted during the acute infection, B6 mice are no longer 
able to control the virus and develop FV-induced disease (129, 245). It was also 
shown that B cells and virus-specific antibodies were important for recovery from FV-
disease (130). FV titres peak rapidly in the acute infection (at day 7 in B6 mice) but 
drop soon after the initial peak when the adaptive immune response, including an 
effective CTL response and development of Th1 CD4+ T cells, develops. This shows 
that an effective T cell response is important during acute FV infection. 
 
The depletion of CD4+ T during acute infection shows the importance of this T cell 
subset. CD4+ T cells provide important help for B cells and the development of 
neutralising antibody responses is vitally important for the recovery from acute FV 
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infection (63, 130). Furthermore, CD4+ T cells are important for efficient CD8+ T cell 
responses during acute infection (215). It has been shown that CD4+ T cells also 
mediate virus control during chronic FV infection., as when CD4+ T cells were 
depleted in this phase viral replication increased dramatically and leukaemia was 
induced (131, 145). It has been shown that CD4+ T cells can provide direct anti-viral 
immunity during chronic infection by secretion of IFNγ rather than offering help to 
effector B cells or CD8+ T cell (145). In contrast, the depletion of CD8+ T cells during 
this phase did not have an effect on virus infection or disease development, as CD8+ 
T cells appeared to be dysfunctional during the chronic phase of infection (131).  
 
Even though CTLs do not to play a major role in chronic infection, they are very 
important during acute FV infection, critical for recovery and at least partially 
dependent on CD4+ T cells (83, 245). CTLs kill FV-infected cells with the help of 
GzmA and B and perforin (338). Furthermore, they secrete high amounts of IFNγ, 
which has direct anti-viral activities and further boosts the cellular immune response. 
1.5.4 Regulatory T cells in FV infection 
The initial clue showing that CD8+ T cells were dysfunctional during chronic FV 
infection came from experiments in which a FV-induced tumour was transplanted into 
naïve and chronically infected mice. Naïve mice were able to mount an efficient 
immune response and reject the tumour, but chronically infected mice were not, 
despite the tumour expressing FV antigens (144). By transferring naïve CD8+ T cells 
specific to the immunodominant CTL epitope into acute or chronically infected mice, 
it was found that CD8+ T cells became dysfunctional during chronic infection, 
resulting in impaired production of GzmA and B, perforin, and IFNγ. This was not 
observed after CD8+ T cell transfer into acutely infected mice (84, 342).  
 
Studies on this dysfunction concentrated on in vitro mixed lymphocyte cultures. It 
was shown that whenever the CD8+ T cells were mixed with CD4+ T cells from 
chronically infected mice they were functionally suppressed, whereas this was not 
the case when CD4+ T cells from naïve mice were added to the culture (144). These 
findings implicated a role for a suppressive CD4+ T cell subset in chronic FV 
infection. The final proof came from an experiment were naïve mice were 
supplemented with CD4+ or CD8+ T cells from chronically FV-infected mice and then 
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challenged with FV induced tumours or unrelated tumours. Mice that had received 
CD4+ T cells were not able to reject the tumour, in contrast to mice receiving CD8+ T 
cells. These results provided evidence that Tregs could be induced during chronic 
viral infections and were involved in establishment of the chronic infection. 
Furthermore, this data also showed that the suppressive effect was not restricted to 
virus-specific cells, as the rejection of unrelated tumours was also suppressed (144). 
 
Further research showed that Tregs suppressed the production of IFNγ by CD8+ T 
cells during chronic infection, and this suppression was not restricted to the CD25+ 
Treg population, as CD25- Tregs were also suppressive (84). Interestingly, it has 
been shown that FV-induced Tregs suppress the effector functions of CD8+ T cells 
but not their proliferation and activation, and these Tregs were readily suppressive ex 
vivo without further stimulation (84). In vitro studies have shown that FV-induced 
Tregs suppress CD8+ T cells in a contact-dependent manner, independent of APCs 
and not dependent on the TCR specificity of the CD8+ T cells (248). 
 
Recently, it has been shown that Tregs expand during acute FV infection with 
elevated levels remaining present in the spleen during chronic infection (340, 341). 
Tregs gain the ability to suppress CD8+ T cell responses at two weeks post infection, 
where viral loads are still high (341). A new mouse model was engineered (DEpletion 
of REGulatory T cells /DEREG mice (172)), expressing the diphtheria-toxin receptor 
under the control of an additional Foxp3 promoter. This mouse has made it possible 
to selectively deplete Foxp3+ Tregs in the immune system. Depletion studies in 
acutely infected DEREG mice have shown that the CD8+ T cell response could be 
augmented (GzmA, GzmB, CD107a) and viral loads were reduced when Tregs were 
deleted (339, 340). Similar results of functional CD8+ T cell recovery (production of 
GzmB, IFNγ, TNFα and IL2) and decrease of viral loads due to Treg depletion were 
shown for the chronic phase of infection with FV (81). Furthermore, it has also been 
shown that Tregs were able to suppress CD4+ T cell responses, especially IFNγ 
production, in the chronic phase of FV infection (215). Although Tregs expanding 
during FV infection suppress virus-specific immune responses, the developmental 
origin and specificity of this action has not yet been determined. Furthermore, the 
mechanism(s) behind the suppressive activity of Tregs during FV infection are not 
clearly defined.  
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1.6 Aims and scope of the work 
CD4+Foxp3+ Tregs constitute a major subset of suppresser T cells. The function of 
Tregs is essential in both the prevention of autoimmune diseases in healthy 
individuals and protection from immune response-mediated tissue damage during 
viral infections. While generally beneficial, these suppressive effects can be limiting 
for anti-viral immune responses, resulting in a delayed or incomplete clearance of the 
pathogen (23). The immunosuppressive role of Tregs in virus-specific immunity was 
first described using the FV model, but has also been reported for viruses causing 
human infections such as HBV, HCV and HIV (181).  
 
The aim of this PhD project was to better define the molecular characteristics of FV-
induced Tregs. For this purpose it was of importance to determine the phenotype 
acquired by Tregs during acute and chronic FV infection by analysing the expression 
of various activation, differentiation, and proliferation markers. Furthermore, it was of 
great interest to determine the specificity and origin of the Treg population and the 
molecular mechanism of expansion during viral infection. This was especially 
important as knowledge on this topic will provide new concepts to therapeutically 
interfere with Treg cell expansion. It was also of interest to determine the mechanism 
of effector T cell suppression mediated by Tregs during acute FV infection. For this 
purpose a recently discovered Treg suppression pathway involving the enzymes 
CD73 and CD39 was investigated by performing experiments in mice deficient for 
these molecules. As a last step, the acquired knowledge about the phenotype and 
function of Tregs in a mouse retrovirus model was translated to the human infection 
with HIV-1, where Treg responses also play an important role in pathogenesis. 
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2. Material 
2.1 Microarray data 
The samples for the microarray data were prepared by Gennadiy Zelinskyy (Institute 
for Virology, University Hospital Essen, Essen, Germany) and the Microarray was 
done on an Affymetric Mouse430_2 chip by Robert Geffers (Immune Regulation 
group, Helmholtz Centre for Infection Research, Braunschweig, Germany). The 
samples for the microarray were CD4+CD25+GFP+ Tregs of DEREGtg mice (172). 
DEREGtg mice express a diphtheria toxin-green fluorescent protein (DT-GFP) fusion 
protein under the control of an additional Foxp3 promoter, which makes it possible to 
sort for live Foxp3+ Tregs (GFP+). In a first step, spleen or bone marrow cells of naïve 
or FV-infected DEREGtg mice, respectively, were enriched for CD4+CD25+ T cells 
using magnetic beads (see 3.12 for MACS isolation). The enriched CD4+CD25+ T 
cells were subsequently subject to cell sorting for GFP+ Tregs (see 3.11.1 for the 
principle of cell sorting). The RNA of these CD4+CD25+GFP+ Tregs was then isolated 
and sent to Braunschweig for microarray analysis. The Treg samples used were 
splenic Tregs from naïve mice and bone marrow Tregs from FV-infected mice (7 or 
15 days post infection (dpi)).  
2.2 Equipment and materials 
Table 2. 1 Equipment 
Equipment Manufacturer 
Accu-Jet Pro Brand, Wertheim, Germany 
Air Clean 600 PCR Workstation STARLAB, Ahrensburg, Germany 
ImmageStream Amnis 
AutoMACS Pro Miltenyi Biotec, Bergisch Gladbach, Germany 
Biofuge fresco  Heraeus, München, Germany 
CellometerTM Auto T4 Cell Counter Nexcelcom Bioscience, Lawrence, MA, USA 
Centrifuge Forma 3L GP4500 Thermo Scientific, Waltham, MA, USA 
Centrifuge 5415R Eppendorf, Hamburg, Germany 
Centrifuge Avanti J-26XPi Beckman Coulter, Krefeld, Germany 
Centrifuge Megafuge 1.0R Heraeus, München, Germany 
Centrifuge Rotina, 420 Hettich, Mülheim a.d.Ruhr, Germany 
Centrifuge Alegra X-1512 BD, San Jose, California, USA 
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Forma Series II water jacketed CO2 
incubator 
Thermo Scientific, Waltham, MA, USA 
Freezer Liebherr premium LIEBHERR, Ochsenhausen, Germany 
Freezer -80 °C Fisher Scientific, USA 
Freezer -80 °C SANYO, Germany 
Handysteps Stepper Eppendorf, Hamburg, Germany 
Heating block  Grant, QBC, Germany 
Heracell 240i CO2 Incubator  Thermo, Dreieich, Germany 
Ice machine ICE-O-Matic, Denver, CO, USA 
Ice machine MF30 Scotsman, Milan, Italy 
Infrared lamp Phillips, Amsterdam, Neatherlands 
Invertoskop Zeiss, USA 
Laminar flow  Labgard ClassII Type2A, Plymouth, MN, USA 
Laminar flow  KOJAIR®, Meckenheim, Germany 
Laminar flow Herasafe Heraeus, München, Germany 
Liquid Nitrogen Vessel Locator4 Thermo Scientific, Waltham, MA, USA 
LSRII flow cytometer, 4 Lasers Becton Dickinson, Heidelberg, Germany 
Minispin Roth, Karlsruhe, Germany 
MoFlo cell sorter Beckman Coulter, USA 
Multi-channel pipettes (50, 200, 300 µL) Eppendorf, Hamburg, Germany 
MultiStend magnet holder and magnets Miltenyi, Auburn, California, USA 
Neubauer cell counting chamber Becton Dickinson, Heidelberg, Germany 
QuadroMACS Miltenyi, Auburn, California, USA 
Reflected-light microscope CK 2 Hund, Wetzlar, Germany 
Refrigerator  LIEBHERR, Ochsenhausen, Germany 
Scales Scout Pro Ohaus, Kirchheim, Germany 
Single channel pipettes (10, 20, 100, 
200, 1000 μL) Eppendorf, Hamburg, Germany 
Sorvall centrifuge fresco Thermo, Dreieich, Germany 
Thermomixer comfort Eppendorf, Hamburg, Germany 
VortexGenie2 Scientific Industries, Bohemia, NY, USA 
Waterbath Isotemp210 Fisher Scientific, USA 
Waterbath GFL, Burgwedel, Germany 
 
Table 2. 2 Materials 
Item Manufacturer 
500 mL filter system Corning, NY, USA 
Amicon Ultra 100 MW filter tube (100 Merck Millipore, Darmstadt, Germany 
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kDa) 
Cannulae (20G; 23G; 27G) Becton Dickinson, Heidelberg, Germany 
Cell culture flasks (T25; T75; T175) Greiner bio-one, Frickenhausen, Germany 
Cell culture multi flask 75 m2 BD Bioscience, San Jose, California, USA 
Cell culture plates, sterile (6; 24; 96 well) Greiner bio-one, Frickenhausen, Germany 
Cell culture plates, sterile (6; 24; 96 well) BD Bioscience, San Jose, California, USA 
CellometerTM Auto T4 counting chamber 
Peqlab Biotechnologie GmbH, Erlangen, 
Germany 
Cell strainer (70 µm; 30 µm) Falcon BD, Heidelberg, Germany 
Cryo.STM, PP with screw cap, sterile Greiner bio-one, Frickenhausen, Germany 
Cryosystems 4000 series 
Marathon Products, San Leandro, California, 
USA  
Cryotubes Wheaton, USA 
Disposable haemocytometers Fisher Scientific, USA 
Disposable syringes (1 mL; 2 mL)  Thermo, Dreieich, Germany 
Erlenmeyer flasks  Schott, Mainz, Germany 
FACS tubes  Becton Dickinson, Heidelberg, Germany 
Forceps, pointed and curved  Oehmen, Essen, Germany 
Glassware Schott, Mainz, Germany 
LeucoseptTM Greiner bio-one, Frickenhausen, Germany 
LS separation columns Miltenyi, Auburn, California, USA 
MicrotestTM cell culture plates, 96-well BD, Heidelberg, Germany 
Nunc MaxiSorp 96-well plate Sigma-Aldrich, Steinheim, Germany 
Parafilm Laboratory film American National Can, Chicago, IL, USA 
Pipet tips (10; 20; 100; 200; 1000; 5000 
µL) 
Eppendorf, Hamburg, Germany 
Pipet tips, sterile (10; 20; 100; 200; 1000 
µL) 
STARLAB, Ahrensberg, Germany 
Plastic pipettes (sterile; 1 mL; 5 mL; 10 
mL; 25 mL) Greiner bio-one, Frickenhausen, Germany 
Plastic pipettes (sterile; 1 mL; 5 mL; 10 
mL; 25 mL) 
BD Bioscience, San Jose, California, USA 
PP screw-cap tubes (15 mL; 50 mL)  Greiner bio-one, Frickenhausen, Germany 
PP screw-cap tubes (15 mL; 50 mL)  BD Bioscience, San Jose, California, USA 
Reaction tubes (1,5 mL; 2 mL)  Eppendorf, Hamburg, Germany 
Scissors, large and small  Oehmen, Essen, Germany 
U-shaped 96-well microplates Greiner bio-one, Frickenhausen, Germany 
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2.3 Laboratory animals 
All animal experiments were performed in strict accordance with the German 
regulations of the Society for Laboratory Animal Science (GV-SOLAS) and the 
European Health Law of the Federation of Laboratory Animal Science Associations 
(FELASA). Protocols were approved by the North Rhine-Westphalia State Agency for 
Nature, Environment and Consumer Protection (LANUV). All experiments were 
performed with mice older than six weeks. The mice were kept in a pathogen-free 
environment with free access to water and standard mouse food. All mice were under 
controlled and regular examination by veterinarians of the University Hospital Essen. 
The mice used in this PhD thesis had the resistance genotype of H-2Db/b, Fv-1b/b, Fv-
2r/r, Rfv3r/r and were bred on C57BL/6 (B6) background. The exceptions are BALB/c 
mice, which are susceptible to FV-induced leukaemia and splenomegaly and were 
used to produce virus stocks in vivo, and Y10A (F1: A.BY x C57BL/10A) mice, which 
are also susceptible to FV and were used to titrate the virus stocks. 
2.3.1 Wild type mice 
BALB/c Harlan Winkelmann GmbH, Borchen, Germany, 
Resistance genotype: H-2Dd/d, FV-2s/s 
 
C57BL/6 (B6)  Harlan Winkelmann GmbH, Borchen, Germany  
    Resistance genotype: H-2Db/b, FV-2r/r 
 
F1: A.BY x C57BL/10A Bred at the Animal Facility, University Hospital Essen, 
(Y10A)    Germany, Resistance genotype: H-2Da/b, FV-2r/s 
2.3.2 Congenic mice 
CD45.1-congenic B6 Genotype: B6.SJL-PtprcaPep3b/BoyJ; Inbred at Central 
Animal Facility, University Hospital Essen, Germany 
2.3.3 Knockout and transgenic mice 
CD8-/- (CD8 deficient) Mice deficient for CD8+ T cells because of a targeted 
disruption in exon 1 of the lyt-2 gene (102). Inbred at the 
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Central Animal Facility, University Hospital Essen, 
Germany. 
 
CD39-/- (CD39-KO) Mice with a targeted disruption of exon 1 in the 
ectonucleotide triphosphate diphosphohydrolase (entpd1) 
gene, which leads to a shorter transcript of the gene and 
no detectable function of the enzymatic protein product 
CD39. Mice were kindly provided by Verena Jendrossek 
(Institute for Cell Biology, University Hospital Essen, 
Germany). MTA: Simon C. Robson (Department of 
Medicine, Beth Israel Deaconess Medical Center, Harvard 
Medical School, Boston, MA, USA) (88). Inbred at the 
Central Animal Facility, University Hospital Essen, 
Germany. 
 
CD73-/- (CD73-KO) Mice with a targeted disruption of exon 3 in the ecto-5’ 
nucleotidase (nt5e) gene, which leads to a shorter 
transcript of the gene and no detectable function of the 
enzymatic protein product CD73. Mice were kindly 
provided by Verena Jendrossek (Institute for Cell Biology, 
University Hospital Essen, Germany). MTA: Linda 
Thompson (Oklahoma Medical Research Foundation, 
Oklahoma City, OK, USA) (300). Inbred at the Central 
Animal Facility, University Hospital Essen, Germany. 
 
Evα3 Mice are doubly transgenic for the TCRα and the TCRβ 
chains of the Env122-141-specific CD4+ T cell clone H18 
(336). Mice were kindly provided by George Kassiotis 
(National Institute for Medical Research, London, UK). 
Inbred at the Central Animal Facility, University Hospital 
Essen, Germany. 
 
GzmB-/- (GzmB-KO) Mice deficient for GzmB due to a targeted disruption of 
the gzmB gene (135). Inbred at the Central Animal 
Facility, University Hospital Essen, Germany. 
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iRhom2-/- (iRhom2-KO) Mice with a deletion of the exons 4-to-15 in the Rhbdf2 
gene encoding iRhom2, a member of the rhomboid 
protein family. iRhom2 regulates the maturation of TACE, 
which in turn controls the shedding of TNFα. Mice were 
kindly provided by Phillip Lang (Department of 
Gastroenterology, Hepatology and Infectious Diseases, 
Heinrich-Heine-University Düsseldorf, Germany) (198). 
Inbred at the Central Animal Facility, University Hospital 
Essen, Germany. 
 
JH-mice Mice lacking mature B cells because of a deficiency in the 
antibody heavy chain Jh gene. Mice were kindly provided 
by Karl Lang (Institute for Immunology, University Hospital 
Essen, Germany) (53). 
 
muMT-mice (µMT) Mice lacking mature B cells due to a targeted disruption of 
the µM gene (exon 1 and 2) and the δ gene (constant 
region, exon 1 to 3). Mice were kindly provided by George 
Kassiotis (National Institute for Medical Research, 
London, UK) (Kitamura et al., 1991). 
 
Nur77-GFP Mice expressing GFP from the nr4a1 (Nur77) gene. GFP 
signal indicates the strength of TCR stimulation (204). 
Mice were kindly provided by Hans Christian Probst 
(University Medical Center, Institute for Immunology, 
Johannes Gutenberg University Mainz, Germany). 
  
TCRtg CD8 TCR transgenic mice specific for the DbGagL FV 
epitope (55). Inbred at Central Animal Facility, University 
Hospital Essen, Germany. 
 
TNFRI-/- Mice were generated by disrupting the coding sequence 
at base pair 535 of the tnfrsf1a gene (231). Mice were 
kindly provided by Karl Lang (Institute for Immunology, 
University Hospital Essen, Germany). 
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TNFRII-/- Mice were generated by targeted disruption of the second 
exon in the tnfrsf1b gene (90). Mice were kindly provided 
by Daniela Männel (Institute for Immunology, University of 
Regensburg, Germany). 
 
TNFRI+II-/- Mice deficient for both TNFRI and TNFRII, generated by 
homozygote breeding of TNFRI-/- and TNFRII-/- mice. Mice 
were kindly provided by Percy Knolle (Institutes for 
Molecular Medicine and Experimental Immunology, 
University of Bonn, Germany). Inbred at Central Animal 
Facility, University Hospital Essen, Germany. 
 
2.4 Chemicals and media 
Chemicals, buffers and media were purchased from Applichem, Invitrogen, Merck, 
Roth and Sigma-Aldrich unless otherwise stated. 
 
3-amino-9-ethylcarbazole (AEC), 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES), 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-gal), adenosine 5’-
(α,β-methylene)diphosphate (AMPCP), acetic acid, autoMACS run and wash buffer 
(Miltenyi Biotec), β-mercaptoethanol (β-ME), bovine serum albumin (BSA), brefeldin 
A (BFA), calcium chloride, dextran, dimethyl sulfoxid (DMSO), disodium hydrogen 
phosphate, Dulbecco´s modified Eagle medium (DMEM) (Gibco) and DMEM high 
glucose (Gibco), ethanol, ethylendiaminetetraacetic acid (EDTA), FACS Clean (BD 
Bioscience), FACS Flow (BD Bioscience), FACS Rinse (BD Bioscience), foetal calve 
serum (FCS) (Biochrom), Ficoll (GE Healthcare), 37 % formaldehyde, formalin, 
FuGENE® transfection reagent (Promega), glucose, hydrogen peroxide (H2O2), 
incidine 8%, isopropanol, L-Glutamine,  magnesium chloride (MgCl2), N-N-
dimethylformamid, penicillin-streptomycin (PenStrep), phosphate buffered saline 
(PBS) (Gibco), picric acid, polybrene A, potassium ferricyanide, potassium 
ferrocyanide, RPMI-1640-Media (Gibco), saponin, sodium carbonate, sodium 
acetate, sodium azide (NaN3), sodium pyruvate, trypan blue, trypsin-EDTA. 
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2.5 Buffer and supplemented cell culture media 
If not stated otherwise all buffer and media were prepared using bi-distilled H2O. 
 
Table 2. 3 Buffers and Media 
Name Ingredients 
AEC working solution 
AEC stock solution was prepared 1:20 in 0.05 M 
sodium acetate and the reaction was started by 
addition of 0.5 µL of 30 % H2O2 per 1 mL of solution. 
AEC stock solution (4 mg/mL) 
20 AEC tablets were solubilised in 100 mL N-N-
dimethylformamid 
Boulin´s solution 
75 mL picric acid, 25 mL 40% formalin, 5 mL acetic 
acid 
Coating buffer for in vitro cell 
stimulation 
0.05 M sodium carbonate pH 9.6 
Complete DMEM for cell lines 
DMEM supplemented with 10 % FCS and 1 % 
PenStrep, sterile filtered if needed 
Complete DMEM for HIV-1 and 
SIVmac-VLP stock production 
DMEM supplemented with 10 % FCS, 1 % PenStrep 
and 50 mM HEPES, sterile filtered 
Complete RPMI for primary cells 
RPMI supplemented with 10 % FCS and 1 % 
PenStrep, sterile filtered if needed 
DC media for human cells 
Complete RPMI supplemented with 500 U/mL hrIL4 
and 1000 U/mL hrGM-CSF, sterile filtered 
DC media for mouse cells 
100 mL RPMI with 10 % FCS, 50 µM β-ME, 4 mM L-
Glutamine, 1 mM sodium pyruvate, 1 % PenStrep, 
supplemented with 1 ng/mL mrIL4 and 5 ng/mL 
mrGM-CSF (both cytokines from cell culture 
supernatant) 
FACS buffer PBS supplemented with 0.1 % BSA and 0.02 % NaN3 
Freezing media FCS supplemented with 10 % DMSO 
HIV-1 titration staining solution 
0.5 mg/mL X-Gal, 4 mM potassium ferrocyanide, 4 
mM potassium ferricyanide, 2 mM MgCl2 in PBS 
MACS buffer PBS supplemented with 0.5 % BSA and 2 mM EDTA 
PBBS 1 L PBS with 1 g glucose 
Sorting buffer PBS with 10 % FCS and 5 mM HEPES 
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2.6 Antibodies and staining reagents 
2.6.1 Characteristics of fluorophores 
 
Table 2. 4 Characteristics of fluorophores 
Dye Full name 
Laser used Emission 
for excitation in nm 
FITC Fluorescein isothiocyanate 525 
AF488 Alexa flour 488 519 
GFP Green fluorescent protein Blue 395/475 
PE Phycoerythrin Laser 575 
PerCP Peridinin-chlorophyll  488nm 675 
PE-Cy5 PE-cyanine5 670 
PE-Cy5.5 PE-cyanine5.5 690 
PerCP-Cy5.5 PerCP-cyanine5.5 690 
PE-Cy7 PE-cyanine7 775 
APC Allophycocyanin 660 
AF647 Alexa flour 647 Red 647 
AF680 Alexa flour 680 Laser 680 
AF700 Alexa flour 700 633nm 723 
APC-Cy7 APC-cyanine7 774 
eF780 eflour780 780 
LD Blue Live/Dead Blue UV Laser 355nm 450 
eF450 eFlour450 450 
Pacblue Pacific Blue Violet 455 
BV421 Brilliant violet 421 Laser 421 
BV605 Brilliant violet 605 405nm 605 
eF650 eFlour650 650 
BV650 Brilliant violet 650 650 
 
 
 
 
  Material 
44 
2.6.2 Antibodies 
Anti-mouse and anti-human antibodies were purchased from eBioscience 
(Affymetrix), BD Bioscience or BioLegend unless otherwise stated. 
2.6.2.1 Mouse reactive antibodies 
Table 2. 5 List of antibodies utilised for staining of mouse cells 
Antibody Conjugate Clone 
AB720 (α-MuLV Env, Isotype 
IgG2b)* Cell culture supernatant - 
BrdU FITC B44 
CD3 purified 145-2C11 
CD4 AF700 RM4-5 
CD8 eF450 53-6.7 
CD11a PE M17/4 
CD11b (Mac1) FITC,  M1/70 
CD25 PerCP, PE-Cy7, APC PC61.5 
CD28 purified 37.51 
CD39 PE Cy5 24DMSI 
CD43 PerCP 1B11 
CD44 FITC, APC IM7 
CD45.1 PE, PE-Cy7, APC A20 
CD62L PE-Cy7 MEL-14 
CD69 FITC, PE H1.2F3 
CD73 PE Cy7 Ty/11.8 
CD103 PE 2E7 
CD107a FITC ID4B 
CD127 eF450 AFR34 
CD152 (CTLA-4) PE UC10-4F10-11 
CD223 (Lag3) PE eBioC9B7W 
Foxp3 FITC, eF450 FJK-16S 
GITR PE DTA-1 
goat-α-mouse Ig HRP** HRP - 
GzmB APC GB11 
Helios PacificBlue 22F6 
ICOS (CD278) PerCP 7E.17G9 
IFN-gamma FITC, APC XMG1.2 
IL2 PE JES6-5H4 
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Ki67 PE-Cy7 B56 
KLRGI APC 2F1 
Nrp-1*** APC 761705 
PD-1 (CD279) PE J43 
PD-L1 (CD274) PerCP MIH5 
TCR-Vβ5 PE, PerCP Cy5.5, biotin MR9-4 
Tetramer I PE - 
Tetramer II APC -  
TIM3 APC 8B.2C12 
TNFRI (CD120a) PE 55R-286 
TNFRII (CD120b)*** APC FAB 
TNFα PE-Cy7, APC MP6-XT22 
* own production, ** Dako, *** R&D Systems 
2.6.2.2 Human reactive antibodies 
Table 2. 6 List of antibodies utilised for staining of human cells 
Antibody Conjugate Clone Application 
Concentration 
per 1x106 cells 
CD3 PerCP-Cy5.5 SK7 FACS 5 µL 
CD3 Unconjugated HIT3a Stimulation 5 µL per 0.5 mL 
CD4 AF700 RPA-T4 FACS 0.5-1 µL 
CD8 AF488 RPA-T8 Sort 5 µL per 0.5 mL 
CD19 AF700 HIB19 FACS 0.5-5 µL 
CD25 BV785 BC96 Amnis 5 µL 
CD25 APC M-A251 Sort 5 µL per 0.5 mL 
CD25 APC-H7 M-A251 FACS 4 µL 
CD127* PE R34.34 Sort 5 µL per 0.5 mL 
CD127 eF450 RDR5 FACS 10 µL 
CTLA-4* Unconjugated BNI3 Block 10 µg/ml 
Foxp3 PE PCH101 FACS 5 µL 
HLA-DR BV570 L243 Amnis 10 µL 
KLRGI** FITC - FACS 1 µL 
TGF-β Unconjugated TW4-2F8 Block 10 µg/mL 
TNFRII*** APC FAB226A FACS 5 µL 
hIgG - - Block 1:50 in 25 µL 
Normal rat serum - - Block 1:25 in 50 µL 
* Beckman Coulter; ** Kindly provided by Hanspeter Pircher (Institute for 
Immunology, University Hospital Freiburg, Germany); *** R&D Systems 
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2.6.2.3 MHC tetramers and F-MuLV specific peptide 
MHC I tetramer  
PE labelled MHC class-I H-2Db tetramer loaded with the peptide AbuAbuLAbuLTVFL 
(DbGagL tetramer, FV gagCD8+ epitope gPr80gag85-93) recognised by DbGagL-
specific CD8+ T cells (9, 55, 262, 283). The MHC class-I tetramer was purchased 
from Beckman and Coulter (Krefeld, Germany) or MBL International Corporation 
(Woburn, MA, USA). 
MHC II tetramer 
APC labelled MHC class-II I-Ab tetramer loaded with F-MuLV Env fn20 peptide 
DEPLTSLTPRCNTAWNRLKL (F-MuLV Env CD4+ T cell epitope Env122-141) (272). 
The MHC class-II tetramer was provided by the NIH Tetramer Facility (Emory 
University, Atlanta, USA). 
CD8 peptide 
The F-MuLV CD8+ T cell peptide was synthesised by PAN Tecs (Tübingen, 
Germany) and reconstituted in 100 % sterile DMSO. Peptide name: FMR-H-2Db 
GagL CD8 epitope. Sequence: AbuAbuLAbuLTVFL (262). 
2.6.3 Discrimination of dead cells 
To discriminate dead from live cells, either Live/Dead aqua or fixable viability dye 
(FVD) eF780 were used. 
2.6.4 Staining reagents 
Table 2. 7 Staining reagents 
Staining Reagent Manufacturer Application Concentration  
      per 1x106 cells 
FVD eF780 eBioscience FACS 1 µL 
Live/death aqua Invitrogen FACS 2.5 µL of a 1:10 dilution 
Phalloidin-APC Invitrogen Amnis 1 µL 
Violet tracer Invitrogen Amnis 0.5 µg 
  Material 
47 
2.7 Biological reagents and cytokines 
Biological reagents and cytokines were purchased at Peprotech, unless otherwise 
stated (hr: human recombinant): hrGM-CSF (granulocyte macrophage colony-
stimulating factor), hrIL4 (interleukin 4), 2’,5’-DiDeoxyadenosine (ddADA). 
 
Human soluble wild type trimetric single chain (sc) TNFα (solTNFα) (169) was kindly 
provided by Peter Scheurich (Institute for Cell Biology and Immunology, University 
Stuttgart, Germany). The trimetric single chain TNFα was engineered by using a 
single chain cassette in which three TNFα domains were genetically liked by short 
peptide linkers (structure: TNFα-linker-TNFα-linker-TNFα). The solTNFα was 
produced by transfecting 293T cells with the TNFα-linker-construct and harvesting 
the cell culture supernatant. The supernatant was then tested for biological activity 
using an NF-κB activation reporter assay using hrTNFα as a control. The material 
was kindly provided by Khanh Le (Institute for Virology, University Hospital Essen, 
Germany)). In the stock used for this study, 15 µL of cell culture supernatant 
(containing solTNFα) was equal to 10 ng/mL hrTNFα. 100 µL cell culture supernatant 
was used to treat mice i.p.. 
 
Complexed TNF (compTNFα, construct: scTNF80(mu)-Flag-TNC), simulating the 
membrane-bound form of TNFα, was kindly provided by Harald Wajant (Division of 
Molecular Internal Medicine, Department of Internal Medicine II, University Hospital 
Würzburg, Germany). To permit self-assembly of three scTNFα, the trimeric scTNFα-
construct was further engineered by linking the cassette N-terminally with the FLAG-
tagged trimerisation domain of chicken tenascin-C (TNC) (scTNFα-Flag-TNC), which 
creates a TNFα nonamer. Furthermore, to make the scTNFα-Flag-TNC more 
specific, mutations which render TNFα specific to TNFRII and not TNFRI were 
introduced, creating the scTNF80-Flag-TNC. This has been described for human 
compTNFα (scTNF80(hu)-Flag-TNC) (240) and for mouse compTNFα 
(scTNF80(mu)-Flag-TNC) (Harald Wajant, unpublished data). The mouse compTNFα 
was utilised in this study. 
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2.8 Standard kits 
Table 2. 8 Standard kits 
Kit Manufacturer 
α-CD3/α-CD28 human or mouse T cell 
stimulation dynabeads 
Invitrogen, Grand Island, NY, USA 
Cytofix/cytoperm intracellular staining kit BD Pharmingen, Heidelberg, Germany 
FITC BrdU Flow kit BD Pharmingen, Heidelberg, Germany 
Foxp3 staining set eBioscience, San Diego, USA 
Human CD14 MicroBeads Miltenyi, Auburn, California, USA 
Human CD4+CD25+ Treg isolation kit Miltenyi, Auburn, California, USA 
Mouse CD4+ T cell isolation kit II 
Miltenyi Biotec, Bergisch Gladbach, 
Germany 
Mouse CD8α (Ly-2) MicroBeads Miltenyi Biotec, Bergisch Gladbach, 
Germany 
Reverse Transcriptase Assay, colorimetric Roche, Basel, Switzerland 
2.9 Cell lines and viruses 
2.9.1 Friend retrovirus complex 
Preparations of FV were obtained from mice infected with the replication competent 
FV complex (see 3.6.1). The FV complex stock contains B-tropic F-MuLV and 
polycythemia-inducing SFFV (62). Two different virus stocks were used: one 
containing only the FV complex (246), for acute infections; and the other containing 
additionally lactate dehydrogenase-elevating virus (LDV), for chronic infections. The 
addition of LDV enables a more stable chronic infection with the FV to be established 
(246). Unless otherwise stated the FV stock without LDV was used. 
2.9.2 HIV-1 JRFL-iGFP 
CCR5-tropic HIV-1 JRFL-iGFP was kindly provided by Benjamin Chen (Mount Sinai 
Medical School, NY, USA (54)). This construct contains a GFP inserted internally into 
Gag between MA and CA and is a variant of an NL4-3-based molecular HIV-1 clone 
(140). For the construct used here the env gene from NL4-3 was replaced with the 
corresponding sequence of JRFL.  
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2.9.3 SIVmac-VLPs 
SIVmac-VLPs were kindly provided by Andrea Cimareli (Ecole Normale Supérieure, 
Lyon, France (118)). These SIVmac-VLPs were synthesised by transfection of the two 
constructs pSIV3 and pVSVg into 293T cells. 
2.9.4 pAdVAntageTM 
pAdVAntageTM vector was used in co-transfections of mammalian cells to enhance 
transient protein expression in 293T cells (Promega). 
2.9.5 Cell lines 
Table 2. 9 Cell lines 
Cell line Source 
AB720-
hybridoma 
Hybridoma cell line produces the monoclonal IgG2b α-MuLV Env antibody 
(244). 
293T Human embryonic kidney cell line (268). 
Mus dunni Murine fibroblast cell line susceptible to infection with FV (173). 
NIH 3T3-GM-
CSF 
Cell line producing mouse GM-CSF (Thomas Blankenstein, Institute for 
Immunology, FU Berlin, Germany). 
NIH 3T3-IL4 
Cell line producing mouse IL4 (kindly provided by Dr. Schmitt, Vienna, 
Austria) 
PK136 
Hybridoma cell line PK136 produces the monoclonal mouse-IgG2a α-
mouse-α-NK1.1 antibody (165). Supernatant was used to deplete NK and 
NKT cells via i.p. injection. 
TZM-bl 
(JC.53bl-13) 
HeLa cell line engineered to express CD4, CXCR4 and CCR5 and a Tat-
inducible Luc and Escherichia coli β-galactosidase reporter gene (235). 
YTS 169.4.2.1 
Hybridoma cell line YTS 169.4.2.1 produces the monoclonal rat-IgG2b α-
mouse-α-CD8 (Lyt-2) antibody (68). Supernatant was used to deplete 
CD8+ T cells in mice by i.p. injection. 
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2.9.6 Depletion antibodies 
CD8+ T cell depletion antibody  Clone 169.4.2.1, produced by YTS 169.4.2.1 
hybridoma cell line. 
NK1.1 depletion antibody  Clone PK136, produced by PK136 
hybridoma cell line. 
TCR-Vβ5 depletion antibody  Clone MR9-4, custom LEAF purified, 
(BioLegend, London, UK). 
2.10 Human samples 
2.10.1 Healthy volunteers 
Blood samples came from healthy HIV-negative individuals recruited by the Hoxworth 
Blood Center (Cincinnati, OH). The samples were not collected for research 
purposes and no identifier was provided, thus the University of Cincinnati Institutional 
Review Board (IRB) has determined this activity to be exempted from IRB review and 
surveillance. These samples were used for in vitro cell culture studies described 
later. Additionally, age- and sex-matched healthy controls were enrolled to provide a 
control group for the comparison to HIV-1 infected study subjects. 
2.10.2 HIV-1 infected volunteers 
Eight untreated HIV-1 infected individuals were enrolled in this study. All patients 
were part of a clinical trial for treatment with tenofovir/emitricitabine (RT-inhibitor) 
300/200 mg tablets and lopinavir/ritonavir (protease inhibitor) 400/100 mg tablets, 
twice daily. None of the patients had opportunistic infections or cancer at enrolment. 
All patients were either untreated or had not received treatment for six months prior 
to the initial blood collection. Blood samples were drawn at various times after the 
initiation of treatment and an initial sample was drawn before treatment. 
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3. Methods 
3.1 Evaluation of the microarray data 
The initial evaluation of the microarray data was performed by Robert Geffers 
(Immune Regulation group, Helmholtz Centre for Infection Research, Braunschweig, 
Germany) and subsequent analysis was performed on the excel files produced. For 
certain markers of interest the absolute values of detection were used to calculate 
the fold changes from naïve to 7 dpi, naïve to 15 dpi and 7 dpi to 15 dpi Treg 
samples. Furthermore, only absolute values that showed a significant signal-to-noise 
ratio were chosen for analysis. When markers were used where more than one 
primer set was available, the mean fold change was calculated. 
3.2 Cell counting 
To count cells, an aliquot of the cell suspension was mixed with 0.4 % trypan blue. 
Dead cells are more permeable than live cells to trypan blue and these cells stain 
blue. An appropriate dilution was chosen to count the cells and only live cells were 
counted for the determination of cell numbers. The cells were counted using either: a 
disposable haemocytometer, a CellometerTM Auto T4 counting chamber or a 
Neubauer counting chamber. The counting was done using a light microscope 
(haemocytometer and Neubauer chamber) or the CellometerTM Auto T4 cell counter 
with the appropriate settings. The Cellometer automatically displayed the absolute 
cell count and dead cells were excluded. For manual cell counting the cell number 
was determined by counting four squares of a big 16-square field in the chamber. 
The absolute cell number was then calculated by multiplying the average cell count 
with the chamber factor (1x104), the dilution applied to the sample and the volume of 
the cell suspension. 
3.3 Preparation of cells for storage 
Cells were spun at 520 xg for 7 min at 4 °C and the supernatant was discarded and 
replaced with the appropriate amount of ice-cold cell freezing media (FCS 
supplemented with 10% DMSO). Cells were then transferred into pre-cooled liquid 
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nitrogen screw-cap tubes and stored for a minimum of 24 hours (to a maximum of 
one week) in an IPA bath at -80 °C. The frozen cells were then transferred into a 
liquid nitrogen tank and stored until use. 
3.4 Re-constitution of cells from storage 
To thaw cells an aliquot was taken out of the liquid nitrogen and quickly thawed in a 
37 °C water bath until almost fully thawed. To prevent damage to the cells by DMSO, 
the cells were diluted in four times the volume of FCS and spun at 520 xg for 7 min at 
4 °C. The cells were re-suspended in media or PBS according to the down-stream 
procedure used, counted and/or directly put into culture dishes.  
3.5 Cell culture of cell lines 
Adherent cells were grown in a monolayer using the appropriate culture medium, 
usually complete DMEM, which at minimum contains 10 % FCS and 1 % PenStrep. 
All cells lines were maintained at 37 °C and 5 % CO2 and checked regularly. 
Depending on the cell line, the cells were passaged as soon as they grew to ~95% 
confluence. To passage cells, the medium was discarded and cells were washed 
once with PBS. Trypsin-EDTA (3 mL) was then added and the cells checked 
frequently for their morphology under a light microscope. When the cells appeared 
round they were carefully re-suspended in 7 mL of complete cell culture media to 
inhibit the trypsin. To wash the cells, they were transferred into a 50 mL tube and 
centrifuged at 520 xg for 7 min. Cells were then counted (if required) and seeded into 
a fresh tissue culture flask followed by incubation at 37 °C and 5 % CO2 until ready 
for use. 
3.6 Virus preparation and titre determination 
3.6.1 FV stock 
3.6.1.1 In vivo production of a FV stock 
To obtain a FV stock, susceptible BALB/c mice were infected intra venous (i.v.) with 
3,000 spleen focus forming units (SFFU) of FV. Nine dpi the mice were sacrificed 
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and the spleens removed. A 15 % spleen homogenate was prepared in PBBS with 1 
mM EDTA. The homogenate was then aliquoted and stored at -80°C until use. 
3.6.1.2 Titre determination of a FV stock 
Titration of a FV stock was done by infecting Y10A mice i.v. with different amounts of 
virus stock. The spleens were removed 14 dpi. During the course of FV infection, 
malignant cell populations develop on the surface of the spleen. These foci can be 
visualised by incubation of the whole spleens in Boulin´s solution which enhances the 
visual contrast of foci on the spleen surface. SFFUs can be determined by counting 
these foci. 
3.6.2 HIV-1 stock 
3.6.2.1 Preparation of an HIV-1 JRFL-iGFP virus stock 
293T cells were harvested and seeded at a concentration of 1x105 cells per well of a 
24-well plate. At 50 % confluence, the cells were transfected with the HIV-1 JRFL-
iGFP plasmid. For transfection the following mixture was prepared with the reagents 
added in the order they appear in the list. 
 
Table 3. 1 Transfection mix for HIV-1 JRFL-iGFP virus synthesis 
Reagent Volume 
DMEM serum-free 45.205 µL 
FuGENE® 3.375 µL 
1 µg HIV-1 JRFL-iGFP  
[700 ng/µL] 
1.4 µL 
0.125 µg pAdVAntageTM vector 
[5836 ng/µL] 
0.02 µL 
Final volume 50 µL 
 
 
The mixture was incubated for 15 min at room temperature and 50 µL were then 
added drop by drop to each well of the 24-well plate. The cells were then incubated 
for the next three days at 37 °C and 5 % CO2. To harvest the virus, the supernatant 
was collected three days later and centrifuged at 600 xg for 7 min at 4 °C to clear any 
cell debris. The virus containing supernatant was concentrated using Amicon Ultra 
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100 MW filter tubes. For this the supernatant was added to the upper chamber of the 
tube and centrifuged at 4000 xg for 10 to 20 min at 4 °C. This step was repeated until 
the whole supernatant containing the virus was concentrated. The virus preparation 
was then aliquoted into 20 to 50 µL aliquots and stored at -20 °C until use.  
3.6.2.2 Titration of an HIV-1 JRFL-iGFP virus stock 
To titrate the virus, TZM-bl cells were harvested and seeded into 12 wells of a 96-
well plate at a concentration of 1x104 cells per 200 µL complete DMEM. The cells 
were left to incubate at 37 °C and 5% CO2 until they were 50-60 % confluent. An 
aliquot of the frozen HIV-1 JRFL-iGFP virus stock was thawed and a 5-fold dilution 
series (1:5-to-1:3125) was prepared in complete DMEM with additional 2 µg/mL 
dextran in each tube. The media was removed from the cells and replaced by 50 µL 
of the virus dilutions. All infections were performed in duplicates. As a negative 
control, two wells were challenged with complete DMEM and dextran. The cells were 
incubated with the virus for 1 hour in the incubator and an additional 50 µL of 
complete DMEM was added to each well followed by incubation for another two days 
under the same conditions. After two days the supernatant was removed and the 
cells were rinsed with PBS. The fixation was carried out with 2 % formaldehyde for 
20 min at 4 °C followed by two washes with PBS. To stain the cells 100 µL of HIV-1 
titration staining solution (0.5 mg/mL X-gal, 4 mM potassium ferrocyanide, 4 mM 
potassium ferricyanide, 2 mM MgCl2 in PBS) was added to each well and left to 
incubate for 2 hours at 37 °C and 5% CO2. To determine the virus concentration the 
number of blue cells were counted in each well using a light microscope. The mean 
number of blue cells for each virus dilution was calculated and multiplied by the 
dilution factor. The calculated values indicate the number of infectious viral particles 
per 1 µL.  
3.6.3 SIVmac-VLP stock 
3.6.3.1 Preparation of an SIVmac-VLP stock 
To prepare SIVmac-VLPs, 1x105 293T cells were seeded per well of a 24-well plate in 
complete DMEM. The cells were left to grow until the wells were 70 to 80 % 
confluent. Cells were transfected with pSIV3 and pVSVg plasmids for SIVmac-VLP 
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production. For transfection the following mixture was prepared and the reagents 
were added in the order they appear in the list. 
 
Table 3. 2 Transfection mix for SIVmac-VLP synthesis 
Reagent Volume 
DMEM serum-free 46.117 µL 
FuGENE® 3.375 µL 
0.67 μg pSIV3  
[1635 ng/µL] 
0.4 µL 
0.33 μg pVSVg  
[4336 ng/µL] 
0.08 µL 
0.125 µg pAdVAntageTM vector 
[5836 ng/µL] 
0.028 µL 
Final volume 50 µL 
 
 
The mixture was then incubated for 15 min at room temperature and 50 µL were 
added drop by drop to each well of the 293T cells. The cells were then incubated for 
the next three days at 37 °C and 5 % CO2. To harvest the SIVmac-VLPs, the 
supernatant was collected and centrifuged at 600 xg for 7 min at 4 °C to clear any 
cell debris. The virus containing supernatant was concentrated using Amicon Ultra 
100 MW filter tubes. For this the supernatant was added to the upper chamber of the 
tube and centrifuged at 4000 xg for 10 to 20 min at 4 °C. This step was repeated until 
the whole supernatant containing virus was concentrated. The SIVmac-VLP solution 
was then aliquoted into 20 to 50 µL aliquots and stored at -20 °C.  
3.6.3.2 Determination of the RT activity of an SIVmac-VLP stock 
The titration of the SIVmac-VLPs was done using the colorimetric reverse 
transcriptase assay (Roche Applied Science) and carried out according to the 
manufacturer’s protocol. In principle, this assay uses the ability of the RT (of the 
SIVmac-VLPs) to synthesise DNA from a hybrid poly (A) x oligo (dT)15 as primer and 
template. The nucleotides used for this reaction are digoxigenin- and biotin-labelled 
and are incorporated in an optimal ratio into the same DNA molecule synthesised by 
the RT. The synthesised DNA is then detected following the principle of a sandwich 
ELISA, where the biotin-labelled DNA binds to a streptavidin-coated plate and an α-
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digoxigenin-peroxidase antibody is added, which also binds to the DNA molecule. To 
finally quantify the RT activity, the peroxidase substrate 2,2'-azino-bis(3-
ethylbenzthiazoline-6-sulphonic acid) is added. The peroxidase catalyses the 
reaction and thereby a coloured product is formed, which can be detected using an 
ELISA reader. The absorbance of the sample is directly correlated to the RT activity 
in the sample. 
3.7 Animals 
3.7.1 Infection with FV 
Mice were i.v. infected into the lateral tail vein using a 27G-hollow needle. For this 
the virus stock was thawed, centrifuged at 17,000 xg for 5 min and the supernatant 
diluted with PBS to reach the required concentration. Usually 2x104 SFFU of FV were 
used for acute infection experiments. For chronic infection experiments 1.5x104 
SFFU of FV containing LDV were used. 
3.7.2 Adoptive cell transfer 
To transfer cell populations, the desired cell population was isolated from the spleen 
and the lymph nodes of naïve mice utilising the MACS technology (see 3.12) and 
diluted to the needed cell concentration in PBS. The cells were then injected i.v into 
the mouse through the lateral tail vein using a 27G-hollow needle.  
3.7.3 Intraperitoneal injection (i.p.) 
The in vivo depletion antibodies were administered via i.p. injection. To do this, mice 
were gently grasped by the skin at the back of the neck and the tail was held back. 
The mice were then brought into a tilted position with their ventral side exposed. In 
this position internal organs are not harmed by the injection. The injection was done 
with a 27G-hollow needle in a 45° angle into the lower abdomen and slowly 
administered. 
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3.7.4 In vivo depletion of cell populations 
To deplete cell populations in vivo, the supernatant of different hybridoma cell lines 
producing the desired antibody (or purchased depletion antibodies) were injected i.p.. 
For depletion of CD8+ cells, the supernatant of the cell line YTS 169.4 was used and 
500 µL were administered every two days starting at different time points post FV 
infection. For the depletion of NK and NKT cells, the supernatant of the cell line 
PK136 was used and 300 µL were administered every four days starting at the day of 
FV infection. TCR-Vβ5+ T cells were depleted using a purchased TCR-Vβ5 depletion 
antibody at a concentration of 300 µg per i.p. injection. This i.p. injection was only 
done once four days after FV infection. The depletion efficiency was assessed via 
cell specific markers using flow cytometry. 
3.7.5 Blocking of CD73 with AMPCP 
To block CD73 in vivo, 200 µg of AMPCP dissolved in PBS was administered i.p. 
every three days starting at six dpi. 
3.7.6 Treatment with TNFα 
To treat mice with different kinds of TNFα (mbTNFα and solTNFα), they were 
injected twice with either mbTNFα or solTNFα every other day via i.p. injection. For 
mbTNFα, 25 µg per injection dissolved in sterile H20 and for solTNFα 100 µL cell 
culture supernatant were used. 
3.7.7 Dissection of mice 
To prepare mice for dissection they were sacrificed using cervical dislocation after 
anaesthesia with isofloran. The mice were then fixed with 23G-hollow needles and 
cut open carefully not to destroy any internal organs. First the cervical, axillary and 
inguinal lymph node were removed. Next the peritoneal cavity was opened and the 
spleen removed by excising both blood vessels. To obtain the bone marrow, both 
hind legs were cut loose and the flesh removed. All organs and tissues were stored 
in PBBS on ice until required. 
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3.7.8 Preparation of spleen or lymph node cell suspensions 
Spleen and lymph nodes were homogenised through a 70 µm cell strainer using the 
plunger of a syringe. All remaining cells were washed from the strainer using PBBS. 
Of these cell suspensions an aliquot was removed to count the cells. Cells were 
centrifuged at 520 xg for 10 min and the supernatant was discarded. Based on the 
cell number, cells were re-suspended in an appropriate volume of buffer suitable for 
the down-stream application.  
3.7.9 Preparation of bone marrow cell suspensions 
A bone marrow cell suspension was achieved by flushing the femur and tibia of each 
hind leg with a 23G-hollow needle with PBBS. An aliquot for counting the cells was 
taken. The cells were subsequently centrifuged at 520 xg for 10 min and the 
supernatant discarded. Based on the cell number the cells were re-suspended in an 
appropriate volume of buffer suitable for down-stream applications. 
3.7.10 Preparation of DCs from a bone marrow cell suspension 
For generating mouse DCs, the bone marrow from a naïve mouse was prepared as 
described above and re-suspended in 50 mL mouse DC media supplemented with 1 
ng/mL mrIL4 and 5 ng/mL mrGM-CSF. 10 mL were then seeded into a 10 cm cell 
culture dish and incubated at 37 °C and 5 % CO2 for seven days. After 24 hours an 
additional 10 mL of supplemented mouse DC media was added to the culture. Five 
days after seeding, the cells were washed once by centrifuging the cell culture media 
at 400 xg for 6 min (these cells are non-adherent). The cells were then re-suspended 
in 20 mL supplemented mouse DC media and cultured for another two days. Seven 
days after initially seeding the bone marrow cells, the differentiated DCs could be 
used for other applications.  
3.8 Infectious centre assay (IC assay) 
To detect the number of infectious centres of FV-infected cells, 2x104 Mus dunni cells 
in 3 mL complete RPMI were seeded into each well of a 6-well plate. The cells were 
then incubated over night at 37 °C with 5 % CO2. The following day mouse cell 
suspensions (derived from spleen or bone marrow of FV-infected mice) were 
prepared, a 10-fold dilution series formed (starting with 1x107 cells) and 1 mL of each 
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dilution was added to a single well of the 6-well plate. The plate was then incubated 
for three days under the same conditions. During this incubation period, infected cells 
spread the infection to the Mus dunni cells via cell-cell contacts. Cell division of the 
Mus dunni transfers the provirus to their daughter cells and an infected cell colony 
forms. To visualise the infected cell clones, the media on the Mus dunni cells was 
discarded and the cells were fixed by overlaying them with 95 % ethanol for 10 min. 
The ethanol was discarded and the plates washed twice with PBS plus 0.1 % BSA. 
The cells were then incubated for 2 hours at room temperature with 600 µL of culture 
supernatant of an AB720 producing hybridoma cell line. This hybridoma cell line 
produces an antibody (AB720) which specifically binds to the Env-protein of F-MuLV 
recognising FV-infected cells.  
 
After two hours the plates were washed twice with PBS plus 0.1 % BSA. 600 µL of a 
1:500 dilution (into PBS) of secondary antibody conjugated to HRP (goat-α-mouse-
IgG2b-HRP (0.05 mol/L)) was added to the cells for 90 min. After the incubation, the 
antibody was discarded and the plates were washed twice with PBS. The cells were 
then incubated for 20 min in the dark with 2 mL of fresh AEC substrate solution. A 
red precipitate is formed by conversion of the soluble substrate AEC in the substrate 
solution into an in-soluble precipitate catalysed by the HRP coupled to the secondary 
antibody. The substrate solution was discarded and the plates were washed twice 
with H2O. After the plates had dried over night the red spots in each well were 
counted and calculated for 1x106 added cells. To determine the IC count per 1x106 
spleen or bone marrow cells the mean off all dilutions was formed. 
 
As a control an additional plate of Mus dunni cells was prepared a day before the 
experiment. Three wells of this plate were left uninfected and the other three wells 
were infected with free F-MuLV (with 8 µg/ml polybrene A to facilitate virus uptake). 
The appearance of red dots after developing the assay indicated functionality. 
3.9 Human samples 
3.9.1 Human peripheral blood mononuclear cell (PBMC) isolation 
Blood samples were obtained from Hoxworth Blood Bank Center (Cincinnati, OH, 
USA). 30 mL of total blood of healthy donors was poured into 50 mL falcon tubes 
containing 10 mL PBS. Ficoll was added after mixing the blood with the PBS by 
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slowly pipetting 10 mL Ficoll underneath the blood-PBS mixture, to prevent mixing 
with the blood-PBS solution. The tubes were then spun at 800 xg for 25 min at room 
temperature and slowed down without brakes to not destroy the layers that had 
formed. After centrifugation, three layers formed with the PBMCs on top of the 
intermediate Ficoll layer. The PBMCs were harvested with a pipette and transferred 
into a fresh 50 mL tube. To wash the PBMCs, cells harvested from 2 Ficoll tubes 
were combined and topped up with PBS to a volume of 50 mL followed by 
centrifugation at 600 xg for 7 min at 4 °C. PBMCs were then re-suspended in 5 mL 
PBS and counted. 
Blood samples of HIV-1 infected subjects enrolled in the clinical trial for treatment 
with tenofovir/emitricitabine (RT-inhibitor) 300/200 mg tablets and lopinavir/ritonavir 
(protease inhibitor) 400/100 mg tablets (twice daily), were prepared in the same way.  
3.10 Stimulation of cells 
3.10.1 Re-stimulation of freshly isolated mouse cells for cytokine 
production 
For the intracellular staining of cytokines (like TNFα, IFNγ and IL2), freshly isolated 
mouse cells were re-stimulated in vitro to provide an enhanced signal. The wells of a 
Nunc MaxiSorp 96-well plate were coated with 50 µL purified α-CD3 antibody (10 
µg/mL) in sodium carbonate coating buffer. The coating of the plate was done for 2 
hours at 37°C or overnight at 4°C. After α-CD3 coating, the plate was washed three 
times with PBS. For re-stimulation of freshly isolated mouse cells, 3x103 cells were 
added to each well in duplicates. The cells were re-suspended in complete RPMI 
supplemented with 50 µM β-ME, 2 µg/mL purified α-CD28 and 2 µg/mL BFA and 
incubated for 5 hours at 37°C. After re-stimulation, the cells were transferred into new 
wells and processed for antibody staining. For controls, a sample was left un-
stimulated but stained with intracellular antibodies and a re-stimulated sample did not 
get stained with the intracellular antibodies. 
3.10.2 Peptide-stimulation of mouse CD8+ T cells with peptide-loaded 
mouse DCs for detection of mbTNFα 
Bead-isolated CD8+ T cells from naïve TCRtg mice were incubated for different 
lengths of time with F-MuLV CD8+ T cell peptide loaded onto mouse DCs in complete 
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RPMI. DCs were loaded with 5 µg peptide (AbuAbuLAbuLTVFL) for 1 hour at 37 °C. 
After loading, the DCs were washed, counted and seeded at a ratio of 1 DC to 5 
CD8+ T cells. After incubation the cells were stained for mbTNFα as described 
(3.11.2 Staining of mouse cells for flow cytometry).  
3.10.3 Unspecific stimulation of mouse CD8+ T cells α CD3/α CD28 beads 
for detection of mbTNFα 
Bead-isolated CD8+ T cells from naïve iRhom2-WT or iRhom2-KO mice were 
incubated for different lengths of time with α-CD3/α-CD28 mouse T cell stimulation 
dynabeads in complete RPMI. Before incubation with the cells the beads were 
washed once on a magnetic holder and re-suspended in the desired volume of 
complete RPMI. The beads were then added to the cells. After incubation, the cells 
were stained for mbTNFα as described (3.11.2 Staining of mouse cells for flow 
cytometry).  
3.10.4 In vitro stimulation of human PBMCs 
For in vitro stimulation of human PBMCs, the cells were thawed and re-suspended in 
complete RPMI. While half of the cells were left un-stimulated, the rest were 
stimulated with α-CD3/α-CD28 human T cell stimulation dynabeads at a 1:1 ratio. 
The beads were washed once on a magnetic holder and re-suspended in the desired 
volume of complete RPMI. The beads were then added to the cells and all cells 
(stimulated und un-stimulated) were seeded in 24-well-plates at a concentration of 
1x106 cells per well and cultured for 24 hours at 37 °C and 5% CO2. 
3.11 Multicolour flow cytometry 
3.11.1 Principle of flow cytometry 
Flow cytometry can be used for the characterisation and quantification of 
heterogeneous cell populations in solution. With this technique it is possible to detect 
surface and intracellular molecules using fluorescence labelled antibodies or 
fluorescently tagged proteins. The cells are labelled and prepared and are then 
measured on a fluorescence-activated cell sorting (FACS) machine. The main 
components of a FACS analyser can be divided in the fluidic system, the optical 
system and the detection system. 
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In a cell solution the cells are randomly distributed in a three dimensional space. To 
detect the fluorescence signal of labelled molecules they need to be focused in a 
stream of single cells. The fluidic system is responsible for this process, whereby the 
cell suspension is taken up by the sample injection port and then usually 
hydrodynamically focused (other methods exist, but are less common) (Figure 3. 1). 
 
After focusing, the cells pass through the optical system and can be analysed. FACS 
machines are equipped with different lasers, mirrors and filters. Two initial 
parameters are acquired by all FACS analysers: forward scatter (FSC) and side 
scatter (SSC). To measure the size of cells, light that is scattered in a forward 
direction (FSC) is used. The granularity of cells is measured by the SSC channel, 
which is the light measured at a 90° angle. Combining the information of the FSC and 
the SSC is used for a pre-selection of cell types in a heterogeneous sample (Figure 
3. 1). 
 
If a FACS antibody labelled cell passes through a light beam emitted by a single 
laser, the different fluorophores sensitive to that specific wavelength of light are 
specifically excited. When the electrons in the fluorophores become excited by the 
laser light they are lifted to a higher energy level and shortly after this they fall back to 
the original energy state emitting energy in the form of photons. The wavelength of 
these released photons is longer than that of the excitation light source, which is part 
of the phenomenon known as Stoke´s shift. The emitted light is reflected, filtered and 
detected with specific sets of optical mirrors, filters and detectors. The mirrors reflect 
the light onto filters, which filter light of specific wavelength. Short pass or long pass 
filters only allow light under or above a certain wavelength (respectively) to pass and 
band pass filters are used to filter a certain range of wavelengths (Figure 3. 1). 
 
The emitted and filtered light is then detected by the detectors (usually 
photomultiplier tubes (PMTs)). These detectors measure the amount of photons and 
their output signal is proportional to the amount of antibody bound to the cell. This 
type of measurement provides the necessary information to quantify and characterise 
the cells within a sample. The optical signal is then amplified and converted into an 
electric signal which can be visualised in the analysis software (Figure 3. 1). 
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Multicolour flow cytometry is made possible by using different fluorophores which 
emit at wavelengths that can be discerned from each another. In this thesis an LSR II 
with four lasers (488 nm, 633 nm, 355 nm and 405 nm) and the software FACS DiVa 
(BD bioscience) and FlowJo7.6.5 (Treestar) were used for acquiring and analysing, 
respectively. The principle of a FACS machine is shown in Figure 3. 1. 
 
 
Figure 3. 1 Schematic showing the principles of the optical and detection systems of a 
flow cytometer. Two lasers (635 and 488 nm) send light trough the sample. The light 
emitted by the sample is then isolated by different filters and sent to the different PMT 
detectors. The PMT detectors transform and enhance the optical signal into an electric 
signal, which can then be visualised in the analysis software on a computer. 
(http://www.abdserotec.com/flow-cytometry-signal-processing.html; 10.02.2014) 
 
It is also possible to sort cells, for this method cells pass through the above described 
system and are immediately characterised by previously established parameters. For 
sorting, the fluidic stream is broken into droplets, containing a cell each. These 
droplets then become charged by passing through an electric field and can be 
diverted into collection tubes by plates of opposite polarity. The principle of cell 
sorting is shown in Figure 3. 2. 
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Figure 3. 2 Schematic showing the principles of cell sorting. After passing through the 
laser system, the flow stream breaks up into droplets containing one cell (under optimal 
conditions). The droplets become charged and are diverted into different collection tubes by 
the deflection plates. (http://www.abcam.com/index.html?pageconfig=resource&rid=12803, 
10.02.2014) 
3.11.2 Staining of mouse cells for flow cytometry 
For flow cytometry cell staining of mouse cells usually 3-7x106 cells per sample of 
freshly isolated mouse cells were transferred into a well of a 96-well U-bottom plate 
and washed with the addition of 100 µL FACS buffer at 520 xg for 3 min at 4 °C. The 
supernatant was discarded by flicking the plate. All following steps were carried out in 
the dark whenever possible. 
3.11.2.1 Extracellular stain of mouse cells 
An antibody mix was prepared in 50-100 µL FACS buffer and added to the cells. The 
cells were re-suspended in the antibody mix and incubated for 15 min at room 
temperature or 30 min at 4 °C. After incubation, the cells were washed by addition of 
100 µL FACS buffer per well and spun at 520 xg for 3 min. The cells were then either 
re-suspended in FACS buffer for further processing or directly transferred into FACS 
tubes for measurement on the LSRII or fixed as described below. For the analysis of 
acquired mouse FACS samples first live single cells were gated to out-gate any debri 
and get a clean population for the performance of subsequent analysis. This 
procedure was the same for all FACS samples. 
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3.11.2.2 Fixation of mouse cells 
Depending on the down-stream intracellular stain performed, the cells were either 
fixed with Cytofix/Cytoperm from BD or with the Foxp3 staining set from eBioscience. 
If only cytoplasmic molecules were to be stained, the Cytofix/Cytoperm kit was used. 
For this the cells were re-suspended in 100 µL fixing buffer and incubated for 5 to 15 
min at room temperature. Next the cells were washed with addition of 100 µL 
Cytofix/Cytoperm wash buffer and centrifuged at 700 xg for 4 min and processed for 
down-stream applications  
 
If nuclear molecules were to be stained, the Foxp3 staining set was used. The cells 
were re-suspended in 100 µL Foxp3 Fix/Perm fixing solution which was prepared 
according to the manufacturer’s instructions (1:4 of Foxp3 Fix/Perm concentrate into 
diluent). The cells were left to fix for 2 to 4 hours at 4 °C. To stop the reaction 100 µL 
Foxp3 Fix/Perm wash buffer was added to each well and the cells were centrifuged 
at 700 xg for 4 min at 4°C and processed for down-stream applications.  
 
For the staining of mbTNFα only fixation with 4 % formaldehyde for 10 min at 4 °C 
was necessary. The cells were then subsequently washed with the addition of FACS 
buffer and centrifuged at 700 xg for 4 min. Subsequently the cells were re-suspended 
in FACS buffer for this application and measured immediately on the LSRII. 
3.11.2.3 Intracellular stain of mouse cells 
For intracellular staining, an antibody mix was prepared in 50-100 µL of either 
Cytofix/Cytoperm wash buffer, for cytoplasmic molecule staining, or Fix/Perm wash 
buffer (Foxp3 staining set), for nuclear molecule staining. The cells were re-
suspended in the antibody mix and stained for 30 min at 4 °C and, after addition of 
100 µL of the appropriate buffer, centrifuged at 700 xg for 4 min. Subsequently, the 
cells were re-suspended in FACS buffer and transferred into FACS tubes for 
measurement on the LSRII. Typically GzmB, TNFα, IFNγ and IL2 were stained using 
the Cytofix/Cytoperm kit, whereas the stain of Foxp3, Helios and Ki67 was typically 
performed with the eBioscience Fix/Perm kit. 
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3.11.2.4 Tetramer class I and class II stain 
A method to detect small populations of virus-specific CD8+ or CD4+ T cells is by the 
use of specific tetramers. MHC class I and class II-tetramers consist of four peptide-
MHC class I or II-complexes, respectively, which are linked by biotin-streptavidin. 
The complex can be detected via conjugated fluorophores in a flow cytometer. The 
peptide used to build the tetramer complex is only bound by the TCR of specific 
CD8+ or CD4+ T cells in combination with the MHC class I or class II, respectively. A 
schematic of the MHC class I and class II tetramers are shown in Figure 3. 3. 
 
 
Figure 3. 3 Schematic showing the organisation of MHC class I or class II tetramers. 
MHC class I tetramers (left) and MHC class II tetramers (right) consist of four MHC class I or 
class II molecules, respectively, linked via biotin (B) to a streptavidin (SA) on the fluorophore 
(PE in this case). The MHC complexes are loaded with a specifically chosen peptide. (41) 
 
 
The tetramer class I stain was done as described for the extracellular flow stain with 
a dilution of 1:200. The tetramer class I stain was also robust to fixation with 
Cytofix/Cytoperm for 8 min. 
 
The tetramer class II stain was carried out by first blocking the cells with 10 µL FC 
block (1:20 in RPMI) for 5 min at room temperature. Subsequently the cells were 
incubated with a 1:100 tetramer class II solution in complete RPMI for 3 hours at 37 
°C and 5% CO2. After incubation the cells were washed and stained for other 
extracellular markers (as described above) and analysed without fixation. Tetramer II 
specific CD4+ T cells were detected by gating on CD4+CD11b- T cells. 
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3.11.2.5 Sample preparation and stain for detection of incorporated 
bromodeoxyuridine (BrdU) 
To determine the proliferation of cells in vivo, mice were fed with BrdU in their 
drinking water. BrdU is a thymidine analogue which becomes integrated into the DNA 
while the cells are in the S-phase of the cell cycle. Mice were fed with a freshly 
prepared 0.8 mg/mL BrdU-drinking water solution every day for three days before 
sacrifice. To determine cell proliferation the mouse organs of interest were prepared 
as described above and an extracellular stain was carried out if needed. The staining 
for BrdU was done according to the manufacturer’s instructions. In short: the cells 
were washed with FACS buffer at 520 xg for 3 min and fixed with the supplied 
fixation reagents in two steps. Then, the DNA was digested with DNase provided in 
the kit for an hour at 37 °C. The intracellular staining was done with 0.5 µL α-BrdU-
FITC antibody for 30 min at 4 °C using the supplied buffer. The cells were then 
washed with the supplied buffer and prepared for FACS measurement in FACS 
buffer. 
3.11.3 Stain of human PBMCs for flow cytometry 
For FACS staining the cells were either harvested from a culture or used freshly 
thawed and were transferred into the wells of a 96-well U-bottom plate (usually 1x106 
cells were used). To wash the cells, the plate was centrifuged at 700 xg for 4 min, the 
supernatant removed with a pipette and washed with 200 µL PBS. For surface 
staining the cells were carefully re-suspended in 25 µL FACS buffer with the addition 
of 20 µg/mL hIgG and incubated for 10 min at 4°C in the dark. All following steps 
were carried out in the dark as much as possible. The appropriate concentration of 
surface-stain antibody-cocktail was added and the cells were left to stain for 30 min 
at 4 °C. Next, the cells were washed with 200 µL FACS buffer and centrifuged at 700 
xg for 4 min at 4 °C. Again, the supernatant was carefully removed using a pipette. 
To prepare the cells for intracellular staining the Foxp3 staining kit was used. 200 µL 
of Foxp3 Fix/Perm fixing solution was used to fix the cells for 30 min at 4 °C. The 
cells were then washed as before and re-suspended in 10 µL Foxp3 Fix/Perm wash 
buffer supplemented with normal rat-serum for intracellular Foxp3 staining for 15 min 
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at 4 °C. After this the antibodies for intracellular staining were added and the cells 
were stained for 30 min at 4 °C. Cells were then washed with the addition of 100 µL 
Foxp3 Fix/Perm wash buffer as before and re-suspended FACS buffer to measure on 
the LSRII. 
3.11.4 Gating strategy of human Tregs for flow cytometric analysis 
To gate on human Tregs a special strategy was utilised. The reason for this is that 
Foxp3 is not only a Treg marker in humans but also a marker for activation. To 
guarantee that only Tregs were considered, the following gating strategy for flow 
cytometric analysis was used (see Figure 3. 4): 
 
 
Figure 3. 4 Gating strategy for human Tregs. To gate human Tregs firstly (A) lymphocytes, 
(B) live cells and (C) singlets were identified. (D) To separate the different lymphocyte 
groups CD3, CD4 and CD19 were used for CD4+ T cells (CD3+CD4+CD19-), B cells (CD3-
CD4-CD19+) and CD8+ T cells and NKT cells (CD3+CD4-CD19-). (F) The CD8+ T cell and 
NKT cell compartment was used to set the gate for Foxp3+ T cells. (E) The same gate was 
then applied to the CD4+ T cell subset to define CD3+CD4+CD19-Foxp3+ Tregs and 
CD3+CD4+CD19-Foxp3- Tcon. 
  Methods 
69 
3.12 Cell isolation with the MACS technology 
3.12.1 MACS isolation of mouse cells 
To isolate mouse CD4+ T cells the mouse CD4+ T cell isolation kit II was used. The 
antibody mix provided only labels non-CD4+ T cells and therefor the pre-activation of 
CD4+ T cells is prevented. In summary, the cells were counted and re-suspended in 
MACS buffer (40 µL buffer per 1x107 cells). To stain all non-CD4+ T cells, a 
biotinylated antibody cocktail was added (10 µL cocktail per 1x107 cells). The cell 
suspension was then incubated for 20 min at 4 °C in the dark. An additional volume 
of 30 µL MACS buffer per 1x107 cells was added. To label the non-CD4+ T cells for 
magnetic separation they were additionally stained with α-biotin magnetic 
MicroBeads (20 µL beads per 1x107 cells). The solution was incubated for 20 min at 
4 °C in the dark. After the incubation period 10-20 times the labelling volume of 
MACS buffer was added and the cells were centrifuged for 10 min at 520 xg. After 
the centrifugation the supernatant was discarded and the cells were re-suspended in 
up to 500 µL MACS buffer per 1x107 cells. To protect the AutoMACS from clogging 
the cells were passed through a 30 µm cell strainer before applying to the MACS 
columns. To enrich CD4+ T cells the Deplete05 programme was used. After 
enrichment the cells were centrifuged, counted and processed for the necessary 
down-stream application. A sample for determining the CD4 T cell purity by FACS 
analysis was always taken. 
 
For the isolation of mouse CD8+ T cells mouse CD8α (Ly-2) MicroBeads were used. 
Using these beads CD8+ T cells are directly labelled. In general, the cells were 
counted and re-suspended in MACS buffer (90 µL buffer per 1x107 cells) and the 
CD8α MicroBeads were added (10 µl beads per 1x107 cells). The mix was incubated 
for 20 min at 4 °C in the dark and subsequently re-suspended in 10-20 times the 
labelling volume of MACS buffer and centrifuged for 10 min at 520 xg. Finally, the 
supernatant was carefully discarded and the cells were processed as described 
above. For magnetic separation of CD8+ T cells the Possel05 programme was used. 
  Methods 
70 
3.12.2 CD14+ cell enrichment from human PBMCs 
For the isolation of CD14+ cells from human PBMCs the cells were either used after 
thawing or directly after PBMC isolation. The cell number was determined and the 
cell pellet was re-suspended in 12 µL MACS buffer per 1x107 cells. 3 µL of human 
CD14 MicroBeads were added per 1x107 cells and incubated for 15 min at 4 °C in the 
dark. The cells were washed with MACS buffer and spun at 520 xg for 7 min at 4 °C. 
In the following the supernatant was discarded and the cells were re-suspended in 1 
mL MACS buffer. For separation, LS columns were prepared on a magnet by adding 
3 mL of MACS buffer. The cells were then added to the column with 500 µL per 
column and additional 9 mL of MACS buffer were used to wash off unbound cells. 
The negative fraction (CD14- cells) was obtained by collecting the flow through. This 
fraction was used for further CD4+ T cell separation as described below. To collect 
the CD14+ fraction the columns were removed from the magnet and placed onto 15 
mL tubes. The cells were washed from the columns using 5 mL MACS buffer and a 
plunger to flush the liquid into the 15 mL tube. The CD14+ cells were then washed 
and spun at 520 xg for 7 min at 4 °C followed by re-suspension in 1 mL PBS plus 2 
% FCS. Depending on the down-stream application the cells were either frozen or 
used immediately. 
3.12.3 CD4+ T cell enrichment from human PBMCs 
To obtain CD4+ T cells, the human CD4+CD25+ T cell isolation kit was used. The 
CD14- fraction of cells was washed at 520 xg for 7 min at 4 °C, re-suspended in PBS 
plus 2 % FCS and counted. The cells were then washed again and re-suspended in 
40 µL MACS buffer per 1x107 cells. 10 µL of CD4+ T cell biotin-antibody cocktail was 
added to 1x107 cells and the mixture was incubated for 10 min at 4 °C in the dark. 
Following this, additional 30 µL of MACS buffer and 20 µL α-biotin MicroBeads per 
1x107 cells were added. The cells were further incubated for 10 min at 4 °C and 
washed and spun at 520 xg for 7 min at 4 °C. After the wash, the supernatant was 
discarded and the cells were re-suspended in 1 mL MACS buffer. For separation, LS 
columns were re-constituted on a magnet by adding 3 mL of MACS buffer. The cells 
were added to the column with 500 µL per column and additional 9 mL of MACS 
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buffer were used to wash off all unbound cells. The negative fraction (CD4+ cells) 
was then obtained by collecting the flow through and was centrifuged at 520 xg for 7 
min at 4 °C and re-suspended in 1 mL PBS plus 2 % FCS. Depending on the down-
stream application the cells were either frozen or used immediately. 
3.12.4 CD4+CD25+ T cell enrichment from human PBMCs 
For some applications Tregs (CD127loCD25hi) and Tcon (CD127hiCD25lo) cells were 
sorted. For this, previously collected un-labelled CD4+ T cells were pre-enriched for 
CD25+ cells using the human CD4+CD25+ Treg isolation kit. The cell number of CD4+ 
T cells was determined and the cells were re-suspended in 90 µL MACS buffer and 
10 µL CD25 MicroBeads per 1x106 cells followed by incubation for 15 min at 4 °C in 
the dark. The labelled cells were then washed with MACS buffer and centrifuged at 
520 xg for 7 min at 4 °C. The supernatant was discarded and the cells were re-
suspended in 1 mL MACS buffer. For separation, LS columns were re-constituted on 
a magnet by adding 3 mL of MACS buffer. The cells were then added to the column 
in 500 µL per column and allowed to flow through. The column was washed with 1 
mL of MACS buffer and the flow-through was transferred to another re-constituted LS 
column. The second column was then washed with 1 mL of MACS buffer. The flow-
through, the negative fraction (CD4+CD25- cells), was collected and centrifuged at 
520 xg for 7 min at 4 °C. Next, the sample was re-suspended in 1 mL PBS plus 2 % 
FCS and kept at 4 °C until the CD4+CD25+ T cells were sorted.  
 
To collect the CD4+CD25+ (enriched) fraction both LS columns were removed from 
the magnet and placed onto a 15 mL tube. The cells were washed from the columns 
using 5 mL MACS buffer and a plunger to flush the liquid through into the tubes. The 
CD4+CD25+ cells were then washed and spun at 520 xg for 7 min at 4 °C and re-
suspended in 2 mL PBS plus 2 % FCS.  
3.13 Sorting of Tregs and Tcon from human PBMCs 
The cells of the CD4+CD25+ enriched fraction were stained with α-CD8, α-CD25 and 
α-CD127 (see Table 2. 6 on page 45 for concentrations) for 30 min at 4 °C. After 
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incubation, the cells were washed with the addition of 8 mL cold PBS plus 2 % FCS 
and spun at 520 xg for 7 min at 4 °C. The supernatant was discarded and 1x106 cells 
were re-suspended in 1 mL cold sorting buffer. Subsequently, the pre-enriched 
CD4+CD25+ T cells were sorted on a MoFlo cell sorter (Flow core facility at Children’s 
Hospital Cincinnati, Ohio, USA) for CD25hiCD127lo (Tregs) and CD25loCD127hi 
(Tcon). After the sort, both fractions were washed and spun at 520 xg for 7 min at 4 
°C and re-suspended in 0.5 mL PBS plus 2 % FCS. 
3.14 Differentiation of MoDCs from CD14+ cells 
CD14+ cells were thawed and counted as described earlier and re-suspended in DC 
media for human cells (complete RPMI media supplemented with 500 U/mL hrIL4 
and 1000 U/mL hrGM-CSF). 5x105 cells per 1 mL were cultured at 37 °C and 5% 
CO2 in a well of a 24-well plate. After 3 days, 330 µL of media were replaced with 
330 µL of fresh DC media. The cells were cultured for an additional day at 37 °C and 
5% CO2. To guarantee the success of differentiation the cells were frequently 
checked for a DC-like morphology under a light microscope.   
3.15 Infection of MoDCs 
On day four of MoDC culture the differentiated DCs in suspension were carefully 
harvested, washed and centrifuged at 520 xg for 7 min at 22 °C. The cells were re-
suspended in 1 mL and counted. According to the cell count, and the number of cells 
to be infected, the amount of virus required was calculated. In general an MOI of 2-3 
was used for HIV-1 JRFL-iGFP and SIVmac-VLPs. To infect the cells, both viruses 
were added to a small volume of cell suspension in complete RPMI and left to 
incubate for 1.5 to 3 hours at 37 °C and 5 % CO2. After incubation, DC media was 
added and 5x105 cells per 1 mL were plated into a well of a 24-well-plate. The cells 
were further incubated at 37 °C and 5 % CO2 for 3 days. The uninfected control cells 
were treated the same way as the infected cells but minus virus. 
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3.16 Sorting of infected MoDCs 
The infection of MoDCs with HIV-1 is poorly efficient thus the infected MoDCs were 
enriched using sorting. DCs were carefully harvested four days after infection with 
HIV-1 JRFL-iGFP and after centrifugation at 520 xg for 7 min (4 °C) were re-
suspended in an appropriate volume of sorting buffer. The cells were sorted on a 
MoFlo cell sorter (Flow core facility at Children’s Hospital Cincinnati, Ohio, USA). The 
gate was set on the GFP+ population including a bit of the GFP- population to enrich 
the sample for HIV-1 JRFL-iGFP infected cells. The uninfected cells were treated in 
the same way to keep experimental conditions the same and GFP- cells were sorted. 
After sorting, the cells were washed with complete RPMI and spun at 520 xg for 7 
min at 4 °C, re-suspended in complete RPMI and counted to determine the cell 
number for subsequent co-cultures. 
3.17 Labelling of human Tcon cells with violet tracker 
For co-cultures CD4+CD14- T cells or CD4+CD14-CD8-CD127hiCD25lo Tcon cells 
were stained with violet tracker. The cells were washed as described before and re-
suspended in 900 µL sterile H2O. 100 µL of a 1:1000 dilution of violet tracker in H2O 
was added and the cells were incubated for 20 min at 37 °C and 5 % CO2 in the dark. 
The reaction was stopped by adding 700 µL FCS and 4 mL PBS. The stained cells 
were then washed, counted and re-suspended in the desired amount of complete 
RPMI for further culture.  
3.18 Co-culture of human cells 
The co-culture of human donor cells was done with autologous cells. In general, 
violet tracker labelled Tcon were co-cultured with sorted infected or un-infected 
MoDCs and Tregs at a ratio of 10:1:10 (5x105 Tcon and 5x104 MoDCs and 5x104 
Tregs) in 500 µL of complete RPMI (supplemented with 10 µg/mL α-CD3 for 
stimulation) in 24-well-plates for 36 hours at 37 °C and 5% CO2. In some cultures the 
Treg inhibitors α-CTLA4 (10 µg/mL), α-TGFβ (10 µg/mL) and ddADA (200 µM) were 
used. For this Tregs were incubated 24 hours prior co-culture with 200 µM ddADA, 
washed subsequently and then co-cultured as described. The other two inhibitors, α-
CTLA4 and α-TGFβ, were directly added to the co-culture. 
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3.19 Acquisition with the Amnis ImageStream 
3.19.1 Principle of the Amnis ImageStream 
The Amnis ImageStream is a combination of a FACS machine and a fluorescence 
microscope. In general it works like a FACS machine, but is also combined with the 
properties of a microscope. Two cameras take pictures of every measured event and 
these events can then be visualised in the acquiring software INSPIRE and analysed 
with the statistical software IDEAS. The ImageStream is a useful machine for 
investigating marker co-localisation, cell morphology, cell-cell interactions and many 
other applications where the visualisation of cells is necessary. Due to its 
characteristics as a FACS machine it can measure more events in a faster manner 
than can be acquired by microscopy alone. These acquired events can be analysed 
using statistical software with a multitude of different applications. For example the 
correlation of two markers can be measured as an indicator of co-localisation.  
3.19.2 Staining for Amnis ImageStream measurements 
After 36 hours the co-cultures were carefully harvested to keep the CD4+:DC clusters 
intact and transferred into a 96-well U-bottom plate for staining. The plate was 
centrifuged at 700 xg for 4 min at 4 °C. The supernatant was carefully taken up and 
the cells were washed again with PBS. For surface staining the cells were carefully 
re-suspended in 25 µL FACS buffer with the addition of 20 µg/mL hIgG and 
incubated for 10 min at 4 °C. The appropriate concentration of surface-stain 
antibodies (α-CD25-BV785 and α-HLA-DR-BV570) was added and the cells were 
incubated for 30 min at 4 °C in the dark. The cells were washed with 200 µL FACS 
buffer and centrifuged at 700 xg for 4 min at 4 °C. To prepare the cells for 
intracellular staining 200 µL of 4 % formaldehyde (methanol free) in H2O was used to 
fix the cells for 20 min at 4 °C in the dark. The cells were then washed as before and 
re-suspended in 50 µL 0.3 % saponin-buffer supplemented with the reagents for 
intracellular staining (phalloidin-APC). Staining was then done for 30 min at 4 °C. 
After the staining the cells were washed as before and re-suspended in 100 to 150 
µL FACS buffer without bubbles, transferred into 1.5 mL tubes and analysed on the 
Amnis ImageStream. 
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4. Results 
4.1 Tregs expand during FV infection in the spleen and bone 
marrow 
Previous work has shown that Tregs play an important role in suppressing the 
effector CD4+ and CD8+ T cell response in FV-infected mice during the acute and 
chronic phase of infection (84, 144, 339, 340). It has also been shown that Tregs 
expand in highly infected organs, like the spleen and bone marrow during the acute 
phase of FV infection (340). Elevated levels of Tregs are still detectable in the spleen 
during the chronic phase of infection (213). During acute FV infection cytotoxic CD8+ 
T cells eliminate the majority of infected cells; however the expanded population of 
Tregs suppresses the cytotoxicity of virus-specific CD8+ T cells. Consequently, 
incomplete immune clearance results in the establishment of a chronic FV infection. 
(213, 339-341). 
 
To confirm the results described above the kinetics of Treg expansion after FV 
infection in B6 mice (20,000 SFFU) was determined in the organs of interest, the 
spleen and bone marrow. Foxp3 is the master transcription factor for Tregs and in 
mice exclusively expressed in these (345). The numbers of CD4+Foxp3+ Tregs per 
1x106 live cells in the spleen and bone marrow for different times post FV infection 
was enumerated (Figure 4. 1 A). The expansion of Tregs peaked at 12 to 14 dpi. 
Furthermore, the frequency of Tregs in the spleen was much higher than the 
frequency of Tregs in the bone marrow. In both organs only slightly elevated levels of 
Tregs were detected at 40 dpi compared to uninfected controls (Figure 4. 1 A).  
 
To investigate the expansion of activated Tregs, Helios, a marker first described for 
nTregs and now rather classed as a marker of Treg activation, was used. When the 
percentage of Foxp3+Helios+ Tregs (activated Tregs) and the percentage of 
Foxp3+Helios- Tregs (non-activated Tregs) was assessed at different time points post 
FV infection, an expansion of activated Tregs was seen after infection in both the 
spleen and bone marrow. In the spleen the frequency of activated Tregs peaked at 
12 to 14 dpi and in the bone marrow around 12 dpi. In contrast, the frequency of non-
activated Tregs did not increase but rather decreased after infection in both organs 
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(Figure 4. 1 B and C). In conclusion, previous data on Treg expansion during FV 
infection was confirmed and an expansion of activated, but not non-activated, Tregs 
that peaked at 12-14 dpi was observed. 
 
 
Figure 4. 1 Time course of Treg expansion in the spleen and bone marrow of FV-
infected mice. B6 mice were infected i.v. with 20,000 SFFU of FV or left un-infected and 
Treg abundance was measured using flow cytometry for spleen or bone marrow cells at 
various times post infection. (A) The numbers of CD4+Foxp3+ Tregs per 1x106 live cells in 
both organs are displayed. The frequencies of activated (Foxp3+Helios+) and not-activated 
(Foxp3+Helios-) Tregs of total CD4+ T cells in (B) the spleen and (C) bone marrow are 
shown. At least four mice per group from two independent experiments were analysed. The 
bars represent the mean and SEM. For statistical analysis a Dunnett’s multiple comparison 
test was carried out with the naïve group as a reference (* < 0.05, ** < 0.005, *** < 0.0005). 
4.2 mRNA expression of Treg-associated genes during acute FV 
infection 
As the time course of Treg expansion during FV infection had been delineated, it was 
important to assess the regulation of various genes associated with Treg activation 
and function during FV infection and for this purpose microarray data was analysed 
(data courtesy of Gennadiy Zelinskyy). The samples used for the microarray were 
CD4+CD25+Foxp3+ Tregs isolated from the spleens of naïve mice or the bone 
marrow of 7 dpi or 15 dpi FV-infected mice (20,000 SFFU). To analyse the data, fold 
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changes of selected genes were calculated. For this calculation the absolute mRNA 
chip signals were used and the fold change of naïve to 7 dpi, naïve to 15 dpi and 7 
dpi to 15 dpi were calculated. Treg markers of interest with detectable signals were 
chosen and divided into four different groups: Treg-associated, T cell activation and 
homing, T cell co-stimulation and inhibition, and T cell proliferation and differentiation. 
For more details on how the samples were analysed please refer to page 51 (3.1 
Evaluation of the microarray data) 
 
Foxp3 and CD25 are classical markers of naïve Tregs and their mRNA levels were 
only slightly up-regulated after 15 dpi compared to naïve Tregs. Nrp1, a marker for 
nTregs, remained largely unaltered at 7 dpi and 15 dpi, but Helios showed an 
increase at 15 dpi. Interestingly, three Treg-associated molecules which are 
expressed on suppressive Tregs, CD73, CD39 and TNFRII, also showed an increase 
at 15 dpi compared to naïve Tregs or Tregs at 7 dpi (Table 4.1, page 78,Treg-
associated).  
 
Within the different T cell activation and homing markers only the mRNAs of CD103 
and CD44 showed an increase 15 dpi after infection, and for CD44 this effect was 
already detectable at 7 dpi (Table 4.1, page 78, Activation and Homing). In contrast, 
all but one (PD-L2, only minimal change) mRNAs for co-stimulatory and inhibitory 
markers showed an increase 15 dpi after infection compared to 0 or 7 dpi (Table 4.1, 
page 78, Co-stimulatory and Inhibitory).  
 
The mRNA expression of the proliferation marker Ki67 and differentiation marker 
KLRG1, both showed high fold changes after infection, and this effect was already 
detected 7 dpi with an even further increase at 15 dpi (Table 4.1, page 78, 
Proliferation and Differentiation).  
 
In conclusion, mRNA expression was altered for most of the Treg markers studied, 
the majority of which were up-regulated at 15 dpi but not at the earlier time point 7 
dpi. This suggested Treg activation during the late phase of acute FV infection and a 
differential protein expression in Tregs of infected compared to naïve mice. 
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Table 4. 1 Microarray analysis of different genes for Tregs. Microarray data (data 
courtesy of Gennadiy Zelinskyy) was used to analyse various mRNA expression profiles in 
Tregs of naïve and infected mice. RNA of splenic CD4+CD25+GFP+ Tregs from naïve 
DEREGtg mice or bone marrow CD4+CD25+GFP+ Tregs of 7 and 15 day infected DEREGtg 
mice were harvested, and an Affymetric Mouse430_2 chip was used. The fold changes from 
naïve to 7 dpi, naïve to 15 dpi and 7 dpi to 15 dpi were calculated and are displayed in the 
table.  
Marker 
Fold change 
naïve to 7 dpi 
Fold change 
naïve to 15 dpi 
Fold change   
7 dpi to 15 dpi 
Treg-associated 
CD25 0.81 1.13 1.39 
Foxp3 0.80 0.96 1.20 
Nrp1 0.98 1.04 1.06 
Helios 0.97 2.12 2.20 
TNFRII 1.03 2.55 2.48 
CD39 1.16 1.76 1.51 
CD73 0.60 1.17 1.94 
Activation and Homing 
CD127 1.10 1.20 1.09 
CD62L 0.53 0.52 0.98 
CD103 0.97 2.14 2.20 
CD44 2.03 2.36 1.16 
CD69 1.03 0.91 0.88 
Co-stimulatory and Inhibitory 
ICOS 0.75 1.15 1.53 
GITR 0.97 1.62 1.68 
CTLA4 0.90 2.10 2.33 
PD-1 0.92 1.41 1.53 
PD-L1 1.18 1.76 1.49 
PD-L2 1.17 1.27 1.08 
Proliferation and Differentiation 
Ki67 1.47 3.66 2.49 
KLRG1 1.88 3.31 1.76 
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4.3 Marker profiles of Tregs and Tcon during acute FV infection 
To validate the marker profiles suggested by the mRNA expression analysis, the 
expression of the proteins were investigated using flow cytometry. The aim was to 
find adequate markers to characterise Treg activation, differentiation and proliferation 
based on findings known for Tcon. For all the following analyses CD4+Foxp3+ Tregs 
and CD4+Foxp3- Tcon from naïve mice and mice infected with FV for 12 days, the 
peak of Treg expansion in the spleen and bone marrow, were compared. B6 mice 
were infected with 20,000 SFFU of FV and the expression of CD25, as the first 
identified Treg marker (254), was analysed. As expected, CD25 expression was 
much higher on Tregs compared to Tcon (Figure 4. 2 A and B). However, no 
increase was seen in the expression levels of CD25 on Tregs or Tcon after FV 
infection (Figure 4. 2 A and B). In contrary, in the bone marrow a lower frequency of 
Tregs expressing CD25 was detectable for infected mice when compared to naïve 
mice (Figure 4. 2 B). The results confirm that high expression of CD25 is a hallmark 
of Tregs but not a useful marker to distinguish activated from non-activated Tregs. 
 
 
Figure 4. 2 Expression of CD25 on Tregs and Tcon in naïve and FV-infected mice. B6 
mice were infected i.v. with 20,000 SFFU of FV or left un-infected and the expression of 
CD25 was measured on Tregs (CD4+Foxp3+) and Tcon (CD4+Foxp3-) using flow cytometry 
for (A) spleen or (B) bone marrow cells at 12 dpi. Multiple independent experiments were 
carried out, with each dot representing a single mouse. The bars represent the mean and 
SEM. For statistical analysis a Student’s t-test was used (ns not significant and *** < 0.0005). 
 
To analyse the activation profile of Tregs in comparison to Tcon, selected T cell 
activation (CD69, CD43, CD11a and CD44) and homing markers (CD62L and 
CD103) were investigated in naïve or mice infected with FV for 12 days by flow 
cytometry. The most common T cell activation (CD69, CD43, CD11a and CD44) and 
homing (CD62L and CD103) markers were chosen.  
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A higher frequency of CD43+ and CD11a+ Tregs was observed in the spleen of 
acutely infected mice compared to naïve mice (Figure 4. 3 B and C, left side). 
Moreover, in the bone marrow higher frequencies of CD69+, CD43+, CD11a+, CD44+ 
and CD62L- Tregs in acutely infected mice compared to naïve mice were detected 
(Figure 4. 3 A – E, right side). However, no difference in the percentage of Tregs 
expressing CD103 was found between naïve and infected mice in either organ 
(Figure 4. 3 F). A similar activation profile after infection was observed for Tcon from 
the spleen or bone marrow (Figure 4. 3 B – E). This confirms an activated phenotype 
for both: CD4+Foxp3+ Tregs and CD4+Foxp3- Tcon, in the spleen and bone marrow 
of FV-infected mice.  
 
Interestingly, in the spleen from FV-infected mice, even higher frequencies of 
activated Tregs compared to Tcon were found. This observation was not entirely true 
for the bone marrow, where Tregs showed lower (CD43+, CD11a+, CD44+ and 
CD62L-) as well as higher (CD69+ and CD103+) frequencies of activated cells 
compared to Tcon. This hinted towards a stronger activation of Tcon in the bone 
marrow (Figure 4. 3 A – F, left and right).  
 
In conclusion, the well described activation and homing markers of Tcon were also 
expressed on Tregs and up-regulated upon FV infection. The use of CD11a and 
CD43 showed to be the most reliable indication of Treg activation, however, CD69, 
CD44 and CD62L can be used but with restriction to bone marrow cells. 
  Results 
81 
 
Spleen
Tregs - naive Tregs - FV Tcon - naive Tcon - FV
0
10
20
30
40
50
ns
ns
%
 o
f C
D
69
+
***
Bone marrow
Tregs - naive Tregs - FV Tcon - naive Tcon - FV
0
20
40
60
80
***
ns
%
 o
f C
D
69
+
***
Spleen
Tregs - naive Tregs - FV Tcon - naive Tcon - FV
0
10
20
30
40
***
***
%
 o
f C
D
43
+
***
Bone marrow
Tregs - naive Tregs - FV Tcon - naive Tcon - FV
0
10
20
30
40
50
60
70
80
90
**
***
%
 o
f C
D
43
+
**
Spleen
Tregs - naive Tregs - FV Tcon - naive Tcon - FV
0
20
40
60
80
100
***
***
%
 o
f C
D
11
a+
***
Bone marrow
Tregs - naive Tregs - FV Tcon - naive Tcon - FV
0
20
40
60
80
100
120
***
***
%
 o
f C
D
11
a+
***
Spleen
Tregs - naive Tregs - FV Tcon - naive Tcon - FV
0
20
40
60
ns
***
%
 o
f C
D
44
+
***
Bone marrow
Tregs - naive Tregs - FV Tcon - naive Tcon - FV
0
20
40
60
80
100
**
ns
%
 o
f C
D
44
+
***
Spleen
Tregs - naive Tregs - FV Tcon - naive Tcon - FV
0
20
40
60
80
100
ns
ns
%
 o
f C
D
62
L-
***
Bone marrow
Tregs - naive Tregs - FV Tcon - naive Tcon - FV
0
20
40
60
80
100
120
*
***
%
 o
f C
D
62
L-
***
Spleen
Tregs - naive Tregs - FV Tcon - naive Tcon - FV
0
10
20
30
ns
ns
%
 o
f C
D
10
3+
***
Bone marrow
Tregs - naive Tregs - FV Tcon - naive Tcon - FV
0
10
20
30
40
50
ns
ns
%
 o
f C
D
10
3
+
***
A
B
C
D
E
F
  Results 
82 
Figure 4. 3 Expression of activation and homing markers on Tregs and Tcon from 
naïve or FV-infected mice. B6 mice were infected i.v. with 20,000 SFFU FV or left un-
infected and the expression of various activation markers on Tregs (CD4+Foxp3+) and Tcon 
(CD4+Foxp3-) were measured by flow cytometry for spleen and bone marrow cells at 12 dpi. 
The markers investigated were: (A) CD69, early activation; (B) CD43 and (C) CD11a, both 
activation; (D) CD44, antigen contact; (E) CD62L and (F) CD103, activation and homing. 
Multiple independent experiments were carried out, with each dot representing a single 
mouse. The bars represent the mean and SEM. For statistical analysis a Student’s t-test was 
used (ns not significant, * < 0.05, ** < 0.005 and *** < 0.0005). 
 
 
T cells express various co-stimulatory and inhibitory receptors when activated, which 
were also stained. Tregs showed to have a higher frequency of cells positive for 
TIM3, ICOS, Lag3, PD-1 and PD-L1 in infected compared to cells from naïve mice in 
both the spleen and bone marrow (Figure 4. 4 A, B, C, E and F). A similar profile was 
observed for Tcon, which shows that these markers can be used for characterising 
Tregs. No changes during infection were found for the expression of CTLA-4 and 
GITR on Tregs (Figure 4. 4 D and G). These two markers are described to be 
important for Treg suppressive function, and showed higher levels for Tregs 
compared to Tcon (Figure 4. 4 D and G). When Tregs and Tcon from infected mice 
were compared to each other, Tregs showed higher expression of all markers in the 
spleen compared to the bone marrow with only two exceptions (Tim3 and PD-L1).  
 
In summary, the co-stimulatory molecule ICOS and inhibitory receptors TIM3, Lag3, 
PD-1 and PD-L1 described for Tcon can also be used to characterise Tregs during 
acute FV infection. Furthermore, CTLA-4 and GITR were mainly expressed on Tregs 
and not Tcon in both organs, which is in line with the literature. 
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Figure 4. 4 Expression of co-stimulatory markers and inhibitory receptors on Tregs 
and Tcon from naïve and FV-infected mice. B6 mice were infected i.v. with 20,000 SFFU 
FV or left un-infected and the expression of various co-stimulatory and inhibitory markers on 
Tregs (CD4+Foxp3+) and Tcon (CD4+Foxp3-) were measured by flow cytometry for spleen 
and bone marrow cells at 12 dpi. The markers investigated were (A) TIM3, (B) ICOS, (C) 
Lag3, (D) CTLA4, (E) PD-1, (F) PD-L1, and (G) GITR. Multiple independent experiments 
were carried out, with each dot representing a single mouse. The bars represent the mean 
and SEM. For statistical analysis a Student’s t-test was used (ns not significant, * < 0.05, ** < 
0.005 and *** < 0.0005). 
 
 
Finally, to characterise the differentiation and proliferative capacity of Tregs during 
FV infection, a number of makers indicating differentiation (CD127 and KLRG1) and 
proliferation (Ki67 and BrdU) were analysed. For BrdU staining mice were fed with 
BrdU in their drinking water for three days before the experiment.  
 
CD127 expressing Tregs were reduced in the bone marrow of infected mice 
compared to Tregs from naïve mice, indicating the differentiation to effector T cells, 
but no changes were seen in the spleen (Figure 4. 5 A). Tregs of FV-infected mice 
showed higher frequencies of KLRG1+, Ki67+ and BrdU+ cells compared to cells from 
naïve mice in both organs (Figure 4. 5 B – D). In addition, Tregs from the spleen of 
FV-infected mice showed to be more differentiated (CD127lo and KLRG1+) and 
proliferated stronger in comparison to Tcon from these mice. However in the bone 
marrow, the frequency of Ki67+ Tcon and Tregs showed no significant differences in 
infected mice and Tregs were more positive for CD127 than Tcon, indicating less 
Treg differentiation compared to Tcon (Figure 4. 5 A and C).  
 
In summary, markers used to show proliferation and differentiation of Tcon can also 
be used for Tregs in infected mice. KLRG1 was a more reliable marker to 
characterise Treg differentiation than CD127 and both Ki67 and BrdU can be used to 
study the proliferation of Tregs during infection. This proved that Tregs proliferate 
during FV infection and show signs of effector T cell differentiation. 
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Figure 4. 5 Expression of differentiation and proliferation markers on Tregs and Tcon 
from naïve and FV-infected mice. B6 mice were infected i.v. with 20,000 SFFU of FV or left 
un-infected. For BrdU staining the mice were fed with BrdU in their drinking water three days 
before they were sacrificed. The expression of differentiation markers: (A) CD127 and (B) 
KLRG1; and proliferation markers: (C) Ki67 and (D) BrdU, of Tregs (CD4+Foxp3+) and Tcon 
(CD4+Foxp3-) were measured using flow cytometry for spleen and bone marrow cells at 12 
dpi. Multiple independent experiments were carried out, with each dot representing a single 
mouse. The bars represent the mean and SEM. For statistical analysis a Student’s t-test was 
used (ns not significant, * < 0.05, ** < 0.005 and *** < 0.0005). 
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4.4 Tregs remain activated and expanded during chronic FV 
infection 
In FV infection, Tregs supress effector T cells, especially CD8+ T cells, and render 
them dysfunctional during the chronic phase of infection (84, 144, 339, 340). When 
Tregs were depleted in the chronic phase of FV infection, CD8+ T cells were 
reactivated and able to significantly lower viral loads (81, 339, 340). This shows that 
Tregs are required to supress CD8+ T cells, suggesting that Tregs remain activated 
during chronic FV infection. The kinetics of virus replication in the different organs 
during FV infection have been investigated by Zelinskyy et al. (340). The virus was 
mostly present in the spleen and bone marrow and to a lesser extent in the lymph 
nodes during the acute phase of infection. However, during chronic FV infection 
higher titres of virus were found in the lymph nodes and spleen and only very low 
titres were detected in the bone marrow (340). Based on these findings, it was 
important to investigate Treg responses in all three organs of chronically infected 
mice. 
 
Investigating the frequencies of Tregs in the spleen, bone marrow and lymph nodes 
of chronically FV-infected mice revealed that they all had significantly increased 
levels of Tregs compared to naïve mice (Figure 4. 6 A to C). Treg activation and 
proliferation during chronic FV infection was investigated. For this analysis three 
markers were chosen: Helios, for activation (Figure 4. 7 A); CD43, for activation 
(Figure 4. 7 B) and Ki67, for proliferation (Figure 4. 7 C). In all three investigated 
organs significantly higher frequencies of Foxp3+Helios+ and CD43+ Tregs were 
observed, indicating activation of Tregs in chronically infected mice. However, for 
Ki67+ Tregs, a lower frequency was measured in the lymph nodes of chronically 
infected compared to naïve mice and no significant changes were seen for the bone 
marrow or spleen. In conclusion higher frequencies of Tregs were present during 
chronic FV infection and these cells were still activated but did not show signs for 
increased proliferation. 
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Figure 4. 6 Treg expansion in mice chronically infected with FV. B6 mice were infected 
i.v. with 15,000 SFFU FV+LDV for four to ten weeks or left un-infected and the frequency of 
CD4+Foxp3+ T cells were evaluated using flow cytometry for: (A) bone marrow, (B) spleen 
and (C) lymph node cells. For statistical analysis a Student’s t-test was used (ns not 
significant, * < 0.05, ** < 0.005 and *** < 0.0005). The bars indicate the mean and SEM. 
 
 
 
Figure 4. 7 Expression of activation and proliferation markers by Tregs in mice 
chronically infected with FV. B6 mice were infected i.v. with 15,000 SFFU FV+LDV for four 
to ten weeks or left un-infected and the expression of different markers on CD4+Foxp3+ 
Tregs was evaluated using flow cytometry for bone marrow, spleen and lymph node cells. 
Two activation markers; (A) Helios and (B) CD43 and one proliferation marker; (C) Ki67 were 
used to characterise the Tregs. For statistical analysis a Student’s t-test was used (ns not 
significant, * < 0.05, ** < 0.005 and *** < 0.0005). The bars indicate the mean and SEM. 
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4.5 Natural Tregs expand in acute FV infection 
After characterising the phenotype of Tregs during acute and chronic FV infection, it 
was of interest to determine their origin. Tregs can be either thymically derived 
nTregs or peripherally induced iTregs. Initially, Helios was recognised as a marker of 
nTregs (286, 301), but recently it was mainly used as marker for Treg activation (7). 
Nrp1, a newly identified marker for nTregs, shows a very similar expression pattern 
on Tregs as Helios, arguing in favour of Helios as an nTreg marker that can be 
induced by certain stimuli (320, 331).  
 
The absolute numbers of Nrp1+ nTregs and Nrp1- iTregs from the spleen (Figure 4. 8 
A) and bone marrow (Figure 4. 9 A) of naïve and 12 to 14 dpi FV-infected mice were 
compared. Nrp1+ nTregs showed a significant increase in numbers from FV-infected 
mice compared to Nrp1+ nTregs from naïve mice for both organs. Moreover, a 
significant expansion of Nrp1- iTregs from naïve to FV-infected mice was found for 
both organs. However, these numbers were significantly lower than the numbers of 
Nrp1+ nTregs in FV-infected mice. The same expansion of Tregs after infection was 
observed for Helios+ and Helios- Tregs in the spleen and bone marrow (data not 
shown). 
 
Interestingly, when the numbers of Helios-Nrp1+ (non-activated nTregs), Helios+Nrp1+ 
(activated nTregs) and Helios+Nrp1- (activated iTregs) were analysed, the highest 
increase in numbers was found for Helios+Nrp1+ Tregs in the spleen and bone 
marrow of 12 dpi FV-infected mice compared to naïve mice and the other sub-
populations in infected mice (Figure 4. 8 B and Figure 4. 9 B). Infected mice did not 
show any increase in numbers of Helios-Nrp1+ Tregs compared to naïve mice. 
However, a significant increase of Helios+Nrp1- iTregs was observed after infection, 
although only very low cell numbers of this subset were detected (Figure 4. 8 B and 
Figure 4. 9 B). In summary, the most prominent subset of Tregs that accounts for 
most of the Treg expansion during FV infection are Helios+Nrp1+ Tregs, which 
suggests that nTregs get activated and expand in response to infection. 
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Figure 4. 8 Numbers of Tregs expressing Nrp1 and Helios in the spleen during acute 
FV infection. B6 mice were infected i.v. with 20,000 SFFU FV for 12 to 14 days or left un-
infected. The numbers of Tregs (CD4+Foxp3) positive or negative for Nrp1 or Helios were 
assessed in the spleen using flow cytometry. (A) Numbers of Tregs positive or negative for 
Nrp1 and (B) the Tregs categorised into Helios-Nrp1+, Helios+Nrp1+ or Helios+Nrp1- subsets. 
For statistical analysis a Student’s t-test was used (ns not significant, ** < 0.005, *** < 
0.0005). The bars indicate the mean and SEM. 
 
 
 
Figure 4. 9 Numbers of Tregs expressing Nrp1 and Helios in the bone marrow during 
FV infection. B6 mice were infected i.v. with 20,000 SFFU FV for 12 to 14 days or left un-
infected. The numbers of Tregs (CD4+Foxp3) positive or negative for Nrp1 or Helios were 
assessed in the spleen using flow cytometry. (A) Numbers of Tregs positive or negative for 
Nrp1 and (B) Treg subsets categorised into: Helios-Nrp1+, Helios+Nrp1+ or Helios+Nrp1-. For 
statistical analysis a Student’s t-test was used (ns not significant, ** < 0.005, *** < 0.0005). 
The bars indicate the mean and SEM. 
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4.6 Vβ5+ Tregs disproportionally expand during acute FV infection 
The discovery that mostly activated nTregs expand during acute FV infection was a 
hint for self-specificity of these Tregs as thymus derived nTregs usually recognise 
self-antigens (269). Identification of self-antigens is not an easy task as virtually any 
expressed self-protein could be a candidate. Therefore the breadth of the TCR Vβ 
usage by Tregs expanding during FV infection was analysed. This analysis was done 
by our collaborators Kim Hasenkrug and Lara Myers (Laboratory of Persistent Viral 
Diseases, Rocky Mountain Laboratories, NIAID, NIH, Hamilton, MT, US).  
 
Fourteen different TCR Vβ chains were examined at the peak expansion of Tregs 
during acute FV infection. These 14 different TCR Vβ chains represent about 70 % of 
all TCR Vβ chains utilised by Tregs in naïve and infected mice. When Tregs from 
naïve and acutely FV-infected mice were investigated for their numbers, all TCR Vβ 
subset showed equal expansion after infection with only one exception (212). The 
Vβ5+ Treg subset showed a disproportional expansion from naïve to acutely FV-
infected mice (Figure 4. 10 A), with the largest fold increase in absolute cell numbers 
compared to all other Vβ Treg subsets (212). 
 
The disproportional expansion of T cell subsets suggests the involvement of 
superantigen stimulation; however no Sag has been described for FV. It is known 
that the Sag encoded by mouse endogenous mtv-9 is able to crosslink the Vβ5 chain 
of T cells with the MHC class II on APCs (Figure 4. 10 B) (3, 324, 326). This leads to 
deletion or anergy of T cells in the thymus, a phenomenon that Tregs are relatively 
resistant to (27, 151, 152, 230, 277). 
 
To investigate the kinetics of Vβ5+ Treg expansion during FV infection, the 
percentage of Vβ5+ Tregs was investigated at various times post infection in the 
spleen (Figure 4. 11 A) and bone marrow (Figure 4. 11 B). In the spleen, Vβ5+ Treg 
expansion peaked at 10 dpi, whereas the peak was seen at 12 dpi in the bone 
marrow. Interestingly, no significant expansion of Vβ5+ Tregs was seen in the chronic 
phase of FV infection (40 dpi) for either organ. In summary, a disproportional 
expansion of Vβ5+ Tregs was detectable in the acute phase of FV infection, which 
was lost during chronic infection. The expansion suggested a role for mtv-9 Sag 
stimulation in Treg expansion. 
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Figure 4. 10 Vβ usage of Tregs during FV infection and the principle of superantigenic 
stimulation. (A) The proportions of TCR Vβ subsets expressed by CD4+Foxp3+ Tregs from 
the spleens of naïve Y10 mice (white bars) and 14 dpi FV-infected mice (black bars) are 
shown. Bars represent the mean and standard deviation from five mice. Only the increase in 
Vβ5+ Tregs was significant (P < 0.05 by t-test). Data courtesy of Kim Hasenkrug and Lara 
Myers. (B) Schematic showing the binding of an mtv Sag to the MHC class II molecule of an 
APC and the Vβ chain of the TCR on a T cell, independent of antigen specificity. The mtv 
Sag is a transmembrane protein. In general, this interaction leads to strong stimulation and 
proliferation of the T cell. 
 
 
 
Figure 4. 11 Kinetic of Vβ5+ Treg expansion during FV infection. B6 mice were infected 
i.v. with 20,000 SFFU FV or left un-infected. The percentage of Vβ5+ Tregs (CD4+Foxp3+) 
was assessed using flow cytometry for (A) spleen and (B) bone marrow cells at various 
times post infection. At least four mice per group were analysed from two independent 
experiments. The bars indicate the mean and SEM. For statistical analysis a Dunnett’s 
multiple comparison test was carried out with the naïve group as a reference (* < 0.05, ** < 
0.005, *** < 0.0005). 
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The marker sets investigated in the previous sections were utilised to detect any 
phenotypical discrepancies between the Vβ5+ and Vβ5- Treg populations during FV 
infection. To test this, the frequency of markers expressed on all Tregs from naïve 
mice were compared to the frequencies of the same markers on Vβ5+ and Vβ5- 
Tregs from FV-infected mice (12 dpi). First, the expression of the classical Treg 
marker CD25 was analysed. This marker was not up- but rather down-regulated on 
both Treg populations after FV infection (Figure 4. 12 A and B) and this down-
regulation was more pronounced for Vβ5- Tregs compared to Vβ5+ Tregs. 
 
Next the expression of different activation (CD43 and CD11a) and a homing marker 
(CD103), especially described for Tregs (269), were assessed. Interestingly, the 
percentages of CD43+ and CD11a+ Vβ5+ Tregs were elevated compared to CD43+ 
and CD11a+ Vβ5- Tregs, respectively, for the spleen but not the bone marrow in 
infected mice. No differences were observed between Vβ5+ and Vβ5- Tregs from 
infected mice for CD69, CD44 and CD62L in the spleen or bone marrow (data not 
shown). Although, the frequency of CD103+ Tregs was not significantly altered 
between naïve and FV-infected mice (Figure 4. 3 F), when Vβ5+ and Vβ5- Tregs from 
infected mice were investigated it was shown that Vβ5+ Tregs expressed higher 
levels of this marker compared to all other subsets (Figure 4. 13 C). In conclusion, 
FV infection induced Treg activation and Vβ5+ Tregs from FV-infected mice showed 
higher levels of activation than Vβ5- Tregs. For the evaluation of Vβ5+ Treg activation 
and homing CD43, CD11a and CD103 showed to be most useful. 
 
Next, two co-stimulatory (ICOS and GITR, Figure 4. 14 A and B) and two inhibitory 
(Lag3 and PD-1, Figure 4. 14 C and D) markers were chosen for the characterisation 
of Vβ5+ and Vβ5- Tregs during acute FV infection. No major differences in the 
frequencies of ICOS+, GITR+, Lag3+ and PD-1+ Vβ5+ Tregs and Vβ5- Tregs from FV-
infected mice were observed in either organ (Figure 4. 14 A – D). Only the frequency 
of Vβ5+ GITR+ Tregs was significantly higher than the frequency of Vβ5- GITR+ Tregs 
in the spleen of FV-infected mice (Figure 4. 14 D, left side). Moreover, Vβ5- Tregs 
showed higher percentages of ICOS+ cells in the bone marrow compared to Vβ5+ 
Tregs (Figure 4. 14 A, right side). In conclusion, the expression of co-stimulatory and 
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inhibitory markers did not vary significantly between Vβ5+ and Vβ5- Tregs from FV-
infected mice. 
 
Finally, the differentiation and proliferation of Vβ5+ and Vβ5- Tregs from FV-infected 
mice were investigated. Vβ5+ Tregs from FV-infected mice were more terminally 
differentiated compared to Vβ5- Tregs in the bone marrow (CD127low and KLRG1high) 
and spleen (KLRG1high) (Figure 4. 15 A and B). Furthermore, Vβ5+ Tregs from FV-
infected mice proliferated significantly more than Vβ5- Tregs in the spleen (BrdU and 
Ki67) and the bone marrow (Ki67) (Figure 4. 15 C and D).  
 
Overall, it was determined that Vβ5+ Tregs showed the phenotype of highly activated, 
short-lived effector cells, with higher levels of activation, differentiation and 
proliferation than Vβ5- Tregs during acute FV infection. 
 
 
Figure 4. 12 Expression of CD25 on Vβ5+ and Vβ5- Tregs during the acute phase of FV 
infection. B6 mice were infected i.v. with 20,000 SFFU FV or left un-infected and the 
expression of CD25 on CD4+Foxp3+ Tregs from naïve mice and Vβ5+ or Vβ5- Tregs 
(CD4+Foxp3+) from 12 dpi mice were measured using flow cytometry for (A) spleen and (B) 
bone marrow cells. Multiple independent experiments were carried out, with each dot 
representing a single mouse. Bars indicate the mean and SEM. Data sets following a 
Gaussian distribution were analysed using a one-way ANOVA with Bonferroni’s multiple 
comparison post-test. Data sets not following a Gaussian distribution were tested using 
Kruskal-Wallis-test with Dunn’s multiple comparison post-test. Statistical significance is 
indicated by asterisks (ns not significant and * < 0.05, ** < 0.005, *** < 0.0005). 
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Figure 4. 13 Expression of activation and homing markers on Vβ5+ and Vβ5- Tregs 
during the acute phase of FV infection. B6 mice were infected i.v. with 20,000 SFFU FV or 
left un-infected. The expression of various activation markers on CD4+Foxp3+ Tregs from the 
spleen and bone marrow of naïve mice or Vβ5+ and Vβ5- Tregs (CD4+Foxp3+) from infected 
mice (12 dpi) were measured using flow cytometry. The markers investigated were: (A) 
CD43, (B) CD11a and (C) CD103. Multiple independent experiments were carried out, with 
each dot representing a single mouse. The bars indicate the mean and SEM. Data sets 
following a Gaussian distribution were analysed using a one-way ANOVA with Bonferroni’s 
multiple comparison post-test. Data sets not following a Gaussian distribution were tested 
using Kruskal-Wallis-test with Dunn’s multiple comparison post-test. Statistical significance is 
indicated by asterisks (ns not significant, * < 0.05, ** < 0.005 and *** < 0.0005). 
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Figure 4. 14 Expression of co-stimulatory markers and inhibitory receptors on Vβ5+ 
and Vβ5- Tregs during FV infection. B6 mice were infected i.v. with 20,000 SFFU FV or left 
un-infected and the expression of various co-stimulatory and inhibitory markers on 
CD4+Foxp3+ Tregs from the spleen and bone marrow in naïve mice or Vβ5+ and Vβ5- Tregs 
(CD4+Foxp3+) from infected mice (12 dpi) were measured using flow cytometry. The markers 
investigated were: (A) ICOS, (B) GITR, (C) Lag3 and (D) PD-1. Multiple independent 
experiments were carried out, with each dot representing a single mouse. Bars indicate the 
mean and SEM. Data sets following a Gaussian distribution were analysed using a one-way 
ANOVA with Bonferroni’s multiple comparison post-test. Data sets not following a Gaussian 
distribution were tested using Kruskal-Wallis-test with Dunn’s multiple comparison post-test. 
Statistical significance is indicated by asterisks (ns not significant, * < 0.05, ** < 0.005 and *** 
< 0.0005). 
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Figure 4. 15 Expression of differentiation and proliferation markers on Vβ5+ and Vβ5- 
Tregs during FV infection. B6 mice were infected i.v. with 20,000 SFFU of FV or left un-
infected. All mice were fed with BrdU in their drinking water for three days before sacrifice. 
The expression of differentiation: (A) CD127 and (B) KLRG1; and proliferation: (C) Ki67 and 
(D) BrdU markers of CD4+Foxp3+ Tregs from the spleen or bone marrow of naïve mice or 
Vβ5+ and Vβ5- Tregs (CD4+Foxp3+) from infected mice (12 dpi) were measured using flow 
cytometry. Multiple independent experiments were carried out, with each dot representing a 
single mouse. The bars indicate the mean and SEM. Data sets following a Gaussian 
distribution were analysed using a one-way ANOVA with Bonferroni’s multiple comparison 
post-test. Data sets not following a Gaussian distribution were tested using Kruskal-Wallis-
test with Dunn’s multiple comparison post-test. Statistical significance is indicated by 
asterisks (ns not significant, * < 0.05, ** < 0.005 and *** < 0.0005). 
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4.7 Vβ5+ Tregs show a higher level of TCR-activation than Vβ5- 
Tregs after FV infection 
After determining that Vβ5+ Tregs display a phenotype of highly activated, short-lived 
effector cells, it was important to investigate the nature of the TCR signal they had 
received. As Vβ5+ Tregs were Sag stimulated (238), it was hypothesised that they 
had received a very strong TCR signal due to the Sag. Nur77-GFP mice were used 
to test this as these mice express GFP dependent on the strength signal received by 
the TCR of T cells. Nur77-GFP mice were infected with FV for 12 days and the GFP 
signal expressed by Tcon, Vβ5+ Tregs and Vβ5- Tregs was investigated. As 
expected, a higher TCR signal strength (MFI of GFP/Nur77) was detected for Vβ5+ 
Tregs from infected mice in comparison to Vβ5- Tregs in the spleen (Figure 4. 16 A) 
and bone marrow (Figure 4. 16 B). Interestingly, the MFI of GFP/Nur77 was higher 
for Tregs in comparison to Tcon, indicating that Tregs received stronger TCR signals 
than Tcon during FV infection.  
 
 
 
Figure 4. 16 Expression of Nur77 in Tcon, Vβ5+ and Vβ5- Tregs from FV-infected mice. 
Nur77-GFP transgenic mice were infected i.v. with 20,000 SFFU FV for 12 days and (A) the 
spleen and (B) bone marrow were analysed for the MFI of Nur77-GFP expression in total 
CD4+Foxp3- Tcon, CD4+Foxp3+Vβ5+ Tregs and CD4+Foxp3+Vβ5- Tregs. Three mice per 
group were analysed and bars indicate the mean and SEM. For statistical analysis a one-
way ANOVA with Bonferroni’s multiple comparison post-test was carried out (* < 0.05, ** < 
0.005 and *** < 0.0005). 
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4.8 The expansion of Vβ5- Tregs is dependent on signals produced 
by effector CD4+ T cells 
It has been shown in a model of bone marrow pathology induced by FV that virus-
specific Tcon from CD4 TCRtg mice induced expansion of Tregs (12). To determine 
what cell subset is responsible for the expansion of Vβ5+ or Vβ5- Tregs a similar 
model was utilised. In this experiment FV-infected mice (CD45.1-) received additional 
CD4+ T cells (CD45.1+) at 4 dpi by adoptive T cell transfer. These additional CD4+ T 
cells were isolated from CD4 TCRtg mice (EVα3-tg, FV-specific Tcon) or CD4 TCRwt 
mice (EVα3-wt). The spleens of the recipient mice were investigated at 7 dpi, which 
is a time point where almost no expansion of endogenous Tregs is detectable (340) 
(Figure 4. 1). This early time point was chosen to ensure that only the transferred, 
and not endogenous, CD4+ T cells could trigger Treg expansion. As control for the 
effective transfer, the numbers of virus-specific MHC class II tetramer+ (TetrII+) donor 
CD4+ T cells were quantified in the spleens of the recipient mice and significantly 
higher numbers were detected in mice that received FV-specific TCRtg CD4+ T cells 
compared to mice that received TCRwt CD4+ T cells (Figure 4. 17 A). Interestingly, 
the frequency of Vβ5-, but not Vβ5+, endogenous Tregs were significantly increased 
for mice that received TCRtg CD4+ T cells in comparison to mice that received TCRwt 
CD4+ T cells (Figure 4. 17 B).  
 
The factor that was produced by the activated TCRtg CD4+ and that most likely drove 
Vβ5- Treg expansion was IL2, which was expressed by a large number of transferred 
TCRtg CD4+ T cells (Figure 4. 17 C). In contrast, the IL2 production by endogenous 
CD4+ or CD8+ T cells was unaffected by the adoptive transfer (Figure 4. 17 D and E). 
In summary, these results suggest that the IL2 required for expansion of Vβ5- Tregs 
(212) was produced by virus-specific Tcon, which did not trigger the expansion of 
Vβ5+ Tregs. 
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Figure 4. 17 Expansion of Treg subsets after adoptive transfer of virus-specific CD4+ T 
cells. CD45.1- B6 mice were infected i.v. with 20,000 SFFU FV for 7 days. 5x106 magnetic 
bead isolated naïve CD4+ T cells from either CD45.1+ x EVα3-tg (FV-specific CD4+ T cells) or 
CD45.1+ x EVα3-wt mice were transferred into FV-infected CD45.1- mice at 4 dpi and the 
spleens were analysed at 7 dpi using flow cytometry. (A) The numbers of MHC class II 
tetramer+ CD4+CD11b- transferred (CD45.1+) cells in the spleen were determined and are 
displayed in the graph. (B) The relative expansion of Vβ5+ and Vβ5- endogenous (CD45.1-) 
Tregs when either virus specific or non-specific cells were transferred was evaluated and is 
shown. The numbers of IL2 expressing (C) activated transferred CD4+ T cells, (D) activated 
endogenous CD4+ T cells or (E) activated CD8+ T cells were measured after unspecific in 
vitro re-stimulation and are displayed in the graphs. Mice from three independent 
experiments were pooled and each dot represents an individual mouse. The bars represent 
the mean and SEM. For statistical analysis a Student’s t-test was used (ns not significant and 
*** < 0.0005). 
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4.9 The expansion of Vβ5+ Tregs is dependent on activated CD8+ T 
cells 
As shown in previous sections, Vβ5+ Tregs expand disproportionally during acute FV 
infection in the spleens of B6 mice (Figure 4. 18 A). To find the factor or cell type 
involved in this expansion, different transgenic mouse strains bred on a B6 
background or NK/NKT cell depleted mice were investigated.  
 
B cells are APCs capable of presenting the Sag required for TCR-stimulation of Vβ5+ 
Tregs (74). When two B cell deficient mouse strains were used: JH mice (Figure 4. 
18 B) and µMT mice (Figure 4. 18 C); no differences in Vβ5+ Treg expansion 
compared to B6 mice were observed. Granzyme B is an important molecule mainly 
produced by CD8+ T cells during acute FV infection (338). However, GzmB-KO mice 
also showed a disproportional Vβ5+ Treg expansion (Figure 4. 18 D). When NK cells, 
which also become activated during FV infection (183) were depleted, also no effect 
on the magnitude of Vβ5+ Treg expansion was observed (Figure 4. 18 E). These 
results suggested that neither B cells nor NK cells were involved in the expansion of 
Vβ5+ Tregs and that GzmB was also not required. 
 
CD8+ T cells play a prominent role in eliminating viral loads during acute FV infection 
and become highly activated by FV (84, 339, 340). Thus, it was of interest to 
investigate their influence on Tregs, especially Vβ5+ Treg expansion, during acute FV 
infection. When CD8+ T cell deficient mice were infected with FV, a lack of Vβ5+ Treg 
expansion was discovered in the spleen at 12 dpi (Figure 4. 19 A). Moreover, when 
CD8+ T cells were depleted in FV-infected mice during the acute phase of infection, 
the expansion of Vβ5+ Tregs was abolished in the spleen (Figure 4. 19 B). 
Interestingly, the overall number of Foxp3+ Tregs in the spleen of infected CD8+ T 
cell depleted mice did not change compared to only FV-infected mice (Figure 4. 19 
C), most likely because the expansion of Vβ5- Tregs was still present even in the 
absence of CD8+ T cells (Figure 4. 19 D). The same effect was also seen in CD8+ T 
cell deficient mice (data not shown). Interestingly, since CD8+ T cell deficient and 
CD8+ T cell depleted mice exhibited higher viral loads compared to wild type mice 
with CD8+ T cells, the expansion of Vβ5+ Tregs was clearly not driven by virus 
replication (data not shown). Thus, CD8+ T cells were identified as the major player 
driving Vβ5+ Treg expansion but not the expansion of the Vβ5- Treg subpopulation 
during acute FV infection.  
  Results 
101 
 
Figure 4. 18 Expansion of Vβ5+ Tregs in different knockout mouse strains or NK/NKT 
cell depleted mice during acute FV infection. (A) Wild type B6 mice (B) JH-mice (B cell 
deficient), (C) µMT-mice (B cell deficient), (D) GzmB-KO mice and (E) NK/NKT cell depleted 
(four times α-NK1.1, 300µL) or non-depleted wild type B6 mice were infected i.v. with 20,000 
SFFU FV (FV) or left uninfected (naïve). The percentages of Vβ5+ were investigated in the 
spleens using flow cytometry at 12 dpi and are shown in the graphs. At least one experiment 
per mouse strain was performed with each dot representing a single mouse. Bars indicate 
the mean and SEM. For statistical analysis a Student’s t-test was utilised (ns not significant, 
** < 0.005 and *** < 0.0005). For analysis of more than two groups a Kruskal-Wallis-test with 
Dunn’s multiple comparison post-test was carried out (ns not significant, * <0.05 and ** < 
0.005). 
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Figure 4. 19 Expansion of Vβ5+ Tregs in CD8+ T cell deficient mice during acute FV 
infection. CD8+ T cell deficient, wild type B6 mice and B6 mice depleted for CD8+ T cells (FV 
+ four times α-CD8, 500 µL) were infected i.v. with 20,000 SFFU FV (FV). As controls CD8+ 
T cell deficient or B6 mice were left uninfected (naïve). The percentages of Vβ5+ Tregs in the 
spleen were investigated using flow cytometry between 8 and 16 dpi in: (A) CD8+ T cell 
deficient (12 dpi) and (B) CD8+ T cell depleted (8 to 16 dpi) mice. The numbers of (C) total 
CD4+Foxp3+ Tregs or (D) CD4+Foxp3+Vβ5- Tregs were calculated per spleen for naïve and 
FV-infected (8 to 16 dpi) mice with or without CD8+ T cell depletion. Bars indicate the mean 
and SEM. (A) For CD8+ T cell deficient mice at least four mice per group were analysed. For 
statistical analysis a Student’s t-test was used (ns not significant). (B - D) For CD8+ T cell 
depleted mice multiple independent experiments were performed with each dot representing 
a single mouse. Data sets following a Gaussian distribution were analysed using a one-way 
ANOVA with Bonferroni’s multiple comparison post-test. Data sets not following a Gaussian 
distribution were tested using Kruskal-Wallis-test with Dunn’s multiple comparison post-test. 
Statistical significance is indicated by asterisks (ns not significant and *** < 0.0005). 
4.10 Vβ5+ Tregs expand via mbTNFα on CD8+ T cells that binds to 
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CD8+ T cells become activated during acute FV infection and produce different 
cytotoxic molecules and cytokines like Gzms, IFNγ, IL2 and TNFα (84, 341). In the 
previous section it was shown that GzmB and IL2 were not required for Vβ5+ Treg 
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expansion (see Figure 4. 17 B and E, and Figure 4. 18 D). Furthermore, IFNγ has 
been shown to be ineffective in inducing Vβ5+ Treg expansion during FV infection 
(Kim Hasenkrug, personal communication). However, CD8+ T cells produce 
substantial amounts of intracellular TNFα (icTNFα) during acute FV infection when 
re-stimulated in vitro (Figure 4. 20 A). icTNFα was measured first, as this gives an 
indication about the potential of CD8+ T cells to produce this cytokine before it is 
secreted. icTNFα is then transported to the surface of the CD8+ T cell as mbTNFα 
and becomes subsequently cleaved from the surface by TACE and released as 
solTNFα (5, 198, 273).  
 
When FV-specific CD8tg T cells were stimulated in vitro with peptide loaded bone 
marrow-derived DCs, presenting their cognate antigen, a strong up-regulation of 
mbTNFα was observed 6 hours after stimulation (MFI = 1812) in comparison to 
control cultures without the epitope peptide (MFI = 665) (Figure 4. 20 B). This high 
surface expression of TNFα was substantially decreased after 24 hours of stimulation 
(data not shown), most likely due to shedding of mbTNFα induced by the cleaving 
enzyme TACE (5, 198, 273). 
 
 
Figure 4. 20 Production of intracellular and membrane-bound TNFα by FV-specific 
CD8+ T cells. (A) B6 mice were infected i.v. with 20,000 SFFU FV or left uninfected and the 
percentage of icTNFα from activated CD8+ T cells (CD8+CD43+) was evaluated for spleen 
cells at 10 dpi using flow cytometry. icTNFα was measured after ex vivo unspecific re-
stimulation. Mice from four independent experiments were pooled and each dot represents 
an individual mouse. The bars represent the mean and SEM. For statistical analysis a 
Student’s t-test was used (*** < 0.0005). (B) CD8+ T cells were bead isolated from CD8tg 
mice and stimulated with bone marrow-derived DCs loaded or not with the cognate antigen. 
After six hours of culture, the CD8+ T cells were subject to TNFα surface analysis using flow 
cytometry. The legend indicates the sample and the MFI of mbTNFα on TNFα+ CD8+ T cells. 
One representative experiment from three is shown. 
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TNFα can bind two different surface receptors, TNFRI and TNFRII. It has been 
shown that TNFRI preferentially binds soluble TNFα, whereas TNFRII has a much 
higher affinity for mbTNFα (120, 121). To analyse if Tregs selectively express either 
receptor during FV infection, Tregs were stained for TNFRI and TNFRII and analysed 
using flow cytometry. TNFRI was only expressed on very few Tregs from the spleen 
of naïve mice (less than 2.5%) and this percentage was not enhanced after FV 
infection for either Treg subset, Vβ5+ and Vβ5- Tregs (Figure 4. 21 A). Furthermore, 
when the MFI of the TNFRI expression was compared between the few cells positive 
for TNFRI no difference was observed between Vβ5+ and Vβ5- Tregs and both 
subsets showed rather down-regulation compared to Tregs from naïve mice (Figure 
4. 21). In a stark contrast, TNFRII was present on approximately 35% of all Tregs 
from the spleen of naïve mice, which increased significantly to over 55% after FV 
infection. Strikingly, there was a significantly higher percentage of TNFRII+Vβ5+ 
Tregs compared to TNFRII+Vβ5- Tregs in FV-infected mice (Figure 4. 21 C). 
Additionally, the MFI for TNFRII expression was significantly increased after FV 
infection for both Treg subsets (Figure 4. 21 D). 
 
 
Figure 4. 21 Expression of TNFRI and TNFRII on Vβ5+ and Vβ5- Tregs during FV 
infection. B6 mice were infected i.v. with 20,000 SFFU FV and the expression of TNFRI and 
TNFRII was measured on Vβ5+ and Vβ5- Tregs from the spleen at 12 dpi using flow 
cytometry. (A) The percentages of Treg subsets positive for TNFRI are shown. (B) Graph 
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showing the MFI for TNFRI expression on TNFRI+ Tregs. (C) The percentages of Treg 
subsets positive for TNFRII are shown. (D) Graph showing the MFI for TNFRII expression on 
TNFRII+ Tregs. The TNFR expression levels of all Tregs (CD4+Foxp3+) from naïve mice are 
shown by the dotted line. Six independent experiments were carried out, with each dot 
representing a single mouse. Bars indicate the mean and SEM. For statistical analysis a 
Student’s t-test was used (ns not significant, * < 0.005 and ** < 0.005). 
 
These results imply that TNFRII, which is relatively selective for mbTNFα, is critically 
involved in Treg and especially Vβ5+ Treg expansion during acute FV infection. To 
test this hypothesis, transgenic mice lacking either TNFRI or both TNFRs were 
analysed for the expansion of Vβ5+ Tregs during FV infection. Bead isolated and 
genetically-labelled (CD45.1-) naïve CD4+ T cells, containing Tregs, from either 
TNFRI-KO or TNFRI+II-KO mice were transferred into FV-infected wild type mice (6 
dpi) (CD45.1+). As a control naïve CD4+ T cells from wild type B6 mice were used. 
This resulted in an expansion of the donor wild type Vβ5+ Treg population in the 
recipient mice at 12 dpi (Figure 4. 22 A). The transfer of Vβ5+ Tregs from TNFRI-KO 
mice resulted in a similar expansion, whereas Vβ5+ Tregs from TNFRI+II-KO did not 
expand (Figure 4. 22 A). A control experiment showed that the transfer of CD4+ T 
cells did not interfere with the expansion of the endogenous Vβ5+ Tregs (Figure 4. 22 
B). Taken together this data suggests that TNFRII is the critical receptor involved in 
Vβ5+ Treg expansion during acute FV infection. 
 
 
Figure 4. 22 Transfer of TNFRI-KO and TNFRI+II-KO CD4+ T cells into FV-infected mice 
and their effect on Vβ5+ Treg expansion. CD45.1+ B6 mice were infected i.v. with 20,000 
SFFU of FV. On day 6 post infection 3-5x106 magnetic bead isolated CD4+ T cells of either 
naïve B6, TNFRI-KO or TNFRI+II-KO origin (all CD45.1- mice) were transferred i.v. and left 
to proliferate for an additional six days. The mice were sacrificed at 12 dpi and the spleen 
cells analysed using flow cytometry. (A) The percentage of Vβ5+ Tregs of the transferred 
(CD45.1-) CD4+Foxp3+ Tregs is shown. The dotted line indicates the mean level of Vβ5+ 
Tregs in the spleen of naïve mice. (B) The percentage of endogenous Vβ5+ Tregs 
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(CD45.1+CD4+Foxp3+) in mice that received CD4+ T cells of different origin is displayed. The 
dotted line indicates the mean level of Vβ5+ Tregs in naive mice. For statistical analysis a 
Dunnett’s multiple comparison test was used with B6 as reference group (ns not significant, 
** < 0.005). 
 
TNFRII has a strong affinity for mbTNFα, a molecule that is expressed on the surface 
of activated FV-specific CD8+ T cells in vitro, as shown above (Figure 4. 20 B). To 
better understand the role of mbTNFα for Vβ5+ Treg expansion, iRhom2-KO mice 
were utilised. These mice lack the expression of the rhomboid family member 
iRhom2 which is critical for the expression of TACE on hematopoietic cells and 
therefore the cleavage and liberation of mbTNFα (5, 198, 273). When iRhom2-WT 
and iRhom2-KO CD8+ T cells were stimulated in vitro with α-CD3/α-CD28 T cell 
stimulator beads, both cell populations up-regulated mbTNFα 6 hours after 
stimulation, with CD8+ T cells of iRhom2-KO mice (MFI = 1619) showing a higher 
signal than CD8+ T cells of iRhom2-WT mice (MFI = 1076) (Figure 4. 23). 
 
 
Figure 4. 23 Expression of membrane-bound TNFα on stimulated iRhom2-WT and 
iRhom2-KO CD8+ T cells. For the evaluation of mbTNFα, CD8+ T cells of iRhom2-WT or 
iRhom2-KO mice were unspecifically re-stimulated in vitro or left unstimulated. After six 
hours the CD8+ T cells were subject to TNFα surface analysis by flow cytometry. The legend 
indicates the sample and the MFI of mbTNFα on mbTNFα+ CD8+ T cells. One representative 
example is shown. 
 
To show that mbTNFα is the important factor for Vβ5+ Treg expansion on CD8+ T 
cells, bead isolated CD8+ T cells from either iRhom2-WT or iRhom2-KO mice were 
transferred into FV-infected CD8+ T cell deficient mice, which do not show a 
disproportionate expansion of Vβ5+ Tregs after FV infection because of their lack in 
CD8+ T cells (Figure 4. 19 A). As expected, the increased levels of mbTNFα on the 
surface of iRhom2-KO CD8+ T cells resulted in significantly enhanced Vβ5+ Treg 
expansion in the recipient mice compared to mice that received iRhom2-WT CD8+ T 
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cells (Figure 4. 24 A). No such difference was seen for the expansion of Vβ5- Tregs 
(Figure 4. 24 B). 
 
Furthermore, when the proliferation (Figure 4. 24 C) and the activation (Figure 4. 24 
D) of the two Treg populations were analysed from mice that received iRhom2-WT or 
iRhom2-KO cells, it was found that the endogenous Vβ5+ Treg populations showed 
higher activation and proliferation in recipients of iRhom2-KO than of iRhom2-WT 
CD8+ T cells. No such effect was seen on Vβ5- Treg proliferation and activation. 
Taken together these data indicate that mbTNFα expressed on activated CD8+ T 
cells provides an important signal required for the activation and expansion of Vβ5+ 
Tregs, whereas Vβ5- Tregs were obviously only dependent on IL2 stimulation. 
 
 
Figure 4. 24 Transfer of iRhom2-WT and iRhom2-KO CD8+ T cells into CD8+ T cell 
deficient mice to trigger Vβ5+ Treg expansion during FV infection. CD8+ T cell deficient 
mice were infected i.v. with 20,000 SFFU FV. Five dpi, 7-8x106 magnetic bead isolated CD8+ 
T cells from either naïve iRhom2-WT or iRhom2-KO mice were transferred via i.v. injection 
into infected CD8+ T cell deficient mice. On day 10 post infection the spleen cells were 
analysed using flow cytometry and the numbers of (A) Vβ5+ Tregs and (B) Vβ5- Tregs per 
million live cells were assessed. The frequency of Vβ5+ or Vβ5- Tregs as: (C) Ki67+ or (D) 
CD43+ in mice that received iRhom2-WT-CD8+ or iRhom2-KO-CD8+ T cells are shown. The 
results of two independent experiments are shown. Bars indicate the mean and SEM. For 
statistical analysis a Student’s t-test was used (ns not significant, * < 0.05 and ** < 0.005). 
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4.11 Expansion of Vβ5+ Tregs with a synthetic TNFRII-ligand in the 
absence of infection 
To analyse if the intercellular communication between Vβ5+ Tregs and activated 
CD8+ T cells can be bypassed, a complexed TNFα nonamer (compTNFα) was used 
which can only bind to TNFRII. As a control recombinant human soluble TNFα, which 
can only bind mouse TNFRI, was used (180). Naïve mice were treated twice i.p. with 
the different forms of TNFα. The solTNFα did not expand Vβ5+ Tregs in naïve mice, 
nor did it influence their proliferation (Figure 4. 25 A and B). Strikingly, the compTNFα 
was able to significantly increase the number of Vβ5+ Tregs per one million spleen 
cells and their proliferation measured by Ki67 expression analysis (Figure 4. 25 A 
and B). This expansion of Vβ5+ Tregs was dependent on the presence of TNFRII as 
shown by the lack of expansion and proliferation in TNFRII-KO mice treated with the 
compTNFα (Figure 4. 25 A and B). In conclusion, this data provides clear evidence 
that Vβ5+ Tregs, which receive a strong TCR signal by the constitutively expressed 
mtv-9 Sag, require TNFRII mediated secondary signalling for their efficient activation 
and expansion. 
 
 
Figure 4. 25 Induction of Vβ5+ Treg expansion with soluble human TNFα or complexed 
mouse TNFα nonamer. Naïve B6 were treated twice (day 0 and day 2) i.p. with 1 ng human 
solTNFα or 25 µg of mouse compTNFα. As a control TNFRII-KO mice were treated with 
compTNFα. Four days after the start of the treatment the animals were sacrificed and the 
spleen cells analysed using flow cytometry. (A) The numbers of Vβ5+ Tregs per million live 
spleen cells and (B) the frequency of Ki67+ cells of Vβ5+ Tregs are shown. Multiple 
independent experiments were carried out, with each dot representing a single mouse. Bars 
indicate the mean and SEM. For statistical analysis a Dunnett’s multiple comparison test was 
performed with the naïve group as reference (ns not significant, ** < 0.005). 
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4.12 Depletion of Vβ5+ T cells augments CD8+ T cell function but 
does not result in reduced viral loads 
In the previous sections it has been shown that Vβ5+ Tregs are highly activated 
during acute FV infection. Furthermore, they expand in response to TNFα presented 
on the surface of activated virus-specific CD8+ T cells. Therefore the biological 
importance of the Vβ5+ Treg subset during FV infection was of great interest. To test 
this Vβ5+ T cells were depleted by antibody treatment and the effector phenotype of 
CD8+ T cells was subsequently determined. The depletion efficiency of the Vβ5 
depletion-antibody was more than 98% for Vβ5+ Tregs and Tcon in the spleen (Figure 
4. 26 A). Importantly, the depletion of Vβ5+ T cells also affected the subset of 
CD8+Vβ5+ T cells, which resulted in a mean of 14.75%±4.06% of all activated CD8+ T 
cells depleted (Figure 4. 26 B). However, despite this reduction in numbers of 
activated CD8+ T cells, no significant loss of activated virus-specific (CD43+TetrI+) 
CD8+ T cells (Figure 4. 27 A) was detected. In contrast, higher frequencies of 
activated GzmB producing (CD43+GzmB+) CD8+ T cells and virus-specific GzmB 
producing (TetrI+GzmB+) CD8+ T cells were observed after Vβ5 depletion compared 
to the non-depleted FV-infected control group (Figure 4. 27 B and C). This showed 
that the Vβ5+ Treg subpopulation played a significant role in suppressing CD8+ T cell 
function during acute FV infection. Surprisingly, despite the elevated cytotoxic CD8+ 
T cell response in Vβ5+ T cell depleted mice, there was no significant difference in 
the viral loads in the spleen of Vβ5+ T cell depleted versus control mice detectable at 
12 dpi (Figure 4. 28).  
 
Overall, the depletion of Vβ5+ Tregs augmented the cytotoxic activity of FV-specific 
CD8+ T cells but at the same time reduced the total numbers of activated CD8+ T 
cells, which might explain why no changes in viral loads were observed after Vβ5+ T 
cell depletion.  
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Figure 4. 26 Vβ5 depletion efficiency of a α-Vβ5 MAb in the spleen of FV-infected mice. 
B6 mice were infected i.v. with 20,000 SFFU FV and one group was treated i.p. with 300 µg 
of α-Vβ5 depletion MAb on day 4 post infection. To check for the depletion efficiency, spleen 
samples were stained for analysis by flow cytometry at 12 dpi. The depletion efficiency for 
(A) Tcon (CD4+Foxp3-) and Treg (CD4+Foxp3+) and (B) activated (CD43+) CD8+ T cells are 
shown as representative dot blots (left – non-depleted, right – depleted). The percentages in 
each gate are displayed in the corners of each quadrant. 
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Figure 4. 27 The CD8+ T cell response in Vβ5-depleted mice. B6 mice were infected i.v. 
with 20,000 SFFU FV and one group was treated i.p. with 300 µg of α-Vβ5 depletion MAb on 
day 4 post infection. The CD8+ T cell response was investigated in the spleen at 12 dpi for 
the frequencies of (A) activated virus-specific (CD43+TetrI+), (B) activated GzmB producing 
(CD43+GzmB+) and (C) activated virus-specific GzmB+ (CD43+TetrI+GzmB+) CD8+ cells using 
flow cytometry. Four independent experiments were carried out with each dot representing a 
single mouse. Bars indicate the mean and SEM. For statistical analysis a Student’s t-test 
was used (ns not significant and * < 0.05). 
 
 
Figure 4. 28 Viral loads in Vβ5-depleted FV-infected mice. B6 mice were infected i.v. with 
20,000 SFFU FV and one group was treated i.p. with 300 µg of α-Vβ5 depletion MAb on day 
4 post infection. An IC assay was performed and the counts of infectious centres per total 
spleens were calculated. Four independent experiments were analysed with each dot 
representing a single mouse. Bars indicate the mean and SEM. For statistical analysis a 
Student’s t-test was used (ns not significant and * < 0.05). 
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4.13 Expression of immune-suppression associated enzymes on 
Tregs during acute FV infection 
After demonstrating that Tregs have a suppressive effect on CD8+ T cells during FV 
infection, it was of interest to determine the molecular mechanism of Tregs mediated 
suppression. Various mechanisms for the suppressive activity of Tregs have been 
described. Thus far, no mechanism for Treg-induced immune suppression in FV 
infection has been defined, but a few possibilities can be excluded. These include 
IL10 (Dittmer U et al., 2004;Iwashiro M et al., 2001) and TGFβ (Robertson S J et al., 
2006) and also CTLA-4 played only a minor role in Treg mediated suppression 
(Iwashiro M et al., 2001). However, Robertson et al. showed that Tregs suppress FV-
specific CD8+ T cells in a cell-contact dependent, APC-independent manner.  
 
GzmB is a serine protease that can, with the help of perforin, kill cells in close 
proximity and has been shown to be produced by Tregs in a FV in vivo tumour model 
(Akhmetzyanova I et al., 2013). CD8+ T cells are potent producers of GzmB during 
FV infection (Zelinskyy G et al., 2006) and CD4+ T cells are also able to produce low 
amounts of this cytokine (195). It was therefore possible that Tregs might induce 
suppression by GzmB-mediated killing of effector T cells. In addition, TNFα can 
mediate apoptosis in adjacent cells and is also produced by CD8+ T cells and Tcon 
during FV infection. However, for both molecules no production by Tregs could be 
detected during acute FV infection (data not shown). 
 
Recently, two molecules that can mediate immune suppression have been 
described: CD73 (ecto-5’-nucleotidase) and CD39 (ecto-nucleoside triphosphate 
diphosphohydrolase 1). These enzymes work in a subsequent reaction in which ATP 
is metabolised to adenosine. Adenosine can then bind to the A2A receptor and 
mediate T cell suppression (34, 78, 162). To determine if this mechanism is involved 
in CD8+ T cell suppression by Tregs during FV infection, the expression of CD73 and 
CD39 on Tregs from naïve and infected mice was investigated. In the spleen of naïve 
and FV-infected mice, Tregs were almost entirely positive for either CD39 (Figure 4. 
29 A, left side) or CD73 (Figure 4. 29 A, right side), but a significant up-regulation of 
CD39 could still be demonstrated after infection. The frequency of Tcon positive for 
CD39 and CD73 was much lower compared to Tregs and CD39 was also up-
regulated upon infection (Figure 4. 29 B).  
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For an effective suppressive function using this enzyme cascade, the expression of 
both molecules on a single cell is important. Most Tregs were positive for both CD39 
and CD73 in the spleen of naïve mice and this percentage significantly increased in 
FV-infected mice. Tcon showed a low percentage of double positive cells in naïve 
mice and this increased only marginally in FV-infected mice (Figure 4. 29 C). Similar 
results were also obtained for the bone marrow (data not shown). In summary, it was 
found that more than 75% of all Tregs express both CD39 and CD73 on their surface 
in naïve and FV-infected mice, which suggests that this pathway might play a role in 
CD8+ T cell suppression during acute FV infection. 
 
 
Figure 4. 29 Expression of CD39 and CD73 on Tregs in the spleen of naïve or FV-
infected mice. B6 mice were infected i.v. with 20,000 SFFU FV or left un-infected and the 
expression of CD39 and CD73 on spleen cells was measured using flow cytometry on (A) 
Tregs (CD4+Foxp3+) and (B) Tcon (CD4+Foxp3-) at 12 dpi. Multiple independent experiments 
were carried out, with each dot representing a single mouse. Bars indicate the mean and 
SEM. For statistical analysis a Student’s t-test was used (ns not significant, ** < 0.005 and *** 
< 0.0005). (C) Representative dot blots are shown for the dual expression of CD39 and 
CD73 on Tregs and Tcon from naïve and infected mice (12 dpi). 
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4.14 Effects of blocking CD73 on T cell responses during acute FV 
infection 
Firstly, the down-stream enzyme, CD73, was tested for its role in Treg mediated 
suppression during FV infection. CD73 was blocked with a small molecule, AMPCP, 
via i.p. injection into FV-infected mice. This methodology for blocking CD73 
enzymatic activity with AMPCP is specific and has been proven effective in mouse 
tumour models (334, 344). To evaluate the effect of this molecular blocking on the 
expression of both enzymes, the numbers of CD39+ and CD73+ Tregs of mice in the 
acute phase of FV infection were investigated. The block of CD73, did not change 
the numbers of CD39+, CD73+ or CD39+CD73+ Tregs per million spleen cells (Figure 
4. 30), and similar results were obtained for the bone marrow (data not shown). 
Furthermore, no alteration of activation and proliferation markers such as Ki67, 
KLRG1 or Helios, were observed on Tregs after AMPCP injection (data not shown). 
However, the used dose has been shown to be effective in blocking CD73 enzymatic 
activity (personal communication Svetlana Karakhanova, Department of 
Dermatology, University of Heidelberg, Germany). Thus the Treg phenotype or 
activation status was not altered, but the suppressive function of the Tregs may still 
be affected by blocking CD73.  
 
To determine any effects on the in vivo suppressive activity of treated Tregs the 
CD8+ and CD4+ T cell response was evaluated in FV-infected mice. CD4+ T cells did 
not increase activation (CD43+CD62L-) in AMPCP treated mice, nor did they show 
any signs of enhanced cytokine production (IFNγ+, IL2+ or TNFα+) in the spleen 
(Figure 4. 31 A and Figure 4. 32 A) or bone marrow (data not shown) compared to 
only FV-infected mice. 
 
CD8+ T cells also did not become more activated in treated compared to un-treated 
mice (CD43+CD62L-), and there were no higher frequencies of activated virus 
specific (CD43+TetrI+), cytotoxin producing (CD43+GzmB+) or CD8+ T cells showing 
signs of recent degranulation (CD43+CD107a+) in the spleen (Figure 4. 31 B) or bone 
marrow (data not shown). Furthermore, when CD8+ T cells were investigated for 
cytokine (IFNγ+, IL2+ or TNFα+) production, no differences between FV-infected and 
the infected AMPCP treated mice were found in the spleen (Figure 4. 32 B) or bone 
marrow (data not shown). 
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Finally, the viral loads in FV-infected and infected AMPCP treated mice were 
investigated and no reduction was seen in the spleen (Figure 4. 33) or bone marrow 
(data not shown). Thus overall, the block of CD73 with AMPCP does not influence 
adaptive T cell immune responses or the viral load during acute FV infection. 
 
 
Figure 4. 30 The numbers of CD39+ and CD73+ Tregs after AMPCP treatment. B6 mice 
were infected i.v. with 20,000 SFFU FV for 12 days and one group was treated i.p. three 
times every other day with 200 µg AMPCP starting from 6 dpi. The numbers of CD39+, 
CD73+ and CD39+CD73+ Tregs in the spleen were measured using flow cytometry and a 
comparison between non-treated infected mice (FV) and AMPCP treated infected mice (FV + 
AMPCP) was carried out. Three independent experiments were done, with each dot 
representing a single mouse. Bars indicate the mean and SEM. For statistical analysis a 
Student’s t-test was used (ns not significant). 
 
 
 
Figure 4. 31 Treatment of FV-infected mice with AMPCP and the effect on activation 
and production of cytotoxic molecules from CD4+ and CD8+ T cells. B6 mice were 
infected i.v. with 20,000 SFFU FV for 12 days and one group was treated i.p. three times 
every other day with 200 µg AMPCP starting from 6 dpi. (A) CD4+ T cells and (B) CD8+ T 
cells from the spleen were assessed for their phenotype. The percentage of activated cells 
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(CD43+CD62L-), activated virus-specific cells (CD43+TetrI+), production of the cytotoxic 
molecule GzmB by activated cells (CD43+GzmB+) and activated cells that recently de-
granulated (CD43+CD107a+) were measured using flow cytometry. A comparison between 
untreated infected mice (FV) and AMPCP treated infected mice (FV + AMPCP) is shown. 
Three independent experiments were conducted, with each dot representing a single mouse. 
Bars indicate the mean and SEM. For statistical analysis a Student’s t-test was used (ns not 
significant). 
 
 
Figure 4. 32 Treatment of FV-infected mice with AMPCP and the effect on cytokine 
production from CD4+ and CD8+ T cells. B6 mice were infected i.v. with 20,000 SFFU FV 
for 12 days and one group was treated i.p. three times every other day with 200 µg AMPCP 
starting from 6 dpi. Before staining for FACS analysis the cells were unspecifically re-
stimulated ex vivo. The percentage of activated cells producing different cytokines 
(CD43+IFNγ+, CD43+IL2+, CD43+TNFα+) was measured by flow cytometry and a comparison 
between untreated acutely infected mice (FV) and AMPCP treated acutely infected mice (FV 
+ AMPCP) is shown for the spleen for (A) CD4+ and (B) CD8+ T cells. Three independent 
experiments were conducted, with each dot representing a single mouse. Bars indicate the 
mean and SEM. For statistical analysis a Student’s t-test was used (ns not significant). 
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Figure 4. 33 Virus titres after AMPCP treatment of FV-infected mice. B6 mice were 
infected i.v. with 20,000 SFFU FV for 12 days and one group was treated i.p. three times 
every other day with 200 µg AMPCP starting from 6 dpi. An IC assay was carried out and the 
count of infectious centres per 1x106 spleen cells is shown for untreated infected mice (FV) 
and AMPCP treated infected mice (FV + AMPCP). Three independent experiments were 
conducted with each dot representing a single mouse. Bars indicate the mean and SEM. For 
statistical analysis a Student’s t-test was used (ns not significant). 
4.15 CD73 knock-out mice show an only slightly enhanced 
cytotoxic CD8+ T cell response during FV infection 
To verify the results from the biochemical blockage experiment, antiviral immune 
responses to FV infection were investigated in CD73-KO mice. Treg cell numbers in 
CD73-KO and CD73-WT mice were normal compared to B6-WT mice and were also 
indistinguishable between FV-infected CD73-WT and CD73-KO mice (data not 
shown).  
 
For effector T cell responses, no differences in activation of CD4+ T cells 
(CD43+CD62L-; Figure 4. 34 A) or cytokine production (TNFα, IL2 and IFNγ; data not 
shown) were found between FV-infected CD73-KO and WT mice. CD8+ T cells play a 
more dominant role for controlling acute FV infection and are therefore more 
susceptible to Treg induced suppression. There was a minor, albeit significant, 
increase in the frequency of activated (CD43+CD62L-) and GzmB-producing 
(CD43+GmzB+) CD8+ T cells in the spleens of FV-infected CD73-KO mice compared 
to WT mice (Figure 4. 34 B). However, no differences for virus-specific (CD43+TetrI+), 
degranulated (CD43+CD107a+) (Figure 4. 34 B) or cytokine producing (TNFα, IL2 
and IFNγ; data not shown) CD8+ T cells were seen between CD73-KO and CD73-
WT mice. Similar results were obtained for CD4+ and CD8+ T cells in the bone 
marrow. 
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Even though CD8+ T cells from CD73-KO mice were slightly more activated and a 
higher frequency were CD43+GzmB+ compared to CD73-WT mice, this had no effect 
on the viral load assessed in the spleen (Figure 4. 35) or bone marrow (data not 
shown) at 10 dpi. In summary, CD73 does not play a major role in Treg mediated 
suppression of CD4+ and CD8+ T cell responses; although a small effect on CD8+ T 
cell activation was found. 
 
 
Figure 4. 34 The effect of CD73-KO on activation and production of cytotoxic 
molecules from CD4+ and CD8+ T cells in FV-infected mice. CD73-WT and CD73-KO 
mice were infected i.v. with 20,000 SFFU FV for 10 days and (A) CD4+ T cells and (B) CD8+ 
T cells from the spleen were analysed. The frequency of activated cells (CD43+CD62L-), 
activated virus-specific cells (CD43+TetrI+), activated cells producing GzmB (CD43+GzmB+) 
and cell that had recently de-granulated (CD43+CD107a+) were measured using flow 
cytometry and are shown. One to three independent experiments with at least four mice per 
group were analysed. Bars indicate the mean and SEM. For statistical analysis a Student’s t-
test was used (ns not significant and * < 0.05). 
 
 
Figure 4. 35 Virus titres of FV-infected CD73-KO mice. CD73-WT and CD73-KO mice 
were infected i.v. with 20,000 SFFU FV for 10 days and an IC assay was performed with 
splenocytes. The count of infectious centres per 1x106 spleen cells was calculated and is 
shown in the graph. At least four mice per group were analysed. Bars indicate the mean and 
SEM. For statistical analysis a Student’s t-test was used (ns not significant). 
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4.16 CD39 knock-out mice show an augmented T cell response 
during acute FV infection without altering viral loads 
After analysing the role of CD73 during FV infection, the role of CD39 was also 
investigated in a knockout mouse model. CD39 is the rate limiting enzyme in the 
cascade of Treg-mediated suppression via CD39 and CD73. To evaluate the role of 
CD39, CD39-KO and CD39-WT mice were infected with FV for 10 days and the 
same immunological parameters as for the CD73-KO/WT mice were analysed. Again 
the CD39 knockout had no influence on the numbers of Tregs in the spleen when 
compared to CD39-WT or B6-WT mice in infected animals (Figure 4. 36 A). In 
contrast, there was a significant increase in Treg numbers in the bone marrow of 
infected CD39-KO mice compared to infected CD39-WT mice (Figure 4. 36 B). 
 
To investigate if the lack of CD39 has an effect on the suppressive function of Tregs, 
the production of cytokines and cytotoxic molecules in CD4+ and CD8+ T cells from 
FV-infected CD39-KO and CD39-WT mice was assessed. After 10 dpi there were no 
significant differences in the activation (CD43+CD62L-) or cytokine production (TNFα, 
IL2 and IFNγ) of CD4+ T cells between CD39-WT and CD39-KO mice in the spleen 
(Figure 4. 37 A and Figure 4. 38 A) or bone marrow (data not shown). However, a 
lack of CD39 led to an increased frequency of activated (CD43+CD62L-), virus 
specific (CD43+TetrI+) and GzmB producing (CD43+GzmB+) CD8+ T cells in the 
spleen (Figure 4. 37 B) and bone marrow of infected mice (data not shown). No 
changes in frequencies of recently de-granulated (CD43+CD107a+) CD8+ T cells 
were detected due to the CD39 knockout (Figure 4. 37 B). Interestingly, for cytokine 
responses, an increase in the frequencies of activated IFNγ producing CD8+ T cells 
was seen in the spleen (Figure 4. 38 B) and bone marrow (data not shown) of CD39-
KO compared to CD39-WT mice. No change in the frequencies of CD43+TNFα+ and 
CD43+IL2+ CD8+ T cells were found in the spleen (Figure 4. 38 B) or bone marrow 
(data not shown) of FV-infected CD39-KO mice compared to infected CD39-WT 
mice. 
 
Finally, as knockout of CD39 increased activated virus-specific, cytotoxin and IFNγ 
producing CD8+ T cell numbers, it was of interest to assess the viral loads in FV-
infected CD39-KO compared to infected CD39-WT mice. No differences in viral loads 
were observed in the spleen (Figure 4. 39) or bone marrow (data not shown); 
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however, a trend towards lower viral loads was seen in CD39-KO compared to 
CD39-WT mice. In conclusion, it was shown that CD8+ T cells from CD39-KO mice 
show a higher activation and production of GzmB and IFNγ compared to CD39-WT 
mice, however this had no effect on viral loads during the acute phase of infection.  
 
 
 
Figure 4. 36 Numbers of Tregs in FV-infected CD39-KO, and CD39-WT mice. CD39-KO, 
CD39-WT and B6-WT mice were infected i.v. with FV for 10 days and the numbers of 
CD4+Foxp3+ Tregs per 1x106 cells were assessed using flow cytometry for spleen and bone 
marrow cells. A comparison of infected CD39-KO, CD39-WT and B6-WT mice is shown: (A) 
for the spleen and (B) the bone marrow. Each dot represents a single mouse. The bars 
indicate the mean and SEM. For statistical analysis a Dunnett’s multiple comparison test was 
carried out with B6-WT as a reference (ns not significant, * < 0.05). 
 
 
 
Figure 4. 37 The effect of CD39-KO on activation and production of cytotoxic 
molecules from CD4+ and CD8+ T cells in FV-infected mice. CD39-WT and CD39-KO 
mice were infected i.v. with 20,000 SFFU FV for 10 days and (A) CD4+ T cells and (B) CD8+ 
T cells from the spleen were analysed. The frequency of activated (CD43+CD62L-), virus-
specific cells (CD43+TetrI+), cells producing GzmB (CD43+GzmB+) and cells that recently de-
granulated (CD43+CD107a+) were measured using flow cytometry and are shown. At least 
six mice per group were analysed. The bars indicate the mean and SEM. For statistical 
analysis a Student’s t-test was used (ns not significant, * < 0.05, ** < 0.005). 
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Figure 4. 38 Cytokine production in CD4+ and CD8+ T cells from FV-infected CD39-KO 
and CD39-WT mice. CD39-WT and CD39-KO mice were infected i.v. with 20,000 SFFU FV 
for 10 days and the frequency of activated cells producing different cytokines (CD43+TNFα +, 
CD43+IL2+, CD43+IFNγ +) were measured using flow cytometry. Before staining for FACS 
analysis the cells were unspecifically re-stimulated ex vivo. The cytokine profiles for: (A) 
CD4+ and (B) CD8+ T cells in the spleen are shown. At least six mice per group were 
analysed. Bars indicate the mean and SEM. For statistical analysis a Student’s t-test was 
used (ns not significant, * < 0.05). 
 
 
Figure 4. 39 Virus titres of FV-infected CD39-KO mice. CD39-WT and CD39-KO mice 
were infected i.v. with 20,000 SFFU FV for 10 days and an IC assay was conducted. The 
count of infectious centres per 1x106 spleen cells was calculated and is shown. At least four 
mice per group were analysed. The bars indicate the mean and SEM. For statistical analysis 
a Student’s t-test was used (ns not significant). 
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4.17 Investigation into the activation profile of human Tregs during 
HIV-1 infection and the influence of HAART 
Tregs play an important role in suppressing anti-viral immune responses in HIV-1 
infection (251). While HIV-1 is a complex retrovirus, from the lentivirus genus, and FV 
is a simple retrovirus, both induce the expansion of Tregs during chronic infection of 
their host. To determine if human Tregs show similar characteristics of activation 
compared to mouse Tregs, the activation of human Tregs in vitro and ex vivo was 
investigated. Four markers, KLRG1, TNFRII, CD25 and CD127, were chosen based 
on the observations made in the FV infection model. To establish if these markers 
could be used to monitor activation of human Tregs, PBMCs from healthy donors 
were TCR stimulated and the levels of marker expression on Tregs were measured. 
Human Tregs were characterised as CD4+Foxp3+, based on the gating strategy 
shown in Figure 3. 4. Three markers (KLRG1, TNFRII and CD25) became 
significantly up-regulated on the stimulated compared to the non-stimulated Tregs. 
CD127 expression was down-regulated, although no significance was detected 
(Figure 4. 40).  
 
Figure 4. 40 The effect of bead-stimulation on the activation of human Tregs. Isolated 
human PBMCs from healthy donors were plated and either not stimulated or stimulated with 
α-CD3/α-CD28 coated human stimulation beads. The cells were then stained and analysed 
using flow cytometry. The percentage of different markers on CD4+Foxp3+ Tregs is 
displayed. The experiment was performed three times and the results were pooled. Bars 
indicate the mean and SEM. For statistical analysis a Student’s t-test was used (ns not 
significant, * < 0.05 and ** < 0.005). 
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Next the expression of these markers was investigated on non-stimulated cells from 
HIV-1 infected individuals. The selected patients were part of a clinical trial studying 
the effect of a specific HAART regime on previously untreated, chronically HIV-1 
positive individuals (non-treated, NT) (for more detail see page 50, 2.10.2 HIV-1 
infected volunteers). Sex and age matched healthy volunteers (healthy control, HC) 
were also enrolled in this study. No significant differences were observed for KLRG1, 
TNFRII and CD25 expression on Tregs between HIV-1 infected individuals and 
healthy controls, although a tendency towards higher expression of TNFRII and 
CD25 was seen in non-treated HIV-1 infected individuals. However, CD127 
expression was significantly reduced from HC to NT, indicating activation of Tregs in 
HIV-1 infected individuals (Figure 4. 41). 
 
 
Figure 4. 41 Markers on Tregs from healthy and untreated HIV-1 infected individuals. 
Isolated human PBMCs of healthy individuals (n=6) (HC) and untreated HIV-1 positive 
individuals (n=8) (NT) were stained and analysed using flow cytometry. The percentage of 
different markers on CD4+Foxp3+ Tregs is displayed. Boxplots indicate the minimum, 
median, maximum and range. For statistical analysis a Student’s t-test was used (ns not 
significant and ** < 0.005). 
 
As mentioned earlier, the enrolled patients were part of a clinical trial, where all 
patients received the same regime of antiretroviral drugs. The blood samples were 
drawn at set time points after the start of HAART (4, 8 and 24 weeks). Interestingly, 
at the time point prior to treatment (0), these individuals displayed a significant 
increase in Treg percentages in the peripheral blood compared to healthy controls, 
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which was lost as the patients began HAART (4, 6 and 24 weeks post HAART) 
(Figure 4. 42). 
 
To evaluate the activation level of Tregs during HAART, the frequencies of KLRG1+, 
TNFRII+, CD25+ and CD127+ Tregs in PBMCs from infected individuals were 
analysed and compared to PBMCs from HC. There were no differences in the 
expression of KLRG1, TNFRII or CD25 detected between HC and HIV-1 infected 
patients receiving HAART (Figure 4. 43). Only the frequency of CD127+ Tregs 
displayed a significant decrease from HC to patients that were untreated or treated 
(Figure 4. 43). In summary, human Tregs can be activated in vitro but the defined 
activation markers (KLRG1, TNFRII and CD25) were not significantly up-regulated on 
Tregs during HIV-1 infection. 
 
 
Figure 4. 42 Percentages of Tregs during HAART of HIV-1 positive individuals. Isolated 
PBMCs from healthy donors (n=6) (HC) and chronically HIV-1 positive individuals (n=8) from 
different time points post HAART (0, 4, 8 and 24 weeks) were stained and analysed using 
flow cytometry. The percentage of CD4+CD25hiCD127loFoxp3+ Tregs of CD3+CD4+ T cells is 
displayed. Boxplots indicate the minimum, median, maximum and range. Statistical analysis 
was done using a Dunnett’s multiple comparison test with the group of healthy individuals as 
reference (** < 0.005). 
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Figure 4. 43 Markers on Tregs from HIV-1 infected individuals before and during 
HAART. Isolated PBMCs of healthy individuals (n=6) (HC) and HIV-1 infected individuals 
(n=8) at different times post HAART initiation (x-axis) were stained and analysed using flow 
cytometry. The percentage of markers on CD4+Foxp3+ Tregs is displayed (marker name at 
the top). Boxplots indicate the minimum, median, maximum and range. Statistical analysis 
was done using a Dunnett’s multiple comparison test with the group of healthy individuals as 
reference (*** < 0.0005). 
 
4.18 Investigation of the suppressive activity of Tregs from HIV-1 
infected patients 
After determining the activation status of Tregs during HIV-1 infection it was of 
interest to analyse the functional activity of these Tregs. In HIV-1 infection it has been 
shown that Tregs have both beneficial and detrimental effects. On the one hand they 
can limit chronic immune activation, thereby limiting immune response mediated 
damage and disease progression, and on the other hand this leads to an ineffective 
anti-viral immune response and chronic infection (206).  
 
To investigate the protective effect of Tregs during HIV-1 infection a model of 
mucosal virus encounter was chosen. For this, human bead-isolated CD14+ cells 
were cultured with IL4 and GM-CSF to differentiate them into monocyte derived DCs 
(MoDCs). These were then infected with HIV-1 JRFL-iGFP and SIVmac-VLPs for three 
days. A productive infection of MoDCs with HIV-1 can be demonstrated via the 
Amnis ImageStream technology detecting the iGFP signal of HIV-1 particles (Figure 
4. 44 A). To analyse the spread of HIV-1 infection, CD4+ T cells were co-cultured with 
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the infected MoDCs. The CD4+ T cells were defined as Tcon (CD4+CD8-
CD25loCD127hi, labelled with violet tracker (VT)) and Treg (CD4+CD8-CD25hiCD127lo, 
labelled with CD25+-BV785) and the formation of clusters was investigated (Figure 4. 
44 B). 
 
Figure 4. 44 In vitro HIV-1 JRFL-iGFP infected MoDC:CD4+ T cell clusters. MoDCs were 
cultured and infected with HIV-1 JRFL-iGFP and SIVmac-VLPs. The infection of MoDCs was 
measured with the Amnis ImageStream technology and a representative example of (A) an 
uninfected (left) and an infected MoDC (right) is shown. (B) HIV-1 JRFL-iGFP and SIVmac-
VLP infected MoDCs were co-cultured with CD4+CD8-CD25loCD127hi Tcon and CD4+CD8-
CD25hiCD127lo Tregs from the same donor. After 36 hours of co-culture the samples were 
stained as indicated (right panel – pseudo colour scheme) and measured with the Amnis 
ImageStream imaging flow cytometer.  
 
To measure the spread of the infection into different cell populations after 36 hours of 
in vitro co-culture, the iGFP signal was investigated for: clusters of MoDCs and CD4+ 
T cells (clusters), MoDCs (DC) and CD4+ T cells (CD4). The highest percentage of 
infection was found in the CD4+ T cell:DC clusters, whereas much lower levels were 
found in single MoDCs or single CD4+ T cells (Figure 4. 45 A). This indicated that 
cluster formation was important to mediate the spread of HIV-1 into CD4+ T cells.  
 
The influence of CD4+ Tregs on cluster formation was investigated, as the inhibition 
of this cluster formation could be a mechanism for Tregs to prevent CD4+ T cell 
infection with HIV-1 via cell-to-cell contacts to DCs. No differences in cluster 
formation were found when Tregs were cultured with infected MoDCs (infDC) and 
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Tcon (plus Treg) in comparison to only infDC+Tcon co-cultures. Furthermore, 
addition of Treg inhibitors: ddADA, α-CTLA-4 and α-TGFβ; to inhibit an array of Treg 
suppression mechanisms, also did not have an effect on cluster formation (Figure 4. 
45 B). This data indicated that Tregs did not directly inhibit the formation of clusters 
between MoDCs and Tcon. 
 
 
Figure 4. 45 Investigation of HIV-1 infection in in vitro co-cultures and the influence of 
Tregs on cluster formation. Infected MoDCs were co-cultured with Tcon and Treg from the 
same donor. After 36 hours of co-culture the samples were stained and measured with the 
Amnis ImageStream imaging flow cytometer for (A) the presence of HIV-1 JRFL-iGFP 
infection in either MoDC:CD4+ T cell clusters (clusters), MoDCs (DC) or CD4+ Tcon (CD4). 
Five different donors were investigated. Boxplots indicate the minimum, median, maximum 
and range. (B) To investigate the cluster formation in different co-culture settings infected 
MoDCs and Tcon (infDC+Tcon), infected MoDCs, Tcon and Tregs (plus Treg) or infected 
MoDCs, Tcon, Tregs with the addition of the inhibitors ddADA, α-CTLA-4 and α-TGFβ (plus 
Inhibitor), were co-cultured and the percentage of clusters forming in the co-culture is shown 
for five different PBMC donors. 
 
It has been shown that Tregs can inhibit the infection of Tcon with HIV-1 in such 
MoDC:CD4+ T cell clusters (Moreno-Fernandez, submitted). The stability of the 
clusters was not influenced by Tregs and can now be excluded as a mechanism of 
Treg-mediated limitation of HIV-1 infection spread. Another possible mechanism for 
Treg mediated suppression of Tcon infection could be the suppression of the actin 
cytoskeleton of DCs and/or Tcon. The intracellular movement of HIV-1 is dependent 
on the cytoskeleton and its suppression could have an influence on the virus spread 
to other cells (Moreno-Fernandez, submitted). Based on this, the actin polymerisation 
at the immunological synapse in co-cultures of HIV-1 infected MoDCs and CD4+ T 
cells was investigated using the iGFP signal-localisation and phalloidin (actin) 
staining. The data revealed a correlation between actin and HIV-1 particles at the 
immunological synapse in co-cultures of HIV-1 infected MoDCs with Tcon (Figure 4. 
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46 A). Most interestingly, this correlation was less strong when Tregs were added to 
the co-cultures, which indicates that Tregs are able to suppress the transport of viral 
particles along the actin cytoskeleton (Figure 4. 46 B).  
 
In summary, it was shown that Tregs did not inhibit cluster formation between HIV-1 
infected MoDCs and Tcon, but the presence of Tregs decreased the actin 
polymerisation in MoDCs and the presence of HIV-1 at the immunological synapse 
between Tcon and HIV-1 infected MoDCs. This is a potential mechanism of Treg 
mediated suppression of DC to Tcon transmission of HIV-1 infection, however the 
molecular basis for this remains to be defined. 
 
 
Figure 4. 46 HIV-1 JRFL-iGFP localization in MoDC:Tcon clusters in the presence or 
absence of Tregs. Infected MoDCs were co-cultured with (A) CD4+CD8+CD25loCD127hi 
Tcon (INF DC:Tcon) or (B) with the addition of CD4+CD8+CD25hiCD127lo Tregs (INF 
DC:Tcon:Treg) from the same donor. After 24 hours of co-cultivation the samples were 
stained and measured with the Amnis ImageStream imaging flow cytometer. The amount of 
phalloidin signal for actin (y-axis: actin at the immunological synapse (IS)) and GFP signal for 
HIV-1 JRFL-iGFP (x-axis: HIV-iGFP at the IS) in DC:Tcon clusters was measured in (A) the 
absence and (B) presence of Tregs. For statistical analysis these two parameters were 
correlated and the p- and r-value are shown. 
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5. Discussion 
Regulatory T cells play an important role in retroviral infections. The effect of Tregs 
on infection can be both beneficial for the host, in limiting immune pathology, and 
detrimental, by promoting the establishment of a chronic infection. Both of these 
effects have been described for Tregs in retroviral infections of humans and mice. 
Currently the precise mechanism(s) of Treg expansion and their functional properties 
during retroviral infections remain to be elucidated (23). This knowledge could 
provide important information to alter Treg responses and induce an improved 
immune response to infection with limited immune pathology.  
 
Overall, the work presented in this thesis has elucidated the influence of effector T 
cells on Treg expansion during FV infection. Tregs become activated during the 
acute phase of FV infection and remain activated in chronic infection. During acute 
FV infection the expanding Treg population was shown to consist of nTregs with a 
subset of IL2-dependent Vβ5- Tregs and a highly activated subset of TNFα-
dependent Vβ5+ Tregs. The discovery of different Treg populations during retroviral 
infection can have important implications for further research in this field. 
5.1 The phenotype of Tregs during retroviral infections. 
One of the main aims of this thesis was to characterise the phenotype of Tregs 
during FV infection. It was shown that Tregs were expanded in the spleen and bone 
marrow during acute FV infection, they proliferated (Figure 4. 1) and displayed an 
activated and differentiated phenotype (Figure 4. 3 and Figure 4. 5). It was thought 
for a long time that Tregs were anergic and did not proliferate in response to 
stimulation. However, this was only established using in vitro models, and in vivo 
studies have clearly shown that Tregs do proliferate in response to stimulation. 
Haribhai et al. demonstrated that Tregs proliferate after immunisation of mice and 
can control the magnitude of primary effector T cell response to a foreign antigen. In 
this model, Treg expansion and contraction paralleled that of Tcon (128). The same 
effect has also been seen during FV infection (340).  
 
The activation and differentiation of Tregs during infection has been described for 
many viruses such as: HIV-1 infection of humans (236), Influenza A virus infection of 
mice (22) or infection of cats with feline immunodeficiency virus (201). Despite a few 
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exceptions like Influenza, the activation and expansion of Tregs has mainly been 
shown in chronic human infections, such as HIV-1, HBV and HSV (reviewed in 
(247)). In the chronic phase of FV infection Treg numbers remained elevated, 
showing an activated phenotype with no proliferation (Figure 4. 6 and Figure 4. 7). 
Similar results were obtained when studying the expansion and activation of Tregs in 
chronic HIV-1 infection. Here, Tregs were expanded and activated in chronically, 
untreated HIV-1 infected individuals (Figure 4. 41 and Figure 4. 42). However, there 
has been conflicting data showing different frequencies of Tregs in patients in distinct 
phases of HIV infection. These discrepancies are likely due to a number of factors 
including: isolation of Tregs from different lymphoid tissues (like blood, lymph nodes 
or GALT), differences in the length of infection, utilisation of different Treg markers 
and the utilisation of different methods to assess Treg numbers (frequencies or 
actual cell numbers) (143). The main targets of HIV-1 are CD4+ T cells which are 
most abundant in lymphoid organs like the lymph nodes and GALT. This results in 
higher viral loads than in the blood and therefore a more pronounced immune 
response. In these organs higher levels of Tregs are detectable, which correlated 
with the increase in viral load (10, 89, 222).  
 
Co-stimulatory markers were also expressed on Tregs during FV infection (Figure 4. 
4). One of these markers was ICOS (Figure 4. 4 B). ICOS+ Tregs have been shown 
to be highly suppressive, highly proliferative and less prone to cell-death (60, 282). 
Furthermore, it was also shown that ICOS is critical for homeostasis and functional 
stability of Foxp3+ Tregs (166). This could indicate that the ICOS+ Tregs have similar 
functional abilities in FV infection, although this point requires further investigation. 
 
Another co-stimulatory marker expressed on Tregs during FV infection was GITR 
(Figure 4. 4 G). GITR is predominantly expressed on CD4+CD25+ Tregs in mice 
(271) and has been associated with the expansion of T cells and Tregs upon 
stimulation, although with a loss of Treg suppressive activity (250, 303). Furthermore, 
it has also been shown that GITR stimulation of Tregs results in a decrease in Treg 
lineage stability and subsequently reduced Treg mediated suppression (250, 260). 
Moreover, the stimulation of Tregs with GITR agonistic antibody abrogated Treg 
mediated suppression in a dose-dependent manner (271). When the same antibody 
was used to treat chronically FV infected mice, transferred FV-specific CD8+ T cells 
were no longer suppressed by Tregs (84). Concluding from this, GITR expression on 
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Tregs and stimulation with agonists could provide an inhibitory mechanism for Tregs, 
and could be beneficial in situations where Treg suppression is detrimental. 
 
The expression of inhibitory molecules on Tregs during acute FV infection was also 
investigated (Figure 4. 4). Strikingly, an up-regulation was seen for all the 
investigated markers (TIM3, PD-1 and PD-L1, Lag3) during FV infection. The 
detection of elevated levels of these inhibitory molecules on Tregs argues towards a 
role in their function. In a systemic model of murine acute myeloid leukaemia, Treg-
mediated suppression of CD8+ T cells was dependent on the expression of PD-1 on 
Tregs (343). Furthermore, it has been shown that Tregs expressing PD-1 and TIM3 
are highly suppressive (256). In contrast, it was reported in chronic HCV infection 
that Treg proliferation was inhibited by PD-1 signalling (239), arguing towards Treg 
suppression by inhibitory receptors. PD-L1 expression was also up-regulated on 
Tregs during FV infection (Figure 4. 4 F). It has been shown that Tregs are able to 
suppress auto-reactive B cells via PD-L1 (116) and blocking of this molecule was 
found to inhibit the suppressive activity of Tregs towards CD4+CD25- Tcon (159).  
 
Lag3 has been shown to interfere with TCR signalling and thereby T cell activation 
(127) and expansion (328). However, the expression of Lag3 is a marker for Tregs 
with potent suppressive activity (139). Lag3 was up-regulated on Tregs during acute 
FV infection (Figure 4. 4 C), which could be an indicator of their suppressive activity. 
 
Wakamatsu et al. demonstrated that Tcon and Treg responded to the same co-
stimulatory and inhibitory signals (CD28, CTLA-4, ICOS, PD-1, BLA and CD80) but 
this induced different clusters of genes (314). Another study has shown that CD28, 
CTLA-4 and PD-L1 differentially control interaction of Tregs or Tcon with APCs, 
resulting in different outcomes for activation (82). This highlights the role of co-
stimulatory and inhibitory receptors for Tregs and provides evidence that they might 
not only represent molecules important for the suppressive mechanisms of Tregs, but 
also implicates that Tregs could be limited in their stimulation and activation by these 
receptors. Due to the expression of different co-stimulatory markers and inhibitory 
receptors Tregs can therefor integrate multiple signals for their own stimulation and 
induction of suppressor functions. 
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5.2 The mechanism(s) of Treg-mediated suppression in retroviral 
infection. 
It is of great importance to define the major mechanisms of Treg-mediated 
suppression in retroviral infections, as this could provide a viable target for future 
immune-based therapies. Multiple mechanisms have been described for Treg-
mediated immune suppression and they are not mutually exclusive. However, 
dominant mechanisms of Treg mediated suppression do exist, depending on a 
number of immunological parameters.  
 
It has been shown in FV infection that Tregs suppress effector T cell responses in a 
contact-dependent manner (248), and that CTLA-4 could have a minor role in 
mediating this suppression (whereas TGFβ or IL10 individually were not involved) 
(144). Interestingly, though, when multiple mechanisms were blocked at the same 
time (CTLA-4, TGFβ and IL10), the reduction in Treg suppressive activity was 
increased (144). This provides evidence for multiple Treg-mediated mechanisms of 
suppression, and that there may be some level of functional redundancy. 
 
In other disease models, it has been shown that Tregs suppress via adenosine 
production by the enzymes CD39 and CD73 (78, 94, 162). Interestingly, mouse 
Tregs have been shown to be mostly positive for CD39 and CD73, suggesting 
adenosine production may be a general mechanism used by mouse Tregs. 
Encouragingly, this same phenotype of CD39+CD73+ Tregs was observed in FV 
infection (Figure 4. 29). To establish if this enzymatic cascade could play a role in 
Treg-mediated immune suppression during FV infection, the influence of CD39 and 
CD73 deficiency on anti-viral immune responses was investigated. CD39, the 
upstream enzyme of the cascade, did play a role, and CD8+ T cell responses were 
elevated in CD39-KO mice (Figure 4. 37 and Figure 4. 38). CD39 has been shown to 
be important in HIV-1 infection, where Tregs need CD39 for their suppressive activity 
(207). The effect of CD39 seen in FV infection was not as dramatic as expected and 
is thus unlikely to be the only immune-suppression pathway involved. It has been 
shown that both enzymes act in a cascade to generate the immunosuppressive 
adenosine which binds to the A2A receptor on Tcon, causing suppression (34, 78, 
162). Interestingly, CD73, which catalyses the production of adenosine, did not play a 
clear role in Treg mediated suppression of either CD4+ or CD8+ T cells in FV infection 
(Figure 4. 31 to Figure 4. 35), leaving a puzzling observation that requires further 
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investigation. Interestingly, CD73 down-regulation on CD8+ T cells was associated 
with immune activation and disease progression during HIV-1 infection. Also a 
functional impairment of the CD8+CD73- T cells compared with CD8+CD73+ T cells 
was detected (305). This argues for an important role of CD73 in CD8+ T cells during 
retroviral infection and may have influenced the outcome of these experiments in FV-
infected CD73-knockout mice. However, it is possible that the effect seen in FV 
infection is solely mediated by the reduction of extracellular ATP levels by CD39, 
resulting in less immune activation. 
 
During HIV-1 infection Tregs can have beneficial effects in the early phase of 
infection by suppressing the transfer of virus from infected DCs to CD4+ T cells. This 
effect is most likely mediated by Treg-induced suppression of the actin cytoskeleton, 
which is important for the transport of HIV-1 particles to the immunological synapse, 
and thus the cell-to-cell transfer of virus (43). It was shown that Tregs were able to 
decrease the actin polymerisation at the immunological synapse between DCs and 
CD4+ T cells, without disrupting the cluster formation among these cells (Moreno-
Fernandez, accepted and Figure 4. 45). Furthermore, Tregs abolished the positive 
correlation of HIV-1 particles and actin accumulation at the interface between DCs 
and Tcon (Figure 4. 46), suggesting Treg-mediated suppression of DCs and/or Tcon. 
However, these results should be regarded as preliminary, and more work is required 
to establish the exact mechanisms behind these observations. 
5.3 The mechanism(s) of Treg expansion during FV infection 
It has been demonstrated in multiple virus infections that iTregs can be induced by 
viral antigen. In influenza A virus infection of mice matrix-1 specific Tregs were found 
to expand (233). Moreover, in infections with chronic viruses like HCV, EBV and HIV, 
virus-specific Tregs were shown to exist (86, 247). In contrast, the CD4+ T cell 
repertoire of FV-specific CD4+ TCRtg mice was determined to be devoid of FV-
specific Tregs during FV infection (12). Furthermore, no FV-specific CD4+ T cell 
expressing Foxp3 were found using the MHCII tetramer technology (148). This 
suggested that FV infection does not induce expansion of virus-specific Tregs and 
prompts the question about the origin of these expanding Tregs.  
 
Tregs expanding during FV infection were shown to express markers of nTregs 
(CD25, CTLA-4, GITR, CD62L and Nrp1) (Figure 4. 2, Figure 4. 3, Figure 4. 4, Figure 
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4. 8 and Figure 4. 9). Since Nrp1 is the most accepted marker for nTregs, this marker 
was used and the expansion of Nrp1+ Tregs was demonstrated to be dominant 
(Figure 4. 8 and Figure 4. 9). This indicated that the main subset of Tregs expanding 
during FV infection consisted of nTregs. This observation is strengthened by the fact 
that no conversion of FV-specific CD4+ T cells into Tregs during FV infection was 
observed (212). Thus in conclusion, a pre-existing pool of nTregs expands during FV 
infection, which is caused by activation and proliferation of these presumably self-
specific Tregs. Indeed, nTregs, which arise directly from the thymus, are usually self-
reactive and recognise self-antigens (44, 73, 75, 175). Therefore, nTregs are 
constantly exposed to their specific antigen in circulation and are thus consistently 
activated, albeit at a low level (154). However, no self-antigen had been described to 
play a role in the expansion of Tregs during FV infection.  
 
To gain further insight into the Treg repertoire, the Vβ usage of Tregs was analysed 
during FV infection and a disproportionate expansion of Vβ5+ Tregs was found 
(Figure 4. 10 and Figure 4. 11) (212). LCMV clone 13 infection of mice was also 
found to preferentially expand Vβ5+ Tregs (238). This shows that viruses from 
different families (LCMV belongs to the family of Arenaviridae) are able to induce the 
disproportionate Vβ5+ Treg proliferation. The expansion of Vβ5+ T cells was restricted 
to Tregs and not observed for peripheral CD4+ Tcon or CD8+ T cells (unpublished 
data and (238)). These results argue for a Treg-specific and immune system-
mediated mechanism of Vβ5+ Treg expansion, independent of exogenous viral 
antigens.  
 
Many ERVs are present in the genome of mice and the mtv ERV family contain a 
Sag in the 3’-LTR open reading frame of the provirus (4, 64). From previous studies it 
is known that the mtv-9 Sag binds to the Vβ5 chain of the TCR, thereby crosslinking 
the TCR with an MHC class II molecule displayed by APCs (3, 324, 326). During 
thymic development this leads to clonal deletion of Vβ5+ T cells in the thymus or 
anergy of T cells in the periphery (27, 151, 152, 277). Despite expressing the mtv-9 
Sag, B6 mice show weak deletion of Vβ5+ T cells in the thymus, due to a lack of 
expression of MHC class II IE molecules, which bind to Sags with high avidity (28). 
This equates to a substantial amount of CD8+ and CD4+ T cells positive for Vβ5 in 
the periphery of adult B6 mice (unpublished data). Additionally, Tregs are relatively 
resistant to clonal depletion by endogenous Sags in the thymus in general (230).  
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Punkosdy et al. could directly show that the LCMV clone 13 induced expansion of 
Vβ5+ Tregs in the periphery was dependent on the expression of mtv-9 (238). In this 
thesis, it was shown that Vβ5+ Tregs receive a stronger TCR signal than Vβ5- Tregs 
(Figure 4. 16), which fits with the results mentioned above. In addition, Punkosdy et 
al. showed that this expansion is MHC class II dependent but CD4+ independent. 
Finally, by utilising CD11c-DTR mice they found that this expansion requires DCs, 
which is in line with the model using Sag stimulation (238). It was also shown that the 
absence of B cells, another subset presenting Sags (157), was not able to abolish 
Vβ5+ Treg expansion (Figure 4. 18), a phenomenon also demonstrated for LCMV 
(238). Interestingly, Punkosdy et al. showed that infection with LCMV clone 13 up-
regulated the mRNA expression of mtv-8 and mtv-9 Sag in DCs (238). This finding 
was the basis for their interpretation that Sag expression levels are critical for the 
magnitude of Vβ5+ Treg expansion. In contrast Myers et al. did not observe such 
changes in mRNA expression for mtv-9 Sag in either DCs or B cells after FV infection 
(212). This argues for a more constitutive signal provided to the Vβ5+ Tregs in the 
periphery by Sag presentation and a dependence of these Tregs on a secondary 
signal for complete expansion.  
 
One possible co-factor that was known to stimulate Tregs was IL2 (77, 103, 224). 
However, IL2 was not involved in expanding Vβ5+ Tregs, as neutralisation of this 
cytokine did not have an effect on Vβ5+ Treg numbers (212). Furthermore, transfer of 
IL2 producing FV-specific CD4+ T cells did not result in expansion of Vβ5+ Tregs 
(Figure 4. 17). This IL2-independent effect is possibly due to a specific activation 
triggered by the Sag stimulation (13, 42, 337). Moreover, it has been shown that 
bacterial Sags are able to stimulate T cell expansion in the absence of IL2 (147).  
 
Depletion experiments showed that activated CD8+ T cells were critical for Vβ5+ but 
not Vβ5- Treg expansion (Figure 4. 19and (212)) and multiple factors produced by 
these cells were investigated. GzmB, IFNγ, and perforin were excluded as second 
signals for Vβ5+ Treg expansion based on the data obtained (Figure 4. 18 and 
unpublished observations). Furthermore, when CD8+ T cells were absent (depleted 
or in CD8+ knockout mice) during FV infection, the viral loads increased drastically 
(data not shown and (212)), showing that viral loads were not a factor involved in the 
expansion. In support of this data, increasing numbers of virus-specific CD8+ T cells 
added via adoptive transfer increased the magnitude of Vβ5+ Treg expansion (212). 
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These results provide evidence for the important role of activated CD8+ T cells in the 
expansion of Vβ5+ Tregs. In LCMV clone 13 infection, depletion of CD11c+ DCs 
resulted in a loss of Vβ5+ Treg expansion, indicating the importance of this subset for 
Vβ5+ Treg expansion (238). However, DCs are crucially important for the priming of 
CTLs during LCMV infection (237) and the depletion of DCs would also restrict CD8+ 
T cell expansion and activation. This indicated an indirect effect of DCs for the 
expansion of Vβ5+ Tregs in LCMV clone 13 infection of mice. 
 
Activated CD8+ T cells produce substantial amounts of TNFα during FV infection 
(Figure (212)). The neutralisation of TNFα led to a decreased frequency and 
activation of Vβ5+ Tregs but not Vβ5- Tregs during infection (212). TNFα is a 
pleiotropic cytokine that exists as a soluble (solTNFα) or a membrane-bound 
(mbTNFα) form. There are two receptors for TNFα, TNFRI and TNFRII. TNFRI binds 
to both forms, however solTNFα binds with a higher affinity (121). TNFRII only has a 
high affinity for mbTNFα (120). In contrast to TNFRI, which mediates mainly pro-
apoptotic pathways, TNFRII does not possess a death domain and promotes anti-
apoptotic signals (66, 155, 156).  
 
In this thesis it was shown that Tregs did not express TNFRI, however a high 
percentage of Vβ5+ Tregs expressed TNFRII (Figure 4. 21). Interestingly, both 
human and mouse Tregs constitutively express TNFRII (57, 214, 308), but it was 
shown that FV infection could further up-regulate TNFRII expression (Figure 4. 21). 
The expansion of Vβ5+ Tregs during FV infection was dependent on the expression 
of TNFRII but not TNFRI on these Tregs (Figure 4. 22 ). Chen et al. were the first to 
show that the interaction of TNFα with TNFRII on Tregs was beneficial for their 
expansion and function (56), and that TNFRII is critical for a stable Treg phenotype in 
inflammatory environments (58). Others have also reported that the expansion of 
Tregs could be invoked using TNFα via a TNFRII-dependent pathway (65, 122, 160, 
227).  
 
It was shown that FV-specific activated CD8+ T cells expressed high levels of 
mbTNFα when they were stimulated with their cognate antigen (Figure 4. 20). 
Furthermore, CD8+ T cells of iRhom2-KO mice, which only express mbTNFα induced 
higher numbers of activated Vβ5+ Tregs than CD8+ T cells from wild type mice 
(Figure 4. 24). Grindberg-Bleyer et al. have demonstrated that in a model of 
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autoimmune diabetes the activated Tcon were able to induce the proliferation of 
Tregs in a TNFα-dependent manner (122). This proved that the activated immune 
system is able to trigger Treg expansion using TNFα. However, no study so far has 
shown that mbTNFα produced during an ongoing immune response is the central 
mediator of Treg expansion. 
 
Rauert et al. engineered a TNFα construct mimicking the membrane-bound form of 
TNFα and showed that this Flag-TNC-scTNF(143N/145R) was able to specifically 
bind to human TNFRII (and not human TNFRI), inducing the alternative NF-κB 
signalling pathway, implicated in T cell proliferation and survival (240). In this thesis, 
the same construct, but specific for mouse TNFRII (unpublished) was utilised. It was 
shown here that the intercellular communication between CD8+ T cells expressing 
mbTNFα during FV infection and TNFRII+Vβ5+ Tregs could be bypassed by this 
synthetic TNFRII-ligand given to naïve wild type mice but not TNFRII-KO mice 
(Figure 4. 25). This data set has highlighted a role for the interaction of mbTNFα and 
TNFRII expressed on Vβ5+ Tregs in the expansion and activation of this Treg subset.  
 
The effect of TNFα on Treg function remains a controversial area of research. 
Valencia et al. and Nie et al. found that TNFα down-modulates the suppressive 
function of CD4+CD25+ Tregs in patients with active rheumatic arthritis, which was 
also shown in a mouse arthritis model (29). When they blocked TNFα, the Treg 
suppressive activity was restored (221, 308), and this effect was shown to be TNFRII 
dependent (214). Another study has demonstrated that TNFα partially abrogated 
Treg mediated suppression of HBV specific T cell responses (280). However, TNFRII 
expressing Tregs have been described in different infections associated with Treg 
expansion, and this correlated with the suppression of pathogen-specific immune 
responses (316) and a strong suppressive activity of TNFRII+ Tregs (203). 
Furthermore, high TNFRII+ expression levels on Tregs were found in type I diabetes 
(252) and in acute myeloid leukaemia where they correlated with low effector T cell 
responses (119). Also, in an experimental metastasis mouse model, Treg expansion 
was TNFRII-dependent and after treatment with TNFα resulted in enhanced 
metastasis (65). Thus the effect of TNFα on Treg expansion and activation is likely to 
be disease and immune-context dependent. 
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Some of the conflicting results may be explained by the nature of the Tregs in the 
different models. Housley et al. showed that nTreg mediated suppression was 
dependent on TNFα, whereas iTregs generated in the presence of TGFβ were not 
(137). Furthermore, the duration and strength of TNFα signalling in Tregs could have 
important implications, as it was reported that longer exposure to TNFα restored Treg 
suppressive effects, whereas short term exposure was inhibitory (56).  
 
Interestingly, Vβ5+ Tregs from an FV-infected mouse showed higher activation, 
differentiation and proliferation compared to Vβ5- Tregs from the same mouse 
(Figure 4. 13, Figure 4. 15 and (212)). This stark activation of Vβ5+ Tregs was also 
demonstrated in the LCMV infection model (238). Stimulation by Sags has been 
reported to induce and activate Tregs in other models (297). This could provide an 
explanation for the higher activation of Vβ5+ Tregs in FV-infected mice.  
 
The mechanisms of Treg expansion have only been partially elucidated in general. 
While iTregs are converted by triggers like IL10, TGFβ, foreign antigen or other 
stimuli, nTreg expansion is thought to be triggered mainly by IL2. IL2 is an important 
survival factor for Tregs and other T cells, but is not produced by Tregs (20, 192, 
261). It was shown that the Vβ5- Tregs require IL2 for their proliferation during FV 
infection (212). These results were confirmed in this thesis and it was demonstrated 
that the IL2 driving the Vβ5- Treg activation and expansion is produced by virus-
specific CD4+ Tcons (Figure 4. 17). On the one side, the production of IL2 has 
beneficial effects for the anti-viral immune response as it is an important survival 
factor for Tcons and CD8+ T cells (171). However on the other side, IL2 also drives 
activation and expansion of Tregs, which in turn suppress anti-viral immune 
responses. Furthermore, it has been reported that IL2, IL2Rα, and IL2Rβ deficient 
mice develop a strong lymphoproliferative syndrome and suffer from severe 
autoimmunity due to impaired Treg responses rather than immune dysfunction, due 
to activation deficiency of Tcons (253, 292, 323). 
 
Overall, it has been shown that the Tregs expanding during FV infection consist of 
two different subsets. These subsets exhibit differences in their phenotype and their 
stimuli requirements during infection. This raises questions about the effect of 
multiple different Treg subsets in human viral infections on immune suppression, and 
their contributions to the specific disease. 
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Humans also harbour many ERV (HERV) sequences in their genome, some of which 
have been shown to have Sag properties. There have been suggestions that HERV-
K18 env causes stimulation of Vβ7+ T cells in humans (72) and in mice (294). 
Furthermore, the expression of HERV-K18 can be induced by infection with different 
herpes viruses (289, 295, 307).  
 
Aside from Sag expression, HERVs have the potential to express viral proteins which 
could have an influence on innate and adaptive immune responses. It has been 
shown that HIV-1 infection leads to the expression of HERVs and that a HERV-
specific CD8+ T cell response is induced, which inversely correlates with HIV-1 
plasma viral loads (107, 296). Individuals who did not receive HAART but were able 
to control HIV-1 viremia had stronger and broader HERV-specific T cell responses 
than patients on HAART/progressors/non-controllers or healthy individuals (265). 
Furthermore, HERV-K specific antibodies were detectable during HIV-1 infection, 
with high titres in elite controllers (200). Interestingly, HIV-1 exposed, seronegative 
individuals showed enhanced HIV-1- and HERV-specific CD4+ T cell responses in 
the GALT compared to the blood (266). This shows that HERV antigens are able to 
prime T cell responses which can have an influence on the outcome of infection with 
an exogenous virus. However, to date, no such priming has been shown for Tregs 
during infection.  
 
In certain cancers, the expression of endogenous retroviral products on tumour cells 
can specifically activate Tregs and subsequently mediate local expansion of Treg 
populations. These Treg populations then function to suppress effector T cell 
responses against the tumour. As an example, it has been shown in a melanoma 
tumour mouse model that ERV expression in melanoma cells was necessary for a 
Treg-mediated immune escape for the tumour (194). However, the authors did not 
look for a direct involvement of ERV-specific Tregs in immunosuppression, although 
it remains possible that this could be a mechanism of immune escape for tumours or 
viral infections by triggering ERV expression (193). Alternatively, ERV antigens could 
provide a TCR signal which is then completed during the immune response by a 
secondary signal to induce full activation and expansion of Treg subpopulations, as 
has been described in this thesis. Overall, (H)ERV antigens could play a more 
important role in shaping the Treg response than is currently appreciated. 
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6. Summary 
The infection of mice with Friend retrovirus (FV) induces the expansion and activation 
of regulatory T cells (Tregs) during acute infection, which remain active throughout 
chronic infection. Tregs are responsible for the suppression of FV-specific CD8+ T 
cell responses, which is associated with the establishment of a chronic infection. In 
this thesis it was shown that the Tregs expanding during FV infection were natural 
nTregs rather than induced iTregs. Furthermore, these Tregs possessed the 
phenotype of activated and differentiated effector T cells, both in acute and chronic 
FV infection.  
 
In a search of Treg specificity, the disproportionate expansion of T cell receptor Vβ5+ 
Tregs in acutely FV-infected mice was observed. It was known that these Vβ5+ Tregs 
are specific for an endogenous retroviral superantigen of the mouse mammary 
tumour virus 9. Investigation of this subset of Vβ5+ Tregs showed that they were 
highly activated and suppressive and that their expansion was surprisingly 
independent of IL2. Vβ5+ Treg expansion was induced by activated effector CD8+ T 
cells that expressed TNFα.  
 
TNFα is a pleiotropic cytokine present in two forms, a soluble (solTNFα) and 
membrane-bound form (mbTNFα), which both preferentially bind to two different TNF 
receptors (TNFR). It was shown that TNFRII but not TNFRI became significantly up-
regulated on Vβ5+ Tregs during acute FV infection. Also, the expansion of Vβ5+ 
Tregs was directly dependent on the presence of TNFRII, but not TNFRI, on the 
surface of these Tregs. FV-specific CD8+ T cells produce substantial amounts of 
mbTNF after stimulation, providing the important factor that binds to TNFRII on Vβ5+ 
Tregs and induces activation and proliferation. The use of CD8+ T cells of iRhom2-
knockout mice, which only express mbTNFα, but no solTNFα, revealed a substantial 
increase in Vβ5+ Treg expansion and activation.  
 
Finally, treatment of naïve mice with solTNFα did not induce expansion of Vβ5+ 
Tregs, whereas the treatment of naïve mice with a synthetic TNFRII ligand did, 
indicating that the intercellular communication between Treg and CD8+ T cells can be 
bypassed by direct stimulation of the TNFRII. 
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In an attempt to clarify the mechanism of Treg mediated suppression of effector T 
cell responses during FV infection the CD39/CD73 pathway was investigated. Here, 
mice that were deficient for either one of these ADP converting enzymes were 
infected with FV. These experiments revealed that the loss of the rate limiting 
enzyme CD39 had a positive effect on effector CD4+ and CD8+ T cell responses, 
whereas no effect could not be demonstrated for the down-stream enzyme CD73.  
In a translational approach Tregs were characterised in the blood of untreated 
chronically HIV-1 infected individuals and shown to be expanded and activated in 
these patients compared to healthy individuals.  
 
Moreover, a possible mechanism of how Tregs help to prevent the transfer of HIV-1 
from infected dendritic cells to conventional CD4+ T cells was investigated. This 
showed that Tregs were able to interfere with the co-localisation of HIV-1 particles 
and actin, as part of the cytoskeleton of cells, at the interface between DCs and T 
cells.  
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7. Zusammenfassung 
Die Infektion mit dem Friend Retrovirus (FV) induziert die Expansion und Aktivierung 
von regulatorischen T Zellen (Tregs) während der akuten und chronischen Infektion. 
Tregs verursachen die Suppression von FV-spezifischen CD8+ T Zellen was mit der 
Etablierung einer chronischen Infektion assoziiert ist. In der vorliegenden Arbeit 
konnte gezeigt werden, dass es während der FV Infektion zu einer Expansion von 
natürlichen nTregs kommt und eher nicht zur Expansion von induzierten iTregs. 
Weiterhin besaßen diese Tregs den Phänotyp aktivierter und differenzierter Effektor 
T Zellen in der akuten sowie in der chronischen Infektion.  
 
Auf der Suche nach der Treg Spezifität wurde die disproportionale Expansion von T 
Zell Rezeptor Vβ5+ Tregs während der akuten FV Infektion entdeckt. Es war bereits 
bekannt, dass diese Vβ5+ Tregs spezifisch für das Superantigen des endogenen 
mouse mammary tumour virus 9 sind. Die Untersuchung der Vβ5+ Tregs zeigte, dass 
diese Zellen aktiviert und suppressiv waren. Außerdem besaßen diese Tregs die 
ungewöhnliche Eigenschaft unabhängig von IL2 in ihrer Expansion zu sein. Die 
Expansion von Vβ5+ Tregs war abhängig von aktivierten Effektor CD8+ T Zellen die 
TNFα produzierten.  
 
TNFα ist ein pleiotropisches Zytokin, welches in zwei Formen vorkommt, eine 
lösliche (solTNFα) und eine membrangebundene (mbTNFα) Form, und diese binden 
mit unterschiedlichen Präferenzen an zwei TNF Rezeptoren (TNFR). Es konnte 
gezeigt werden, dass TNFRII, aber nicht TNFRI, während der akuten FV Infektion 
signifikant auf Vβ5+Tregs hoch reguliert wurde. Die Expansion der Vβ5+ Tregs war 
direkt abhängig von der Expression von TNFRII aber nicht TNFRI auf ihrer 
Oberfläche.  
 
FV-spezifische CD8+ T Zellen produzieren mbTNFα nach Stimulation, welches an 
TNFRII auf Vβ5+ Tregs bindet und das wichtige Signal für die Expansion und 
Aktivierung dieser Zellen bietet. Durch den Einsatz von CD8+ T Zellen aus iRhom2-
Knockout Mäusen, welche nur mbTNFα aber nicht solTNFα exprimieren, konnte eine 
substantielle Expansion und Aktivierung von Vβ5+ Tregs gezeigt werden.  
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Letztendlich konnte gezeigt werden, dass die Behandlung von Mäusen mit solTNFα 
nicht zu einer Expansion von Vβ5+ Tregs führte, wohingegen die Behandlung mit 
einem synthetischen TNFRII Liganden die Expansion von Vβ5+ Tregs verursachen 
konnte. Hierdurch konnte gezeigt werden, dass es möglich ist die Kommunikation 
zwischen Tregs und CD8+ T Zellen durch die Stimulation von TNFRII zu umgehen. 
 
In einem Ansatz, um den Mechanismus der Treg vermittelten Suppression von 
Effektor T Zell Antworten gegen FV zu bestimmen, wurde der CD39/CD73 Weg 
untersucht. Hierzu wurden Mäuse infizierten die für je eines dieser ADP 
konvertierenden Enzyme defizient waren. Es wurde gezeigt, dass der Verlust des 
reaktionslimitierenden Enzyms CD39 einen positiven Effekt auf die Effektorfunktion 
von CD4+ und CD8+ T Zellen hatte. CD73 hingegen, welches später im 
Stoffwechselweg auftaucht, hatte keinen Effekt wenn es nicht vorhanden war.  
 
In einem transnationalen Ansatz wurden Tregs von unbehandelten chronisch HIV-1 
infizierten Patienten im Blut charakterisiert. Es konnte gezeigt werden, dass die 
Tregs dieser Patienten im Vergleich zu nicht infizierten Personen expandiert und 
aktiviert waren. Weiterhin, wurde ein möglicher Mechanismus untersucht bei dem 
Tregs wichtig sind um den Transfer von Virus aus infizierten dendritischen Zellen zu 
CD4+ T Zellen zu inhibieren. Dies zeigte, dass Tregs in der Lage waren mit der Ko-
lokalisation von HIV-1 Partikeln und Aktin, einem Bestandteil des Zytoskeletts von 
Zellen, an der Synapse zwischen DCs und T Zellen zu interferieren. 
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9. Appendix 
9.1 List of Abbreviations 
A  
α Anti 
AB Antibody 
ADP Adenosine diphosphate 
AEC 3-amino-9-ethylcarbazole 
AF Alexa Flour 
AICD Activation-induced cell death  
AIDS Acquired immunodeficiency syndrome  
AMP Adenosine monophosphate 
AMPCP Adenosine 5’-(α,β-methylene)diphosphate 
ANOVA Analysis of variance between groups 
APC Allophycocyanin 
APC Antigen presenting cell 
ATP Adenosine triphosphate 
B  
β-ME β-mercaptoethanol 
B6 C57BL/6  
BFA Brefeldin A 
BLT Bone marrow-liver-thymus 
BrdU Bromodeoxyuridine 
BSA Bovine serum albumin 
BV Brilliant Violet 
C  
°C Celsius 
CA Capsid 
cAMP Cyclic adenosine diphosphate 
CCR5 C-C chemokine receptor type 5 
CD Cluster of differentiation 
cGAS Cyclic-guanosine monophosphate-adenosine monophosphate synthase 
CLIP Class II-associated invariant chain peptide 
CO Colorado 
CO2 Carbon dioxide 
compTNFα Complexed tumour necrosis factor α 
CTL Cytotoxic CD8+ T cell 
CTLA-4 Cytotoxic T lymphocyte antigen-4 
CXCR4 C-X-C chemokine receptor type 4 
Cy Cyanine 
D  
DC Dendritic Cell 
ddADA 2’,5’-DiDeoxyadenosine 
DEREG Depletion of Regulatory T cells 
DMEM Dulbecco´s modified Eagle medium 
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DMSO Dimethylsulfoxid 
DNA  Deoxyribonucleic acid 
dpi Days post infection 
DR5 Death receptor 5 
dsDNA Double-stranded deoxyribonucleic acid 
dsRNA Double-stranded ribonucleic acid 
DT Diphtheria toxin 
E  
EDTA Ethylendiaminetetraacetic acid 
eF eFlour 
ELISA Enzyme-linked immunosorbent assay 
ENTPD1 Ectonucleotide triphosphate diphosphohydrolase  
Env Envelope 
ERV Endogenous retroviruses  
F  
FACS Fluorescence-activated cell sorting 
FC Fragment, crystallisable 
FCS Foetal calve serum 
FELASA Federation of European Laboratory Animal Science Association 
FELASA European Laboratory Animal Science Association  
FITC Fluorescein isothiocyanate  
F-MuLV Friend murine leukaemia virus  
Foxp3 Forkhead box protein 3 
FSC Forward scatter 
Fv Friend virus susceptibility factors 
FV Friend virus complex 
FVD Fixable viability dye 
G  
g g-force 
g Gramm 
G phase Gap phase 
Gag Group-specific antigen 
GALT Gastro-intestinal associated lymphoid tissue 
GFP Green fluorescent protein 
GITR Glucocorticoid-induced tumour necrosis factor receptor family related gene  
GmbH Gemeinschaft mit beschränkter Haftung 
GM-CSF Granulocyte macrophage colony-stimulating factor 
gp Glycoprotein 
GVHD Graft-versus-host disease  
GV-SOLAS German regulations of the Society for Laboratory Animal Science 
Gzm Granzyme 
H  
H2O Water 
H2O2 Hydrogen peroxide 
HAART Highly active antiretroviral therapy 
HCV Hepatitis C virus  
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
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HERV Human endogenous retroviruses 
HIV-1 Human immunodeficiency virus-I 
HLA-DR Human leukocyte antigen-DR 
hr Human recombinant 
HRP Horse reddish peroxidase 
HSV Herpes simplex virus 
I  
i.p. Intra peritoneal 
i.v. Intra venous 
IC assay Infectious centre assay 
ICER Inducible cAMP early repressor 
ICOS TCR-inducible co-stimulatory receptor  
icTNFα Intracellular tumour necrosis factor α  
IDO Indolamine 2,3-dioxygenase  
IFN Interferon 
Ig Immunoglobulin 
iGFP Interdomain green fluorescent protein 
IL Interleukin 
IL Illinois 
IL2R IL2 receptor 
IN Integrase 
IPEX Immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome 
IRB Institutional Review Board 
iTreg Induced regulatory T cell 
K  
kDa Kilo Dalton 
KLRG1 Killer cell lectin-like receptor G1 
KO Knockout 
L  
L Litre 
Lag3 Lymphocyte-activation gene 3 
LANUV North Rhine-Westphalia State Agency for Nature, Environment and  
Consumer Protection 
Laser Light amplification by stimulated emission of radiation 
LD Blue Live/Dead Blue 
LDV Lactate dehydrogenase elevating virus 
LTR Long terminal repeats  
Luc Luciferase 
M  
µg Micrograms 
µL Microlitre 
µM Micromolar 
M Molar 
M phase Mitosis 
m2 Square metres 
MA Matrix 
MA Massachusetts 
MAb Monoclonal antibody 
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mac Macaque 
Mac1 Macrophage-1 antigen 
MACS Magnetic assisted cell sorting 
mbTNFα Membrane-bound tumour necrosis factor α 
mCAT-1 Cationic amino acid transporter  
MDA-5 Melanoma Differentiation-Associated protein 5 
mg Milligrams 
MgCl2 Magnesium chloride 
MHC Major histocompatibility complex 
min Minutes 
MIP Macrophage inflammatory protein 
mL Millilitres 
MLV Murine leukaemia virus 
mM Milimolar 
MMTV Mouse mammary tumour virus  
MN Maine 
MoDC Monocyte derived dendritic cells 
mr Mouse recombinant 
mRNA Messenger ribonucleic acid 
MTA Material transfer agreement 
mtv Endogenous mouse mammary tumour virus 
mu Murine 
MuLV Murine leukaemia virus 
MW Molecular weight 
N  
NaN3 Sodium azide 
NC Nucleocapsid 
NFAT Nuclear factor of activated T cells 
NF-κB  Nuclear factor κB  
ng Nanogramm 
NIH National Institute of Health 
NK Natural killer cell 
NKT Natural T killer cell 
nm Nanometres 
Nrp1 Neuropilin 1 
ns Not significant 
nt5e Ecto-5’ nucleotidase 
nTreg Natural regulatory T cell 
O  
OH Ohio 
ORF Open reading frame 
P  
p Plasmid 
Pacblue Pacific Blue 
PAMP Pathogen associated molecular pattern 
PBMC Peripheral blood mononuclear cells 
PBMC Peripheral blood mononuclear cells 
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pbs Primer binding site 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
PD-1 Programmed death 1 
pDC Plasmacytoid DC 
PD-L1 Programmed death ligand 1 
PE Phycoerythrin 
PenStrep Penicillin-streptomycin 
PerCP Peridinin-chlorophyll 
pH Potentia Hydrogenii 
PhD Doctor of Philosophy 
PIC Pre-integration complex  
PMT Photomultiplier tube 
Pol Polymerase 
ppt Polypurine tract 
PR Protease 
PRR Pattern recognition receptor 
R  
R Repeated region or short terminal repeats 
Rag Recombination-activating gene 
RANTES Regulation on activation, normal T expressed and secreted 
rER Rough endoplasmic reticulum 
Retrovirus Reverse transcriptase oncovirus 
RIG-I Retinoic acid-inducible gene I 
RNA Ribonucleic acid 
RSV Respiratory syncytial virus 
RT Reverse transcriptase 
RTC Reverse transcription complex 
S  
S phase Synthesis 
Sag Superantigen 
sc Single chain 
SEM Standard error of the mean 
SFFU Spleen focus forming units 
SFFV Spleen focus forming virus 
SIV Simian immunodeficiency virus 
solTNFα Soluble tumour necrosis factor α 
spi-1 Spleen focus forming virus proviral integration site-1 
SSC Side scatter 
ssRNA Single-stranded ribonucleic acid 
SU Surface glycoprotein  
T  
TACE Tumour necrosis factor α convertase 
TAP Transporter associated with antigen processing 
Tcon Conventional CD4+ T cells 
TCR T cell receptor  
Tfh T follicular helper cell 
tg or TG Transgene 
  Appendix 
167 
TGFβ Transforming growth factor β 
Th Helper T cell 
TIM3 T cell immunoglobulin domain and mucin domain 3 
TLR Toll-like receptor 
TM Transmembrane glycoprotein  
TM Trade mark 
TNC Tenascin-C 
TNFR Tumour necrosis factor receptor  
TNFRSF Tumour necrosis factor receptor superfamily 
TNFα Tumour necrosis factor α  
TRAIL Tumour-necrosis-factor-related-apoptosis-inducing ligand 
Tregs Regulatory T cells 
tRNA Transfer ribonucleic acid 
U  
U3/5 Unique 3'/5' 
UK United Kingdom 
USA United States of America 
UV Ultra violet 
V  
VLP Virus like particle 
VSVg Vesicular stomatitis virus g 
W  
wt or WT Wild type 
X  
X-gal 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside 
XLAAD X-linked autoimmunity-allergic dysregulation syndrome 
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